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ABSTRACT 
 
Diseases affecting the Central Nervous System (CNS), consisting of the brain 
and spinal cord, will account for an estimated 11.84% of all deaths by 2015, 
with few effective treatment options. This is partly a consequence of poor 
penetrance of blood-borne molecules, including almost all therapeutics, into 
the CNS. This is due to the existence of a blood-brain barrier, severely limiting 
potential therapeutic intervention. Nanoparticles are diverse nanoscale 
particles that have recently been demonstrated to be able to improve drug 
penetrance across the blood-brain barrier, by targeting endogenous transport 
systems. However, further methods to improve their general delivery to the 
CNS and specific delivery to different regions of the CNS are required. 
Here, agent-based modelling has been utilised to simulate blood flow in a 
capillary at the blood-brain barrier. This modelling approach has 
demonstrated the importance of a number of biological, physiological and 
physical factors that affect nanoparticle uptake to the CNS. This model was 
used to demonstrate how the fluid dynamics in capillaries enhances 
nanoparticle distribution to the vessel wall interface. These simulations have 
demonstrated that by tuning nanoparticle properties, including ligand density, 
receptor-ligand affinity and size, general delivery by transcytosis can be 
improved. Moreover, particular nanoparticle formulations can target high 
levels, but not low levels, of receptor expression at the blood-brain barrier 
thus providing a method to improve specific delivery into particularly CNS 
regions. Furthermore, nanoparticles can be formulated to stabilise 
nanoparticle binding under different flow conditions. In particular during 
regional blood flow increases, called functional hyperaemia, which aid access 
of nutrients to that region of the CNS. It is predicted from these simulations 
that this could be harnessed to further improve specificity of delivery. Finally, 
chemotactic nanoparticles are shown to have an improved distribution to the 
vessel wall interface and penetration through the CNS tissue. 
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CHAPTER 1: INTRODUCTION 
 
1.1 CLINICAL MOTIVATION 
1.1.1 The Central Nervous System 
The nervous system is a network of cells that are involved in rapid 
communication around the body. It is split into two major parts, the peripheral 
nervous system (PNS) and the central nervous system (CNS). The PNS 
consists of the sensory neurones and motor neurones. Sensory neurones 
detect certain stimuli and relay messages to the CNS. The motor neurones 
distribute instructions from the CNS to peripheral tissue to affect activity, for 
example, cause a muscle to contract. The CNS consists of the brain and 
spinal cord. Its major function is in processing information from the PNS and 
co-ordinating the activity of the body. It is responsible for many of the higher 
functions of humans and animals including, consciousness, memory, learning 
and language. It is a highly complex organ with different regions having 
specific functions. The CNS contains a number of different cells that 
contribute to CNS function in various ways, as summarised in Figure 1.1. 
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Figure 1.1: Cells of the Central Nervous System. A summary of the functions of 
different CNS cells. 
 
1.1.2 Burden of Disease 
The CNS is a highly delicate tissue and has a reduced reparative and 
regenerative capacity compared to many other tissues (Fawcett and Asher, 
1999). Therefore diseases of the CNS, generally, have a high morbidity and 
mortality rate. It is estimated that ~1 billion worldwide individuals have a 
neurological disease with diverse presentations from migraines to fatal 
neurodegenerative diseases. Furthermore, neurological diseases are 
responsible for 12% of global deaths with current projections suggesting that 
the burden of such diseases will increase by the year 2030 (WHO, 2007). This 
is because many CNS diseases tend to affect older individuals and global life 
expectancies are increasing. Neurological diseases are numerous and highly 
diverse, they can be broadly characterised as cerebrovascular diseases, 
neurodegenerative diseases, neurodevelopmental psychiatric diseases and 
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infectious diseases. A summary of the relative impact of selected neurological 
diseases is given in Figure 1.2. 
 
 
Figure 1.2: Relative Global Deaths for Selected Neurological Disorders. (WHO, 
2007) 
 
Cerebrovascular diseases refer to diseases that adversely affect the function 
of the vasculature supplying the CNS. This includes haemorrhages, where 
blood vessels rupture and leak blood into the CNS tissue itself, and ischaemia 
where blood supply to the tissue is insufficient. These two diseases often 
result in damage to the underlying neurological tissue causing a neural insult 
known as a stroke (Lipton, 1999, Fewel et al., 2003). Neurodegenerative 
diseases are characterised by neural cell death causing partial or complete 
loss of certain CNS functions, these include disease such as Alzheimer’s and 
Parkinson’s disease. The neurodevelopmental diseases are caused by 
abnormalities in CNS development and include schizophrenia and autism 
spectrum disorders. 
 
1.1.3 Drug Delivery into the Central Nervous System 
There are very few current effective treatment options for most CNS 
disorders, this is a consequence of several key factors. Firstly, the 
understanding of both molecular and tissue level factors that cause 
pathogenesis in most CNS disorders is relatively poor. Secondly, whilst 
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classical animal in vivo models can give some insights into pathogenesis in 
these disorders, compared to many other non-neurological models of disease, 
these models do not correlate as well with the clinical manifestations in 
humans (Markou et al., 2009). Thirdly, diagnosis of neural disease usually 
occurs after the onset of clinical symptoms, which often occur long after initial 
damage and at a point where intervention efficacy will be vastly reduced 
(Dekosky and Marek, 2003). However, one of the most important factors in 
the lack of adequate treatment options is the exclusion of many potential 
therapeutic molecules from the CNS tissue. It is believed that over 98% of 
small molecular weight therapeutics and nearly all of large molecular weight 
therapeutics are unable to penetrate into the CNS. This is due to the evolution 
of blood-brain barriers, which act to tightly regulate exchange of molecules 
between the blood and the CNS tissue (Abbott et al., 2010, Pardridge, 2005). 
In order to improve general treatment strategies aimed at the CNS, novel 
methods to deliver a wider range of molecules to the CNS are needed. The 
following sections introduce the anatomy, physiology and biology of the CNS 
and the barriers. The knowledge of these features is vital for understanding 
how molecules can be delivered to the CNS, can be distributed to targets 
within the CNS and are cleared from the CNS. 
 
1.2 ANATOMY OF THE CENTRAL NERVOUS SYSTEM 
The CNS is made up of two phases, a cellular phase bathed in interstitial fluid 
(ISF) and an acellular phase filled with cerebrospinal fluid (CSF). The fluid of 
these two phases can freely interact across a layer of specialised epithelial 
cells known as the ependyma. Dynamics of these two fluid phases and their 
interaction together are important for the understanding of how the CNS is 
able to distribute molecules to their required location and remove unwanted 
molecules from the CNS (Davson and Segal, 1995, Abbott, 2004).  
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1.2.1 Interstitial Fluid 
The ISF contains all of the cells that are responsible for the specialised CNS 
function. These include, but are not limited to, neurones, astrocytes, microglia, 
oligodendrocytes and pericytes. Therefore delivery of potential therapeutics 
into the ISF is essential for having any positive therapeutic effect. The ISF is 
mainly produced by the extensive blood-brain barrier that is discussed later in 
Section 1.3.1. Transport through the ISF has been shown to involve diffusion, 
bulk flows and more recently through astrocyte-mediated convection called 
the glymphatic pathway (Abbott, 2004, Mendelsohn and Larrick, 2013, Iliff et 
al., 2013). The CNS, despite its high metabolic activity and high sensitivity to 
toxic compounds lacks an extensive lymphatic system. It was believed that 
the CNS completely lacked a lymphatic system, however recently it was 
demonstrated to be present lining the dural sinus in the meninges (Louveau et 
al., 2015). The lymphatic system in peripheral tissue is responsible for the 
drainage and removal of toxic materials, trafficking the waste back for 
degradation by the liver via the blood. Abbott and colleagues described 
pathways of least resistance through the ISF. These typically occurred in the 
perivascular space around larger blood vessels and in astrocyte lined tracks 
along neuronal axons. Both of these mechanisms would result in a relatively 
inefficient mechanism of transport of material through the ISF (Abbott, 2004), 
as it relies on diffusion alone. However recent work has demonstrated a new 
system, termed the glymphatic system, which appears to explain this 
apparent discrepancy (Iliff et al., 2013, Mendelsohn and Larrick, 2013). Fluid 
from the CSF influxes through the para-arterial space, a space formed 
between the outside of arteries and astrocytic endfeet that surround the 
arteries. This fluid flows out of the para-arterial space by a convective flow 
maintained by astrocytes through the water channel aquaporin 4. The 
convective flow continues across the ISF towards the para-venous space, a 
space surrounding the cerebral veins. The para-venous space effluxes to the 
lymphatic system of the neck, eventually reaching the liver for degradation via 
the blood. This convective flow therefore washes away waste products 
forming an effective waste removal mechanism (Yang et al., 2013, 
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Nedergaard, 2013, Xie et al., 2013, Mendelsohn and Larrick, 2013). However, 
since this system is hypothesised to be a major route for toxic protein 
clearance, it may be impaired in neurodevelopmental disorders or ageing, 
contributing to the build up of protein plaques and tangles (Mendelsohn and 
Larrick, 2013). 
 
1.2.2 Cerebrospinal Fluid 
The CSF is an acellular fluid contained within a series of interlinked fluid sacs 
called ventricles and in the subarachnoid spaces (See Figure 1.3). Studies 
have shown that the bulk of the fluid is produced at the various choroid 
plexuses within the brain (Davson and Segal, 1995). The CSF then flows 
through the ventricular system, entering the subarachnoid spaces before 
draining out at the arachnoid membranes. The CSF offers the brain 
mechanical protection in response to trauma, buoyancy (Carpenter et al., 
c.1976), a route for waste clearance to venous blood and a source of non-
neuronal signalling (Milhorat and Hammock, 1983, Rapoport, 1976). Gupta 
and colleagues were the first group to look extensively at the fluid dynamics 
throughout the entire system using computational modelling based on 
magnetic resonance imaging (MRI) data. One of the most interesting findings 
was that in certain regions of the CNS, fluid dynamics approached simple 
diffusion. These regions corresponded particularly to specific locations within 
the CNS. It was hypothesised that these regions would permit increased ISF-
CSF interaction than areas where CSF flow is higher. Therefore CSF-borne 
molecules may be selectively accrued in these regions (Gupta et al., 2010). 
CHAPTER 1: INTRODUCTION 26 
 
Figure 1.3: Structure of the Central Nervous System and Ventricular System. 
The CNS consists of the brain and spinal cord. There are three major barriers 
indicated, the blood-brain barrier that feeds the ISF, the blood cerebrospinal fluid 
barriers that feed the CSF in the ventricular system and the sub-arachnoid 
membranes where CSF leaves the sub-arachnoid spaces to return to the blood. Flow 
of CSF is indicated by arrows from its origin in the choroid plexuses to the site of 
removal at the arachnoid villi. Adapted from (Abbott et al., 2010) 
 
1.3 BARRIERS OF THE CENTRAL NERVOUS SYSTEM 
There are a number of barriers of the CNS, these are the blood-brain barrier, 
the blood-cerebrospinal fluid barriers and the arachnoid membranes. These 
barriers share a common function in the regulation of transport between the 
periphery and the CNS. The barriers vastly reduce the ability of most 
molecules freely diffusing between adjacent cells, known as by the 
paracellular route. This is through the presence of specialised intercellular 
junctions, called tight junctions, between neighbouring cells of the barrier 
(Figure 1.4). In the absence of the paracellular route, cells mediate the 
exchange of substances through the intracellular route. These barriers can, 
therefore, act as the gatekeepers of the CNS. Consequently, understanding 
Introduction
Signalling in the central nervous system
Neurons within the central nervous system (CNS) communicate
using a combination of chemical and electrical signals, and precise regu-
lation of the local ionic microenvironment around synapses and axons is
critical for reliable neural signalling. It has been argued that this was one
of the chief evolutionarypressures leading to the developmentofmecha-
nisms for maintaining the homeostasis of the neural microenvironment
(Abbott, 1992). Barrier layers at the key interfaces between blood and
neural tissue play a major role in this regulation (Abbott et al., 2006).
CNS barriers
All organisms with a well developed CNS have a blood–brain
barrier (BBB) (Abbott, 2005). In the brain and spinal cord of mammals
including humans, the BBB is created by the endothelial cells that
form the walls of the capillaries. The combined surface area of these
microvessels constitutes by far the largest interface for blood–brain
exchange. This surface area, depending on the anatomical region, is
between 150 and 200 cm2 g-1 tissue giving a total area for exchange
in the brain of between 12 and 18 m2 for the average human adult
(Nag and Begley, 2005).
A second interface is formed by the epithelial cells of the choroid
plexus facing the cerebrospinal ﬂuid, which constitute the blood–
cerebrospinal ﬂuid barrier (BCSFB). The CSF is secreted across the
choroid plexus epithelial cells into the brain ventricular system
(Brown et al., 2004), while the remainder of the brain extracellular
ﬂuid, the interstitial ﬂuid (ISF), is derived at least in part by secretion
across the capillary endothelium of the BBB (Cserr et al., 1981; Cserr
and Patlak, 1992; Abbott, 2004; Dolman et al., 2005). ISF and CSF are
free to communicate at several locations; different experimental
studies have estimated the contribution of ISF to CSF as 10–60%
Fig. 1. Barriers of the brain. There are three principal barrier sites between blood and brain. (a) The BBB proper, which is created at the level of the cerebral capillary endothelial cells
by tight junction formation. It is by far the largest surface area for exchange and in the adult human is between 12 and 18 m2 in surface area. No brain cell is further than about 25 μm
from a capillary, so once the BBB is crossed, diffusion distances to neurons and glial cell bodies for solutes and drugs are short. Targeting a drug across the BBB is therefore the
favoured route for global delivery of drugs to all brain cells. (b) The blood–CSF barrier (BCSFB) lies at the choroid plexuses in the lateral, third and fourth ventricles of the brain where
tight junctions are formed between the epithelial cells at the CSF-facing surface (apical surface) of the epithelium. Some drugs and solutes enter the brain principally across the
choroid plexuses into CSF, while others enter via both the BBB and BCSFB. (c) The arachnoid barrier. The brain is enveloped by the arachnoid membrane lying under the dura. The
arachnoid is avascular but lies close to the superior sagittal sinus and is separated from it by the dura. The arachnoid is a multi-layered epithelium with tight junctions between cells
of the inner layer that form an effective seal. Arachnoid villi project into the sagittal sinus through the dura and a signiﬁcant amount of CSF drains into the sinus through these valve-
like villi which only allow CSF movement out of the brain to blood. Transport across the arachn id membrane is not an importa t route for the entry of solutes into brain (adapted
from Kandel et al., 2000, with permission).
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their biology is integral to achieving improved CNS delivery systems (Abbott, 
2005, Abbott et al., 2010, Pardridge, 2005). 
 
 
Figure 1.4: Structure of Tight Junctions at the Blood Brain Barrier. Adhesion 
junctions are formed between adjacent cells using adheren proteins that link to the 
cell cytoskeleton. Tight junction proteins confer tight junction properties and are 
present in addition to adheren proteins (Abbott et al., 2010). 
 
1.3.1 Blood Cerebrospinal Fluid Barriers 
The blood-cerebrospinal fluid barriers are found within two distinct structures, 
the choroid plexuses and the circumventricular organs (CVOs) (Langlet et al., 
2013, Davson and Segal, 1995). These structures are both characterised by a 
high density of fenestrations (controlled pores through endothelial cells) and 
the lack tight junctions, thus permitting free exchange of material from the 
blood to the tissue. However barrier function instead occurs at the specialised 
ependyma that interface the extracellular fluid (ECF) of the choroid plexus to 
the CSF. The choroid plexus’s main function is in generating the CSF. The 
ependymal cells that make up the blood-cerebrospinal fluid barrier perform 
this function. However, the ependymal cells also have tight intercellular 
The effectiveness of the tight junctions appears to be regulated via
the intracellular scaffold proteins ZO-1, ZO-2 and Z0-3 which link the
junctional molecules claudin and occludin via cingulin to intracellular
actin and the cytoskeleton (Wolburg and Lippoldt, 2002; Bauer et al.,
2004; Wolburg et al., 2009). Alterations in both intracellular and
extracellular calcium concentration can modulate tight junction
assembly (Balda et al., 1991; Abbott, 1998; Abbott et al., 2006), and
alter the electrical resistance across the cell layer and the effectiveness
of the tight junctions as a barrier. Many of the cell types associated
with brainmicrovessels, includingmicroglia and astrocytes, and nerve
terminals adjacent to the endothelial extracellular matrix/basal
lamina release vasoactive agents and cytokines which can modify
tight junction assembly and barrier permeability (Rennels et al., 1983;
Abbott et al., 2006).
Induction and maintenance of many blood–brain barrier proper-
ties, including formation of tight junctions and the polarised
expression of transporters in the luminal and abluminal endothelial
membranes, depends on a close association with astrocytes (Rubin
et al., 1991; Abbott, 2002; Wolburg et al., 2009). Tight junction
formation between cerebral endothelial cells in culture can be in-
duced by the use of astrocyte-conditioned medium, evidence for
action of soluble inducing factors (Neuhaus et al., 1991; Abbott, 2002;
Lee et al., 2003). More recently, induction by pericytes, neurons and
cells of monocyte lineage has also been described (Abbott et al., 2006;
Nakagawa et al., 2009). As several inducing factors for different
features of the BBB phenotype have been identiﬁed, it is clear that
barrier induction involves multiple agents and cell types. Two-way
exchange of signalling molecules and induction of some features via
the extracellular matrix or close cell:cell interaction add further
complexity to the induction process (Abbott, 2002; Begley, 2004a,b;
Abbott et al., 2006).
Transport across the BBB
Several potential routes for permeation across the BBB are shown
in Fig. 4.
Passive partitioning into brain
A wide range of lipid-soluble molecules can diffuse though the
BBB and enter the brain passively (Liu et al, 2004). There is a general
correlation between the rate at which a solute enters the CNS and its
lipid solubility, usually determined as the logD octanol/buffer
partition coefﬁcient at pH 7.4 (Clark, 2003). In contrast with logP
which refers to the partitioning of one species, most commonly
neutral, logD includes neutral and ionized species present in
solution (Krämer, 1999; Waterhouse, 2003). Factors which restrict
the entry of compounds into the CNS are a high polar surface area
(PSA) (greater than 80 Å2), and a tendency to form more than 6
hydrogen bonds, a factor which greatly increases the free energy
requirement of moving from an aqueous phase into the lipid of the
cell membrane (Clark, 2003; Gleeson, 2008). The presence of
rotatable bonds in the molecule and a molecular weight in excess
of 450 Da also appear to restrict BBB permeability. A high afﬁnity of
binding to plasma proteins with a low off-rate can also signiﬁcantly
reduce CNS penetration. However, these mol cular and physico-
chemical factors are not always an absolute indication for CNS
penetration and activity and there are many examples of effective
CNS active drugs in clinical use which do not comply with these
general rules for BBB penetration (Bodor and Buchwald, 2003).
Bases, which carry a positive charge, have an advantage over acids
when penetration of the BBB is considered and it is probably the
cationic nature of these molecules and an interaction with the
Fig. 3. Structure of BBB tight junctions. The tight junctional complex comprises occludin, claudins 3 and 5, and possibly other claudins. Cadherins of the adherens junctions provide
structural integrity and attachment between the cells, and are necessary for formation of tight junctions. The barrier to diffusion and the high electrical resistance of the BBB appear
to be largely due to the properties of claudins 3 and 5 (see text). The claudins associate and bind to each other across the intercellular cleft. A different ratio of the claudin mix may
subtly alter tight junctional properties and their tightness. Occludin has simil r associations across the cleft but does not form th restric ive pore to small ions. The claudins and
occludin are linked to the scaffolding proteins ZO-1, ZO-2 and ZO-3, linked in turn via cingulin dimers to the actin/myosin cytoskeletal system within the cell. Activation of the actin
cytoskeletonmay be initiated by a rise in intracellular calcium, for example resulting from ligand binding to the B2 bradykinin receptor, andmay change the conﬁguration of claudins
and occludin thus modifying the tight junctional properties. The role of the junction-associated molecules (JAMs, members of the immunoglobulin superfamily) is unclear, but they
appear to act as cell-adhesion molecules for leukocytes (updated from Begley, 2007 and other sources, see text).
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junctions and therefore form the essential barrier function at the choroid 
plexus, as demonstrated in Figure 1.5 (Abbott, 2005, Langlet et al., 2013). 
The CVOs function in communicating between the CNS and peripheral blood. 
They can be secretory, secreting signals in response to neural activity, or 
sensory, signalling to the CNS in response to peripheral blood signals. The 
mediators of these signals are cells called tanycytes that sit within the 
ependymal layer. This layer forms the barrier properties at the CVOs and 
makes the tanycytes ideally placed to interface between the blood and the 
CNS, via the CSF, as demonstrated in Figure 1.5.(Abbott, 2005, Langlet et al., 
2013). Interestingly the function of the CVOs would require highly efficient 
CSF-ISF crosstalk in the local region, therefore these regions are likely to 
favour exchange of molecules, as reported by Kurtcuoglu and co-workers 
(Kurtcuoglu et al., 2007).  
 
 
Figure 1.5: Organisation of the Blood-Cerebrospinal Fluid Barriers. Structure of 
the blood cerebrospinal fluid barriers at both the choroid plexus and the 
circumventricular organs. The endothelium is fenestrated at both barriers and 
therefore freely permeable between tissue and blood. However the barrier function is 
formed by the ependymal cells in both barriers. In the CVOs, tanycytes are 
interspersed in the ependymal barrier but still form tight junctions thus maintaining 
barrier integrity between the perivascular space of the CVOs and the CSF. 
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The blood cerebrospinal fluid barriers are generally regarded as a poor way to 
deliver therapeutics to the CNS. This is because it relies on the CSF flow and 
ISF exchange to reach potential targets. The work by Gupta and co-workers 
raises the intriguing prospect that using the choroid plexus may favour 
delivery into specific regions of the CNS (Gupta et al., 2010). The CVOs 
however may present a far more interesting site for delivery of therapeutics as 
they are optimised to interact between the blood and particular regions of the 
CNS, for example the median eminence CVO and the proximal CNS tissue in 
the hypothalamus (Langlet et al., 2013). Moreover, delivery of effector 
molecules to tanycytes potentially could be used to influence tanycyte signals 
to the CNS, thus effecting specific CNS functions (Langlet, 2014). 
 
1.3.2 Arachnoid Membranes 
The arachnoid membranes border the CSF-filled subarachnoid spaces. Tight 
junctions are formed by a layer of arachnoid cells to provide a physical barrier 
between the sub-arachnoid space and venous blood of the sagittal sinus 
(Figure 1.6). Interspersed within the arachnoid membranes are arachnoid 
granulations or villi that permit the drainage of CSF into the venous blood. 
Since it is mainly a drainage point, the arachnoid membranes don’t present a 
practical access point for therapeutic delivery. Furthermore, to penetrate key 
areas of the brain would require the ability to move against the bulk flow of the 
CSF (Abbott, 2005, Abbott et al., 2010).  
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Figure 1.6: The Arachnoid Barrier. The arachnoid barrier is present underneath the 
skull, the CSF in the sub-arachnoid spaces can cross into the venous blood, such as 
the superior sagittal sinus, through arachnoid villi. The arachnoid cells provide barrier 
function. 
 
1.3.3 Blood Brain Barrier 
The most important and well studied of the barriers is the blood-brain barrier. 
The blood-brain barrier constitutes a surface area of 20 m2, thus making it the 
largest interface between the blood and the CNS. Moreover the barrier sits 
directly between the blood and the ISF, providing the shortest route from entry 
point to target (Pardridge, 2005). The barrier function occurs at the level of the 
endothelial cells that constitute the blood vessel walls supplying the CNS 
tissue, but is regulated by a number of associated cells including pericytes, 
astrocytes, microglia and neurones, which collectively form the neurovascular 
unit, as demonstrated in Figure 1.7 (Abbott et al., 2010).  
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Figure 1.7: Structure of the Neurovascular Unit. Endothelial cells constitute the 
vessel walls of blood vessels. Tight junction proteins form tight inter and intracellular 
junctions. Pericytes surround the endothelial layer, sharing a basal lamina with the 
endothelial cells. Projections from astrocyte cells contact the vessel at end-feet 
structures. Graphic produced by Silvia Bianco based on the image by Miller (Miller, 
2002) and initial sketches provided by Gavin Fullstone and Giuseppe Battaglia. 
 
The barrier functions to vastly reduced the unregulated exchange of 
molecules between the blood and the CNS. It achieves this by the lack of 
fenestrations (see Figure 1.8), and tight junctions between neighbouring cells. 
This ‘physical barrier’ restricts the passage of almost all molecules with the 
exception of small lipophilic molecules including oxygen. Moreover, potentially 
harmful molecules that have the correct physical and chemical properties to 
permit passage across the blood brain barrier may be subject to broad-
specificity efflux transport or metabolic degradation. These are known as the 
‘transport barrier’ and ‘metabolic barrier’ properties of the blood brain barrier 
respectively (Abbott et al., 2010, Pardridge, 2005, Zlokovic, 2008). 
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Figure 1.8: Structure of Endothelium. Cross-sections of continuous endothelium 
(A) found at the blood-brain barrier compared to fenestrated endothelium found in 
other tissues, such as the kidney and the choroid plexus (B). (Cleaver and Melton, 
2003). 
 
The almost universal exclusion of vital molecules for basic function of the 
CNS, such as glucose, amino acids and nucleotides, by passive diffusion 
mechanisms means that the endothelium must transport essential molecules 
from the blood to the CNS and vice versa by active transport or facilitated 
diffusion. These mechanisms of transport are discussed in more detail in 
section 1.4. A summary of the blood brain barrier’s structure and function is 
presented in Figure 1.9. 
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Figure 1.9: Function of the Blood-Brain Barrier. The blood-brain barrier consists 
of continuous endothelium that lacks fenestrations and has tight junctions between 
cells, thus presenting a physical barrier to the free exchange of most molecules. 
Some molecules that cross are removed by efflux transporters (transport barrier) or 
by degradation by enzymes (metabolic barrier). In order to obtain necessary 
molecules, the blood-brain barrier regulates transport through the cell. 
 
The blood-brain barrier is generally cited as the best access point to the CNS 
for therapeutic delivery, as it permits short transit time to targets and has the 
potential to reach all areas of the CNS. However, being able to access all 
areas of the CNS could lead to potential off-target effects and given the fragile 
nature of the CNS this may be catastrophic. Whilst the blood-brain barrier 
presents an interesting site for delivery, methods to achieve specific delivery 
at certain points of the barrier are necessary for future progression of CNS 
therapeutic design. In the remainder of this thesis, methods to improve 
general and specific delivery across the blood-brain barrier directly into the 
ISF are explored. 
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1.4 TRANSPORT AT THE BLOOD BRAIN BARRIER 
1.4.1 Small Molecule Transport 
There are a number of different transport mechanisms that occur at the blood-
brain barrier, as demonstrated in Figure 1.10. The simplest is that of passive 
diffusion, where molecules with particular properties are able to diffuse across 
the barrier in a concentration dependent manner. Molecules that can 
passively diffuse across the barrier are generally small (<500Da) and lipid 
soluble (Pardridge, 2005). More recently, improved methods for analysing the 
relationships between structural and chemical properties with brain 
penetrance have been used. The most thorough is that of Quantitative 
Structure Activity Relationship (QSAR) analysis, which uses training libraries 
of molecules with known penetrance properties to predict the likelihood of 
candidate molecules penetrating the CNS. Several such studies have been 
performed with the most commonly studied variables being, polar surface 
area (PSA), octanol-water partition coefficient (logP) and the number of 
hydrogen bond acceptors/donors. The PSA is the sum of the surface area of 
all polar atoms and generally needs to be <90 Å2 to breach the blood-brain 
barrier. logP is a measure of hydrophobicity and correlates with increase in 
blood-brain barrier permeation, the optimal range has been found to be 1.5-
2.7. The use of such analysis may be of aid in modifying potential candidate 
molecules for improved CNS penetrance or eliminating poor candidates from 
high-throughput screening studies. However, in all these studies, the small 
training libraries used have limited the accuracy of prediction. Moreover, such 
an approach still limits the scope of therapeutic molecules to a small subset of 
molecules (Clark, 2003, Zhang et al., 2008b). 
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Figure 1.10: Transport at the Blood-Brain Barrier. Examples of the major 
transport systems across the blood-brain barrier and cargo that utilise them (Abbott 
et al., 2010) 
 
The majority of transport occurs through molecular transporters, membrane 
proteins that shuttle the molecule across the cell membrane. These include 
broad-specificity efflux transporters that remove molecules from the CNS and 
several metabolite transporters. The broad-specificity of efflux transporters 
leads to the removal of many potential therapeutic molecules from the CNS, 
thus decreasing penetrance. The most widely studied of these are P-
glycoprotein (Pgp) and the multidrug resistance proteins (MRPs) (Abbott et 
al., 2010, Pardridge, 2005). Inhibition or knockout of Pgp, coupled with 
application of molecules that are a substrate of Pgp has been demonstrated 
to permit improved delivery of potentially therapeutic molecules to the CNS 
(Sadeque et al., 2000, Mayer et al., 1996, Schinkel et al., 1995, Schinkel et 
al., 1994). 
 
negatively charged glycocalyx (heparan sulphate proteo-glycans)
and phospholipid head groups of the outer leaﬂet of the cell
membrane that facilitate their entry.
The movement of the blood gases oxygen and carbon dioxide
across the BBB is diffusive and the dissolved gases move down their
concentration gradients. Oxygen supply to the brain and carbon
dioxide removal are thus blo d-ﬂow dependent, so as long as cerebral
blood ﬂow remains within physiological limits, gas transport is ade-
quate. The negatively charged bicarbonate ion has a very low passive
permeability across the BBB.
Solute carriers (SLCs) in the BBB
The barrier t paracellular diffusion potentially isolates the brain
from many essential polar nutrients such as glucose and amino
acids necessary for metabolism and therefore the BBB endothelium
must contain a number of speciﬁc solute carriers (transporters) to
supply the CNS with these substances. The formation of tight
junctions essentially confers on the BBB the properties of a
continuous cell membrane, both in terms of the diffusional
characteristics imposed by the lipid bilayer, and the directionality
and properties of the speciﬁc transport proteins present in the cell
membrane. Examples of BBB solute carriers (SLC transporters) are
listed in Table 2.
Most polar molecules cannot diffuse through cell membranes and
thus all cells express a large number of SLCs in the cell membrane
(Zhang et al., 2002). The brain endothelial cells forming the BBB
express transport proteins for a wide variety of solutes and nutrients,
mediating ﬂux into and out of the brain. Some of these transport
proteins are polarised in their expression and are inserted into either
the luminal or abluminal membrane only, others are inserted into
both membranes of the endothelial cells (Betz et al., 1980; Begley,
1996; Mertsch and Maas, 2002; Abbott, 2002; Begley and Brightman,
2003; Nag and Begley, 2005; Ohtsuki and Terasaki, 2007; Roberts
et al., 2008; Bernacki et al., 2008). The orientation of these
transporters may therefore result in preferential transport of
substrates into or across the endothelial cell and the direction of the
transport may be from blood to brain or brain to blood. A further
function of the tight junctions in the lateral cell membranes is to act as
a ‘fence’ in the membrane and segregate transport proteins and lipid
rafts, to either the luminal or abluminal membrane domain, and to
prevent their free movement from one side of the endothelium to the
other, thus preserving the polarity of the barrier.
ATP-binding cassette transporters (ABC transporters) in the BBB
When comparing brain penetrance with lipid solubility (lipophi-
licity) a large number of solutes and drugs have a much lower CNS
Fig. 4. Routes of transport across the BBB. (a) Solutes may passively diffuse through the cell membrane and cross the endothelium. A higher lipid solubility and several other physico-
chemical factors favour this process (see text). (b) Active efﬂuxcarriers (ABC transporters)may intercept someof these passively penetrating solutes andpump themoutof the endothelial
cell eitheras theydiffuse through the cellmembraneor from the cytoplasm. PgpandBCRPare strategicallyplaced in the luminalmembraneof theBBBendothelium.MRPs1–5⁎ are inserted
into either luminal or abluminalmembranes; there appear to be some species differences in both the polarity and the isoforms ofMRPs expressed at the BBB (Begley, 2004a,b). (c) Carrier-
mediated inﬂux via solute carriers (SLCs)may be passive or primarily or secondarily active and can transportmany essential polarmolecules such as glucose, amino acids and nucleosides
into the CNS. The solute carriersmay be bi-directional, the direction of net transport being determined by the substrate concentration gradient (1), unidirectional either into or out of the
cell (2/3), or involve an exchange of one substrate for another or be driven by an ion gradient (4). In this last case the direction of transport is also reversible depending on electrochemical
gradients. (d) RMT requires receptor binding of ligand and can transport a variety of macromolecules such as peptides and proteins across the cerebral endothelium (transcytosis). AMT
appears to be induced in a non-speciﬁc manner by positively charged macromolecules and can also transport across the endothelium. Both RMT and AMT appear to be vesicular-based
systemswhich carry theirmacromolecule content across the endothelial cells. (e) Leukocytes cross theBBBeitherbyaprocess of diapedesis through the endothelial cells (penetratingclose
to the tight junctional regions), or via modiﬁed tight junctions. The junction-associated molecules (JAMs) and the cell surface protein CD99 may interact with the leukocytes to initiate
diapedesis. Tight junctionmodulation can result from signals from cells associatedwith the brain endotheliumor be induced pharmacologically;molecular re-arrangement of the proteins
of the tight junctions results in complete or partial opening of the paracellular aqueous diffusional pathway (modiﬁed from Begley, 2007).
18 N.J. Abbott et al. / Neurobiology of Disease 37 (2010) 13–25
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1.4.2 Immune Cell Migration 
The blood-brain barrier is also the site where immune cells can migrate into 
the CNS. Generally the CNS is regarded as a largely immune system 
privileged area, with immune function being predominantly provided by the 
resident microglia (Hanisch and Kettenmann, 2007, Kreutzberg, 1996). Small-
scale entry of immune cells from the blood for non-pathological surveillance of 
the CNS does occur, but large-scale migration of immune cells into the CNS is 
generally the hallmark of diseases such as multiple sclerosis (Hickey et al., 
1991, Ransohoff et al., 2003). In order to use this entry portal to effectively 
deliver molecules to the CNS tissue requires delivering to the immune cells, 
migration across the barrier and release unaltered into the CNS. 
 
1.4.3 Vesicular Transport 
In addition to solute and immune cell transport, there are some endocytic or 
vesicular based transport mechanisms. These transport systems involve the 
invagination of the membrane around the substrate that buds off from the 
plasma membrane to create a spherical membrane structure around the 
cargo, known as a transport vesicle. These vesicles are then sorted for 
recycling, degradation via the endocytic pathway or for transport to the 
opposite membrane, a process known as transcytosis (Mellman, 1996, 
Broadwell et al., 1988). Vesicular transport mechanisms at the blood-brain 
barrier are believed to occur at a reduced frequency compared to other 
continuous endothelium in other tissues. In skeletal muscles, for example, 
there are 4-5 times as many vesicular structures (Claudio et al., 1989, Reese 
and Karnovsky, 1967). 
Transcytosis can be both receptor-mediated or adsorptive-mediated. 
Adsorptive-mediated transcytosis occurs as a result of a strong interaction 
between a cargo molecules (or molecules) and the endothelial wall. Cargo 
molecules of adsorptive transcytosis are usually strongly cationic to induce 
the necessary strong interaction with the negatively charged glycocalyx and 
cell membrane of the endothelium (Hervé et al., 2008). Receptor-mediated 
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transport has gained wide interest as it provides the capability to control 
uptake across the blood-brain barrier by tagging cargo with specific ligands. A 
number of different cargo molecules are known to be able to induce 
transcytosis, including transferrin, lactoferrin, melanotransferrin, 
apolipoproteins and insulin (Abbott et al., 2010). The best studied is that of 
transferrin, a protein that transports iron to tissue. Transferrin is an 80kDa 
protein that can induce both endocytosis and transcytosis at the blood-brain 
barrier. The transferrin receptor is expressed only on the apical side of the 
endothelial barrier. The exact mechanisms for triggering the transcytosis or 
endocytosis route are poorly understood. In endocytosis the receptor-
transferrin complex is recycled intact but after the loss of its iron ions, unlike in 
most cases where the ligand-receptor complex is broken prior to receptor 
recycling (Yamashiro et al., 1984, Hopkins, 1983). Interestingly, transferrin 
has a major role in myelination of neurones, therefore it is possible that due to 
the increased transferrin demand the receptor expression at the barrier may 
be increased in white matter (high abundance of myelinated neurones) 
regions of the brain compared to grey matter (absence of myelinated 
neurones) (Monteros et al., 1999, Todorich et al., 2009). 
Lrp1 (low density lipoprotein receptor-related protein 1) and its ligands are the 
second mostly widely studied of the receptor-mediated transcytosis systems 
at the blood-brain barrier. Lrp1 transports a number of low density lipoproteins 
(LDLs) across the blood-brain barrier (Herz and Marschang, 2003). Lrp1 is 
expressed on both the apical and basolateral sides of the blood-brain barrier 
and by most of the cells of the CNS including pericytes, astrocytes, neurones, 
microglia and oligodendrocytes (Urmoneit et al., 1997, Gaultier et al., 2009, 
Herz and Marschang, 2003). In the other cells of the CNS, Lrp1 is involved in 
signalling and endocytosis. Targeting Lrp1, due to its wide expression 
throughout the CNS, confers the capability to deliver to all cells within the 
CNS but will inevitably lead to off-target effects. 
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1.5 METHODS FOR THE STUDY OF THE BLOOD BRAIN BARRIER 
The blood-brain barrier function can be studied in a number of ways including 
in vivo, in vitro, ex vivo and theoretical approaches. This is summarised in 
Figure 1.11, with more detail on each method provided in the remainder of 
this section.  
 
 
Figure 1.11: Methods to Study the Blood-Brain Barrier.  
 
1.5.1 In vitro Models of the Blood-Brain Barrier 
The easiest method to study the blood-brain barrier is using in vitro methods, 
culturing endothelial cells alone or co-culturing with other regulatory cells such 
as pericytes and astrocytes. Many studies of the blood-brain barrier require 
the endothelial cells to be polarised, where cells distinguish between the two 
sides of the cell (the tissue or basolateral side and the blood or apical side). 
These studies routinely use a semi-permeable insert, called a transwell, which 
can be placed within a standard culture plate (see Figure 1.12). 
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Figure 1.12: Diagram of Transwell. The transwell (A) cultures endothelial cells on a 
semi-permeable membrane, thus allowing definition of the apical and basolateral 
sides of the cell. A section of the semi-permeable membrane insert is shown with 
pores from the top (B) and from the side (C). 
 
In addition to the endothelial layer, supporting cells such as astrocytes and 
pericytes can be grown on the bottom of the media dish or the reverse side of 
the transwell insert. The physical barrier properties of the endothelial layer 
can be assessed using permeability studies, typically sucrose or dextrans, or 
by measurement of the trans-endothelial electrical resistance (TEER), which 
measures the resistance of ionic movement across the cell layer in units of Ω 
cm-2. These models permit a facile method for large-scale screening and 
pharmacokinetic studies. However, the lack of physiologically accurate 
arrangement of cells, the absence of flow, the differences between in vivo and 
in vitro cells and a reduced tightness of the barrier limit this methods utility. 
Previously, several attempts have been made to address some of these 
issues. The most frequent measure of barrier tightness is the TEER that is 
compared to the in vivo values. Butt and colleagues measured the TEER in 
anaesthetised rats and demonstrated TEER values up to 5900 Ω cm-2 with an 
average of ~1400 Ω cm-2 (Butt et al., 1990). Most of the in vitro transwell 
models made with immortalised cell lines reach a maximum of ~200 Ω cm-2. 
Patabendige and co-workers have developed transwell models from primary 
porcine endothelial cells with a mean TEER value of ~800 Ω cm-2, still 
significantly lower than that of the in vivo TEER (Patabendige et al., 2013). 
Introduction of flow in transwell models and similar models also increases the 
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TEER values in a variety of different cell lines (Cucullo et al., 2013, Griep et 
al., 2013, Cucullo et al., 2008, Neuhaus et al., 2006). The introduction of flow 
has achieved a maximum of >700 Ω cm-2 for the human brain microvascular 
endothelial cell (HBMEC) line (Cucullo et al., 2013, Griep et al., 2013). 
Although all these methods are useful for screening, different cell lines and 
culture techniques also vary other properties of the barrier such as transporter 
expression (Poller et al., 2008). 
 
1.5.2 In vivo Models of the Blood-Brain Barrier 
The most biologically relevant methods for studying the blood-brain barrier are 
by using in vivo animal models. The most commonly used animal models of 
the blood-brain barrier are mice (Mus musculus) and rats (Rattus norvegicus). 
The development of the barrier has been well characterised in these 
organisms and has close functional and structural agreement with the human 
barrier. However, in vivo studies are limited by poor quantitation of CNS 
delivery and by the cost and complexity of utilising live imaging techniques on 
these animals. Recently, the presence a blood-brain barrier has been 
demonstrated in the small teleost zebrafish (Danio rerio) early in 
embryogenesis by dye permeability studies, expression of tight junction 
proteins and association of other cells of the neurovascular unit. The zebrafish 
embryo offers optical clarity making it highly suitable for in vivo live imaging 
using light and confocal microscopy. Whilst it can be expected that zebrafish 
would have reduced translational benefit to humans than rodents, it offers 
capabilities that make it ideal for high throughput in vivo screening to 
complement rodent studies (Eliceiri et al., 2011, Fleming et al., 2013, Jeong et 
al., 2008). 
 
1.5.3 Ex vivo Models of the Blood Brain Barrier 
Along with animal studies, testing on human or rodent ex vivo tissue can be 
used (Abbott et al., 2006, Dallaire et al., 1991, Joo and Karnushi.I, 1973). The 
use of human tissue has a major advantage in improving translational work 
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from animal models to humans. However ex vivo tissue can be considerably 
more difficult to elucidate biological mechanisms than in vitro systems due to 
the added complexity of slices (Abbott et al., 2006, Dallaire et al., 1991, Joo 
and Karnushi.I, 1973). Furthermore, blood-brain barrier studies using ex vivo 
slices are limited by the lack of blood flow and the frequent complete collapse 
of blood vessels due to the loss of blood pressure. 
 
1.5.4 In silico and Mathematical Models of the Blood Brain Barrier 
The previous sections describe classical biological approaches to the study of 
the blood-brain barrier. However, modelling approaches increasingly are 
being used to understand and predict various functions of the blood-brain 
barrier. These modelling approaches include mathematical descriptions of 
pharmacokinetics and prediction of molecule permeability. Pharmacokinetics 
uses equations or a series of equations to describe the clearance, transport 
and distribution of molecules within the CNS. A number of groups have 
successfully produced CNS focused pharmacokinetic models of various 
scales from just the barrier itself, to the whole circulatory system (Westerhout 
et al., 2012, Badhan et al., 2014, Wong et al., 2013). In Section 1.2.4 the use 
of QSAR modelling, a method that predicts permeability of molecules based 
on physical and chemical properties, was described. In the next sections two 
methods of in silico modelling, which have been used with success in other 
fields, are discussed. This work aims to apply these methods to study the 
transport across the blood-brain barrier, 
 
1.6 COMPUTATIONAL FLUID DYNAMICS 
Transport from the blood to the CNS across the blood-brain barrier is reliant 
on distribution through the circulatory system. Therefore, understanding the 
dynamics of blood flow is important for study of distribution and uptake at the 
blood-brain barrier. The dynamics of a fluid can be described by three coupled 
partial differential equations, collectively known as the Navier-Stokes 
equations. These are the conservation of mass, the conservation of 
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momentum and the conservation of energy. The conservation of momentum is 
given in its general form as: 
 𝝆 𝝏𝒗𝝏𝒕 + 𝒗 ∙ 𝜵𝒗 = −𝜵𝒑+ 𝜵 ∙ 𝝉+ 𝑭          (1.1) 
 
where ρ is the density, t is time, 𝜵 is the del operator, 𝒗 is the velocity, 𝒑 is the 
pressure, 𝝉 is the 2nd order stress tensor and F is the force. The conservation 
of mass is given as: 
 𝝏𝝆𝝏𝒕 + 𝜵 ∙ 𝝆𝒗 = 𝟎         (1.2) 
 
and finally the conservation of energy is: 
 𝝆𝑪𝒑 𝝏𝑻𝝏𝒕 + 𝒗.𝜵 𝑻 = − 𝜵.𝒒 + 𝝉:𝑺− 𝑻𝝆 𝝏𝝆𝝏𝑻 |𝒑 𝝏𝒑𝝏𝒕 + 𝒗.𝜵 𝒑 + 𝑸          (1.3) 
 
where Cρ is the specific heat capacity at constant pressure, T is the absolute 
temperature, q is the heat flux vector, S is the rate of strain tensor and Q is 
the heat sources. 
Computational fluid dynamics (CFD) is the use of computational methods to 
solve or reconstitute these equations in set conditions and geometry. The 
ultimate goal in CFD methods is to solve the equation for conservation of 
momentum (Equation 1.1), whilst simultaneously satisfying Equation 1.2 and 
1.3. The complexity of the equations and the non-linearity of many of the 
terms mean that exact solutions are rare and limited to a number of specific 
cases where the non-linear terms are eliminated or do not need to be 
considered such as in Poiseuille’s flow or Stoke’s flow. Where exact solutions 
are not available, a number of techniques have been developed to find a 
solution to the equations with good concordance with flow measurements. 
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Many of these focus on breaking down the geometry into smaller segments 
and solving in each segment to obtain a solution for the whole geometry. This 
is known as discretisation of the Navier-Stokes equations.  
 
1.6.1 Discretisation of the Navier-Stokes Equations 
There are many different methods for finding a solution to the Navier-Stokes 
equations, the oldest is that of the finite difference method. The finite 
difference method uses a uniform square mesh grid and the differential or 
strong form of the Navier-Stokes equations to solve fluid flow. The reliance on 
such a mesh structure makes it inadequate for solving blood flows within 
complex geometry. Subsequently, two further methods were developed to 
increase the capacity of CFD methods to deal with complex multi-dimensional 
geometry and particularly curvature. These methods are the finite volume and 
finite element methods. These methods use the integral or weak form of the 
Navier-Stokes equations to iteratively assess flow in more complex geometry. 
The finite volume method solves the weak form of the Navier-Stokes 
equations at discrete mesh points. The finite volume refers to a small but finite 
volume at each mesh point. The finite volume method evaluates flux at the 
surface of the finite volume under the proviso that the flux entering a given 
volume is the same as the volume exiting an adjacent volume, as a result the 
conservation of mass is preserved and therefore the finite volume method is 
referred to as a conservative method. 
The finite element method (FEM), like the finite volume and finite difference 
method, uses a mesh of the whole geometry and evaluates the fluid dynamics 
at each discrete subdomain, called an element. The finite element method is 
particularly adept at approximating partial differential equations across a 
domain with set boundary conditions. For example, a stationary wall of a pipe 
would be said to be a no slip boundary, therefore at elements located on this 
boundary the fluid velocity is equal to 0 (Ferziger and Perić, 2002). 
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1.6.2 Lattice-Boltzmann Method 
The CFD methods presented in the previous section are methods of 
discretisation of a problem across a large-domain by breaking the domain up 
into smaller components. The lattice-Boltzmann method is an alternative 
method for evaluating fluid flow over large domains. However, rather than 
being based on discretisation of macroscopic scale partial differential 
equations (the Navier-Stokes equations), the lattice-Boltzmann method is 
based on a series of models of particles kinetics at the micro- and meso- 
scopic scale that produce a collective flow model over a large domain that 
conforms to the macroscale Navier-Stokes equations. One of the major 
advantages of the lattice-Boltzmann method is its ease of scalability onto 
parallel high performance computing systems (Chen and Doolen, 1998). 
 
1.7 COMPUTATIONAL FLUID DYNAMICS AND THE BLOOD 
The vasculature system is a series of interconnected blood vessels that act to 
carry nutrients and signals to tissues whilst simultaneously removing waste 
products from tissues. Blood flow through the vascular system is driven by a 
pressure gradient from contraction of the heart. CFD methods have been 
successfully applied to modelling various aspects of the vasculature and the 
behaviour of the blood. These approaches have improved insight into 
angiogenesis (the formation of new blood vessels from existing ones) 
(Bernabeu et al., 2014, Bentley et al., 2008), atherosclerosis (Krams et al., 
1997, Steinman et al., 2002) and transport (Korin et al., 2012, Liu et al., 
2012). However a number of important considerations are required when 
modelling the blood using such methods.  
 
1.7.1 Blood Vessel Architecture 
Blood vessels are highly heterogeneous in architecture and function. The 
major vessels are arteries and veins, large vessels that carry blood to and 
away from the tissues respectively. Arteries deliver blood from the heart and 
feed the microvasculature, vessels that distribute the blood throughout the 
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tissue to maximise transport to the entire tissue. The veins then remove blood 
from the microvasculature and return it back to the heart. The 
microvasculature contains three major vessel types, arterioles, capillaries and 
venules. The arteries directly feed arterioles that supply the most numerous 
vessels, the capillaries (Alberts et al., 2002). Capillaries are the major site of 
transport between blood and tissue and can vary greatly in size from a few 
micrometres to tens of micrometres in diameter. Their small diameter is 
crucial to capillary function in maximising the surface area of the wall to the 
volume of the blood. Capillaries feed into venules that remove the blood from 
the tissue and return it to the veins. Architecture of the microvasculature is 
complex as vessels branch into the capillary bed, as can be seen in the image 
of the retinal vasculature in Figure 1.13.  
 
 
Figure 1.13: The Retinal Vasculature. Depth Coloured Image of the Retinal 
Vasculature using Ultrahigh Sensitive Optical Microangiography. Red = Ganglion Cell 
Layer, Green = Inner Plexiform Layer, Blue = Outer Plexiform Layer. Adapted from 
(An et al., 2011) 
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1.7.2 Properties of the Blood and Vasculature 
The blood itself has a number of fluid properties that make it complex to 
model using CFD methods. Firstly, the blood is a non-Newtonian fluid, which 
means that the viscosity of the blood changes according to shear stress in a 
non-linear fashion. This is a result of the particulate nature of the blood as 
cells or cell fragments make up 40-45% (v/v) of the blood, a measure known 
as the haematocrit (Baskurt and Meiselman, 2003). The vast majority of the 
cells are RBCs (RBCs), also known as erythrocytes, however the immune  
system’s white blood cells and platelets are also present. The non-cellular 
fluid within blood is known as plasma and is a Newtonian fluid. The presence 
of cells alters the density and viscosity properties of blood, key terms used 
within CFD methods. Furthermore, in the microvasculature, blood cells are 
similar to the diameter to the vessel wall and therefore have a high influence 
on properties of flow within the blood (Baskurt and Meiselman, 2003, 
McWhirter et al., 2009, McWhirter et al., 2011, Schmid-Schönbein et al., 
1969). The Fåhræus-Lindqvist effect is one such property where the apparent 
viscosity of the blood decreases as the capillary diameter decreases. This is 
the result of RBCs congregating at the centre of the capillary leaving an 
acellular or cell-free phase at the vessel walls. This cell-free phase has a 
lower viscosity than the rest of the blood providing a path of least resistance 
for blood flow (Fahraeus and Lindqvist, 1931). 
 
1.8 CEREBROVASCULATURE STRUCTURE AND FLOW REGULATION 
In order to improve delivery across the blood-brain barrier from the blood, it is 
important to understand specific aspects of flow regulation in the cerebral 
vasculature. Two distinct mechanisms, autoregulation and neurovascular 
coupling carry out regulation of cerebral blood flow. 
 
1.8.1 Cerebral Pressure Autoregulation 
The cerebral blood flow is integral to maintaining CNS homeostasis, as low 
blood flow would result in ischaemia of the brain and high pressure would lead 
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to increased intracranial pressure. Therefore the CNS has evolved a system 
to regulate the cerebral blood flow and keep it at a constant level regardless of 
changes to systemic blood pressure. This mechanism is known as 
autoregulation and the exact mechanism is poorly understood (Peterson et al., 
2011, van Beek et al., 2008). However, it is known to involve changes in 
vascular tone and is attenuated in blood vessels ‘denuded’ of endothelial 
cells, suggesting an integral role of the endothelium itself (Harder, 1987, 
Rubanyi et al., 1990). Other mechanisms have been proposed including 
specific roles for vascular smooth muscle cells (vSMCs), suggesting a more 
complex regulatory system. 
 
1.8.2 Neurovascular Coupling and Functional Hyperaemia 
The CNS has the highest energy demand of the organs in the body. It is 
believed to contribute 20% of the total energy expenditure of the body, despite 
contributing to just 2% of its total mass. This demand for energy is the result 
of the aerobic respiration that must occur to feed the active transport required 
in undertaking neuronal signalling, particularly in repolarisation after an action 
potential (~47% of total energy consumption) and active uptake of 
neurotransmitters from synapses (~34% of total energy consumption) (Attwell 
and Laughlin, 2001). In order to reduce wastage of energy and improve 
efficiency, the CNS has developed a feedback system to increase delivery to 
regions of the CNS that are active. This feedback mechanism is called 
neurovascular coupling and acts by increasing the local cerebral blood flow, 
known as functional hyperaemia (Attwell and Laughlin, 2001, Roy and 
Sherrington, 1890). The detection of this increase in blood flow is the basis for 
using functional magnetic resonance imaging (fMRI), to associate certain 
stimuli or tasks with regional CNS activity (Villringer and Dirnagl, 1995). 
Functional hyperaemia is mediated through dilation of the vSMCs that 
regulate dilation and constriction of the arterioles in the microvasculature. The 
dilation of the arterioles increases blood flow entry from the arteries into the 
arteriole. Consequently blood flow is increased throughout the rest of the 
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connected microvasculature network, as seen in Figure 1.14 (Attwell et al., 
2010).  
 
 
Figure 1.14: Mechanism of Functional Hyperaemia. In the absence of local neural 
stimulation, vSMCs contract and constrict the arteriole (A). After neural stimulation, 
the vSMCs dilate, allowing more blood flow to pass through the arteriole and the 
downstream microvasculature network (B). 
 
The traditional pathway of neurovascular coupling shown is mediated by 
neuronal and astrocytic control, using a variety of different signalling 
pathways. Recently, the release of the neurotransmitter glutamate has been 
demonstrated to contribute majorly to the regulation of the functional 
hyperaemia response, with the response being propagated through both 
neurones (Busija et al., 2007, Ma et al., 1996) and astrocytes (Gordon et al., 
2008, Metea et al., 2007, Peng et al., 2002, Peng et al., 2004, Porter and 
McCarthy, 1996).  
It has been known since the work of Dore that pericytes express contractile 
proteins (Dore, 1923). Recently this has gained renewed interest due to the 
concept that pericytes may contribute to neurovascular coupling by altering 
capillary diameter. Furthermore, they have distinct features that make them 
ideal for this role, particularly their proximity to neurones compared to 
arterioles and their ideal location to work in syndicate with blood vessels and 
neurones. This would suggest pericytes have the capacity to regulate capillary 
diameter and therefore blood flow through capillaries. A number of in vitro, ex 
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vivo and in vivo experiments have demonstrated that pericytes can contract 
when stimulated with electrical and chemical stimuli (Hamilton et al., 2010). 
Peppiatt and colleagues were the first group to observe contraction of 
pericytes in capillaries in vivo, however the method of induction and degree of 
constriction led to questioning of whether this occurs in more physiological 
conditions as it led to almost complete occlusion of the capillary (Peppiatt et 
al., 2006). This conclusion was supported by the work of Stefanovic and 
colleagues who used two-photon laser scanning microscopy to find a dilation 
of the capillary bed of 10.9±1.2% that contributed an estimated 18% of the 
functional hyperaemia response in rats (Stefanovic et al., 2008). In contrast, 
Fernandez-Klett and co-workers used a similar methodology and found that 
although pericytes were contractile in vivo, the functional hyperaemia 
response was mediated by the arterioles in mice (Fernandez-Klett et al., 
2010). The different findings of these studies may suggest a differential 
regulation of functional hyperaemia in rats and mice. However, Hall and co-
workers have more recently demonstrated that pericytes can dilate in vivo, in 
both rat and mice models, in response to glutamate and that this pericyte-
mediated mechanism of functional hyperaemia occurs prior to arteriole dilation 
and may contribute more to the overall observed changes in blood flow (Hall 
et al., 2014). What appears to be unanimous between these studies is that 
pericytes are contractile in vivo and that this does seem to be a contributing 
component of the functional hyperaemia response, though the relative 
significance and mechanisms of regulation still require further study. It is a 
distinct possibility that the pericyte mechanism acts in a rapid temporal 
capacity prior to the arteriole-mechanism and/or to fine tune arteriole-
mediated functional hyperaemia at the capillary level. Pericytes may also 
contribute towards flow autoregulation. 
 
1.8.3 Cerebrovascular Abnormalities in Disease 
The previous sections give details on regulation of blood flow in normal 
conditions. However, changes in blood vessel architecture and blood flow 
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regulation itself have been demonstrated in a number of diseases and ageing. 
In many instances, it is unclear whether these changes are causative or 
consequential factors of the disease, but are often considered to be 
contributing factors to the pathological progression of the disease. For 
example, it may be considered in ischaemia, where blood flow is insufficient 
for CNS function, the ischaemia may contribute to neuronal or glial damage. 
However, initial neuronal and glial damage may likewise reduce the 
effectiveness of neurovascular coupling and therefore lead to a breakdown of 
the functional hyperaemia response and consequently result in ischaemia. 
Changes in blood flow in specific diseases may affect design of therapeutics 
in order to maintain sufficient delivery to the site of action within the CNS. 
Here, the cerebrovascular changes, observed in several diseases and during 
normal ageing, are described. 
Alzheimer’s has one of the best-characterised links with cerebral blood flow 
changes. Several reports have even shown neurovascular response defects 
in high-risk individuals carrying the important risk APOE4 allele before the 
onset of clinical manifestations of the disease itself (Bookheimer et al., 2000, 
Ruitenberg et al., 2005, Sheline et al., 2010, Smith et al., 1999a). 
Furthermore, Bell and colleagues have demonstrated structural differences in 
the cerebral vasculature of the hippocampus in apoe-/- mice stably 
transfected with the human risk allele APOE4, compared to the control and 
non-risk human APOE2 or APOE3 transfected mice. In the APOE4-mice the 
length of the microvasculature measured was significantly shorter than in the 
control or APOE2 and APOE3 mice (Bell et al., 2012). 
Vascular degeneration has also been observed in brain slices of Parkinson’s 
disease patients. Overall, capillaries were significantly less abundant, reduced 
in length, larger in diameter and with a reduced number of branching events 
when compared with normal brain slices (Guan et al., 2013). Derejko and 
colleagues have also demonstrated differences and deficiencies in the 
general cerebral blood flow of Parkinson’s patients and furthermore a 
significant deficiency in blood flow to the parietal and temporal lobe of 
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Parkinson’s patients with dementia when compared to those without a clinical 
dementia manifestation (Derejko et al., 2006). 
Decline of cerebral blood flow has been demonstrated to occur in ageing with 
particular reductions in the limbic and associated cortices being proposed to 
being causative of the cognitive decline associated with ageing (Martin et al., 
1991). In cat models, functional hyperaemia has been demonstrated to be 
impaired in ageing due to alterations in the microvasculature (Li and Freeman, 
2010). Furthermore, structural changes in the cerebral microvasculature have 
been observed in the ageing rat along with loss and morphological changes of 
pericytes (Hughes et al., 2006). The loss of pericytes may contribute to 
reduction in functional hyperaemia response in ageing individuals. 
 
1.9 AGENT-BASED MODELLING 
1.9.1 Agent-based Modelling for System Analysis 
Agent-based modelling is a type of modelling specifically designed for 
systems analysis. It deconstructs a system into components, known as 
agents, and assigns mathematical expressions to describe their behaviour. 
Subsequently, by combining the different agents together in simulations, 
through agent-agent and agent-environment interactions, emerging systems 
behaviour can be observed. Biological systems are highly complex involving 
many components, across many different scales, from single molecules 
through to whole cells, tissues, whole organisms and populations of 
organisms. Moreover, they are inherently dynamic and often contain complex 
and spatially heterogeneous features. Manipulation of single components 
within biological systems, by traditional experimental methods, is often difficult 
due to their inherent complexity. Traditional differential equation methods are 
limited by their poor representation of dynamic and spatially complex systems. 
Agent-based modelling is based on rules obtained, directly or indirectly, from 
experimental methods. Agents within agent-based simulations can be given 
spatial identifiers, providing more rigorous modelling of spatially complex 
systems than by other modelling methods. Furthermore, it allows facile 
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manipulation of parameters inaccessible through more conventional 
techniques to provide system level trends, to complement traditional 
experimental approaches.  
 
1.9.2 Parallel Computing 
Agent-based simulations, though powerful in terms of predictive capabilities, 
are often limited in simulation size by the CPU (Central Processing Unit) 
power and memory availability. This can be addressed by utilising distributed 
computing, distributing work and memory across several CPUs, commonly 
referred to as cores. This creates an entire new problem, how to efficiently 
access data from agents or functions operating on non-self cores. There are 
several different ways to approach this issue and to optimise this process to 
achieve maximum ‘speed up’ of the simulation. Most of these methods focus 
on using the message passing interface (MPI), a communication system that 
can send data between cores (See Figure 1.15).  
 
 
Figure 1.15: Serial and Parallel Computing for Agent-based Applications. 
Agents exchange data through a shared memory in serial computing (A). However in 
parallel computing (B), each core contains a separate memory, cores must 
communicate with each other through the message passing interface. 
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The speed of the simulation is usually limited on how long these 
communications take to send to the relevant cores. The speed of 
communication depends on the ‘interconnect’ between cores. MPI coding 
requires specialist knowledge and needs extensive optimisation to minimise 
‘overheads’ of parallelisation. Moreover, small changes to the code may 
necessitate the repeating of the optimisation steps, limiting flexibility in reusing 
sections of code for different applications. 
 
1.9.3 The Flexible Large-scale Agent-based Modelling Environment 
A wide variety of agent-based modelling platforms are available, many of 
which provide established toolkits for agent-based simulations. The most 
popular platforms include, but are not limited to, Repast, SWARM and 
MASON. However, one of the major drawbacks of most of the available 
platforms is their programming in Java. Java is a highly accessible language 
that performs well in web-based platforms. However, it is not an optimal 
language for use on high-performance computing systems. FLAME (Flexible 
Large-scale Agent-based Modelling Environment) is a generalised agent-
based modelling platform designed in collaboration between the University of 
Sheffield’s Department of Computer Science and the Science and Technology 
Facilities Council’s Rutherford Appleton Laboratory in 2003. FLAME is 
designed to permit the building of both serial (non-distributed computing) and 
parallel (distributed computing) agent-based models without any change in 
the user input code. It has been used to study non-biological systems such as 
the European economy (Deissenberg et al., 2008) and biological systems 
such as keratinocyte colony formation (Sun et al., 2008, Sun et al., 2007), 
development of the epidermis (Adra et al., 2010, Sun et al., 2009, Li et al., 
2013) and Escherichia coli’s oxygen response (Bai et al., 2014). Its design 
was particularly tailored for large-scale simulations on high performance 
computers in a number of ways. Firstly, it utilises the C language that has 
been used extensively in high performance computing and has many 
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established tools such as Open Multi-processing (OpenMP) and the MPI. 
These two tools represent the most prominent parallel programming tools in 
use on high performance computers. Secondly, the normal prerequisite of 
knowledge of MPI programming is not necessary for building parallel 
applications using FLAME, as FLAME builds the MPI simulation code from 
non-MPI functions programmed by the user. FLAME therefore allows a 
greater range of users to utilise high performance computing for agent-based 
modelling. Finally, FLAME contains an inherent method for optimising parallel 
agent-based models that reduces the requirement for repeated optimisation 
by the user (Chin et al., 2012). 
In FLAME, the user defines agents; their respective memory variables; their 
respective functions to carry out and data access requirements for those 
functions, from other functions. This is achieved in a basic form using XMML 
(X-Machine Markup Language). The functions themselves are then coded in a 
separate function file or files coded in the C language. FLAME utilises these 
two user-generated codes to construct an iterative-based executable model in 
either serial or parallel.  
FLAME uses message boards for communications between agents. The 
XMML file declares these message boards and the variables stored on them. 
Functions that require data on the message boards read through all the 
messages on a particular message board and by using filtering can access 
the required data. In serial, agents can read and write to this board rapidly as 
it is maintained in the local memory. However, in parallel each core has its 
own message board that must be synced with the other boards. When a 
function adds data to a message board, a message is generated to update 
the other message boards (as seen in Figure 1.16).  
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Figure 1.16: Parallelisation of Agent-based Models using FLAME Message 
Boards. (Chin et al., 2012) 
 
Whilst messages are in transit, no function can read data from the message 
board. FLAME’s approach to parallelisation uses a scheduler that prioritises 
work that will generate communications between cores. Whilst the messages 
are sent in the background, it will then perform all possible work not 
dependent on those communications, in order to reduce overhead times 
associated with parallelisation (as demonstrated in Figure 1.17).  
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Figure 1.17 Dependency Graph and FLAME Scheduler for a Simple Receptor 
Binding Model. In the dependency graph (left), 3 functions are displayed, the 
function ‘Ligand: Bind Receptor’ is dependent on the carrying out of the preceding 
function ‘Ligand: Move’ and also the message ‘Receptor Location.’ The message is 
generally limiting to the speed of the process, therefore the scheduler (right) 
prioritises the function that generates the message, ‘Receptor: Location.’ Whilst the 
message is transferring in the background, the scheduler will perform the function 
‘Ligand: Move’ as it is not dependent on the message. This reduces the lag time that 
the message-dependent function ‘Ligand: Bind Receptor’ must wait to receive the 
message before it can use it to perform useful work. 
 
The use of distinct functions in FLAME also allows the capability to easily add 
functions to and remove functions from a simulation, whilst still providing the 
inherent parallelisation optimisation described. This enables the user to 
systematically include and exclude certain functions and agents, thus giving 
profound flexibility in simulation to best answer the research question. 
 
1.9.4 Agent-based Modelling for Biology 
Agent-based modelling has far reaching applications, from the economy to 
crowd behaviour. However, recently its use for biological modelling has 
gained interest. Biological systems are characterised by their inherent 
complexity and more traditional methods such as in vitro or in vivo 
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approaches are not always adequate for understanding how a highly complex 
system operates. Agent-based modelling can give unique insight and 
predicative capabilities as it relies on a bottom up approach, therefore 
complementing more traditional methods. Moreover, the advance in and 
increasing accessibility of high performance computing systems means there 
is more power for accurate modelling of such complex systems. Agent-based 
modelling has been used successfully across many different scales in 
biological systems, in the remainder of this section we summarise some of 
these. 
The NFκB pathway is an immune system pathway that has been implicated in 
atherosclerosis and cancer. Molecular scale agent-based modelling was 
utilised to demonstrate that after activation of the NFκB pathway, a pool of 
spatially sequestered NFκB inhibitor, IκB, bound to the actin cytoskeleton 
could be released and aid the rapid temporal resolution of the NFκB response 
(Pogson et al., 2008).  
Sprouting angiogenesis is the process by which new blood vessels sprout 
from existing vessels. This process involves complex cell selection dynamics 
into tip cells and sprout cells. Agent-based modelling was utilised to 
demonstrate how this selection occurs in response to vascular endothelial 
growth factor (VEGF-A) by Notch-Delta-like Ligand 4 lateral inhibition (Bentley 
et al., 2008, Jakobsson et al., 2010).  
Multiple sclerosis is a brain disorder characterised by the breakdown of the 
blood-brain barrier leading to immune cell migration into the brain tissue. 
Pennisi and colleagues, used a multi-scale agent-based model of the blood-
brain barrier during multiple sclerosis to model the efficacy of treatment 
strategies that aid blood-brain barrier repair against those that protect the 
blood-brain barrier against further damage. They demonstrated that 
treatments that encourage repair are often less effective than treatments that 
reduce further damage (Pennisi et al.).  
Jackson and colleagues used agent-based modelling to investigate the 
foraging behaviour of the Pharaoh ant, Monomorium pharaonis. The Pharaoh 
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ant is a blind tropical ant that lives in large colonies formed of a number of 
smaller interlinked colonies. A key aspect to their survival is the ability to 
locate food and co-ordinate the foraging of new food sources to be collected 
and brought back to the colony. Agent-based modelling, using ants as 
individual agents, elucidated a complex co-ordination mechanism involving 
the deposition of pheromone trails to food source. Ants joining these trails can 
orientate towards the nest by a system of bifurcations, thus allowing individual 
ants to both forage for new food sources and return to the nest effectively 
(Jackson et al., 2004, Jackson et al., 2007, Robinson et al., 2005). 
 
1.10 NANOTECHNOLOGY 
1.10.1 Nanotechnology for Drug Delivery 
Nanotechnology is a greatly emerging field with wide-range of potential clinical 
applications, including in diagnostics, imaging agents and controlled 
therapeutic delivery. A particular area of interest is the use of nanoscale 
particles, called nanoparticles, to deliver a wide-range of potential therapeutic 
cargo molecules to specific locations within the body by modification of 
nanoparticle properties. Nanotechnology in drug delivery is a relatively young 
technology in application to drug delivery and therefore it is rapidly evolving to 
create more sophisticated nanoparticles for drug delivery applications. 
Nanoparticles can be split into two major categories, “hard” and “soft”, based 
on the chemistry of their formation. Hard nanoparticles describes 
nanoparticles formed by strong covalent, metallic or ionic bonds. These 
include metal nanoparticles such as gold or silver and carbon nanotubes. 
These particles are often defined by their rigid structure and lack of flexibility. 
Soft nanoparticles describe nanoparticles formed by numerous weaker 
interactions such as hydrophobicity, hydrogen bonding and Coulombic forces. 
These include, lipid-based liposomes, polymer-based polymersomes and 
protein nanoparticles. Soft nanoparticles offer much more flexibility and 
reduced rigidity compared to their hard counterpart and are more reminiscent 
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of the soft interfaces of cell membranes. Hybrid nanoparticles containing a 
hard nanoparticle core but a soft outer surface also exist. 
Nanoparticle properties such as size, shape and surface chemistry can be 
modified for particular properties depending on the application. Fine-tuning 
these properties can aid nanoparticle interactions with the host system. 
Generally there are several key properties that need to be addressed: 
 
• Toxicology 
• Drug retention and release 
• Half-life 
• Bio-distribution 
• Biodegradation and clearance 
 
1.10.2 Nanoparticle Toxicology 
Nanoparticles for use in drug delivery must be able to be used effectively 
without causing harmful side effects to the patient. Nanotoxicology is a 
complicated field due to the dependence on properties such as drug retention, 
half-life and bio-distribution, discussed later in this section. Nanoparticles are 
often designed based on chemicals or bulk materials with a known 
toxicological or biological profile. However, when changing the arrangement of 
these materials into nanoparticles, the size, shape and surface chemistry are 
vastly different to the original material, which may alter how they interact in a 
biological system, compared to the individual components. For example, gold 
in its bulk form is highly inert but in a nanoparticle becomes much more 
reactive and can be used in catalysis of certain reactions. This is a result of 
the small size increasing the surface area to volume ratio (Haruta, 2003). 
Generally, cationic nanoparticles are regarded as having a higher cytotoxicity 
than anionic nanoparticles because of their increased ability to penetrate 
cellular membranes (Goodman et al., 2004, Chen et al., 2009). 
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1.10.3 Drug Retention and Release 
A major consideration in utilising nanoparticles for drug delivery is in what you 
want to deliver and how the nanoparticle formulation must be adapted to 
deliver the therapeutic agent effectively and intact. For example, a 
nanoparticle designed to deliver a small hydrophobic drug may be quite 
different than one designed to deliver a large hydrophilic antibody. The most 
common way to carry drugs is through “complexing” and “encapsulating” the 
drug(s). Complexing involves forming a direct interaction with the drug such 
as covalent or ionic bonding to the nanoparticle. However, this requires 
creating an interaction that is either stable but maintains the drug in an active 
form or stable only until the desired point of release. Encapsulating a drug 
involves incorporating the therapeutic agent within the structure of the 
nanoparticle itself. Ideally, encapsulating therapeutic agent protects the drug 
from exposure until the desired target is reached. 
In order to release drugs from nanoparticles at the site of action requires 
careful design of nanoparticles. One of the most common methods of drug 
release is through stimuli-responsive nanoparticles that release their cargo in 
response to particular stimuli such as pH, light, temperature and chemical 
modification (Ganta et al., 2008). The idea being to find a particularly stimulus 
present at the site of action, for example, pH or temperature changes in 
tumour tissues (Gerweck and Seetharaman, 1996), pH-changes in the 
endocytic pathway (Cain et al., 1989) or chemical modification by tissue-
specific enzymes. 
 
1.10.4 Nanoparticle Half-life and Bio-distribution 
Regardless of the route of administration, nanoparticles must be able to 
traverse biological barriers in order to enter and persist within the body until 
the target site is reached. The body has evolved a number of sophisticated 
barriers to prevent the free access of foreign material to the body. One of the 
most critical is that of the immune system. The immune system is responsible 
for maintaining whole body homeostasis, particularly in eradication of foreign 
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material and repair of cellular or tissue damage. It is adept at recognition of 
non-self entities, triggering their subsequent destruction. Furthermore, after 
exposure to a foreign-body, “immunity” is developed so that the foreign body 
is more rapidly recognised and destroyed in future. Nanoparticles, to persist 
within the body, must be able to circumvent this defence mechanism. Most 
nanoparticles are sequestered by part of the immune system called the 
reticuloendothelial system (RES), also known as the mononuclear phagocyte 
system (MPS), a system of immune cells resident in tissues including the 
spleen, liver, lungs, bone marrow and lymph nodes (Van Furth, 1982, Owens 
and Peppas, 2006). 
“Immune stealth” describes the stages of designing nanoparticles to have a 
reduced interaction with the immune system. Size, shape and surface 
chemistry have all been demonstrated to be able to modulate immune cell 
interactions. Perhaps the best studied is surface modification of nanoparticles 
to prevent immune cell interactions. Surface charge of nanoparticles is known 
to affect the non-specific binding of soluble factors in the body forming a 
hydrated layer called the “corona.” Binding of soluble factors leads to a 
process called opsonisation where the particle is more readily recognised by 
the immune system and tagged for destruction (Storm et al., 1995). Reduction 
of surface charges or the inclusion of polymers like poly [ethylene glycol] 
(PEG) on the outer surface reduces nanoparticle elimination by the immune 
system. PEG and similar polymers have a highly favourable interaction with 
water and thus recruit a protective water sheath around the nanoparticle 
consequently lowering non-specific interactions with other materials and cells 
(Gref et al., 2000, Owens and Peppas, 2006). The consequent reduction in 
“protein fouling” to the nanoparticle corona is believed to be responsible for 
the reduced clearance of PEG-coated nanoparticles. Hamad and colleagues 
demonstrated that the molecular weight of PEG was a key factor in its 
interaction with the complement system of the immune system (Hamad et al., 
2008). The complement system is a collection of soluble inactive circulatory 
proteins that when activated trigger an innate immune response. They found 
that higher molecular weight PEGs increased activation of the alternative 
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complement pathway, leading to opsonisation of the PEG molecules. Michel 
and co-workers likewise established that the architecture of PEG affected its 
protein adsorption properties (Michel et al., 2005). Recently, it has been 
demonstrated that PEG exposure can result in the production of anti-PEG 
antibodies (Ishida et al., 2007, Wang et al., 2007, Środa et al., 2005). This 
consequently was responsible for an increased blood clearance rate. 
Moreover, repeated administration demonstrated an antibody-led immunity to 
PEG-based nanoparticles, potentially reducing their effectiveness in 
subsequent future administration (Środa et al., 2005). It is estimated that 
approximately 1 in 4 healthy people now have anti-PEG antibodies, a 100-fold 
increase across the previous 20 years, thus demonstrating a future reduction 
in the efficacy of this strategy (Garay et al., 2012). 
Size is the next best-studied property for the clearance of nanoparticles. It has 
been shown systemically administered nanoparticles, greater than 200 nm in 
size, will readily accumulate in the Kuppfer cells of the liver and also in the 
spleen (Maeda et al., 2000, Owens and Peppas, 2006). Size also impacts the 
filtration properties of the nanoparticles from the blood. Small sized 
nanoparticles, of less than 6 nm, are susceptible to filtration by the kidneys 
and removal via excretion of urine (Choi et al., 2007). Larger nanoparticles, up 
to 40-60 nm in size, may be subject to blood extravasation, the leakage 
through pores in the endothelial wall in discontinuous/sinusoidal or 
fenestrated endothelium. It has been mooted, as a consequence of these 
clearance profiles, that nanoparticles of a size range of 40-100 nm should 
have improved half-lives within the systemic circulation and therefore are 
more suitable for general drug delivery systems (Alexis et al., 2008). 
Shape has also been shown to aid evasion of the immune system, the 
Discher group have previously used tubular micelles to compare the half-life 
of different shaped nanoparticles. They concluded that the half-life can reach 
a maximum of 5 days for poly [ethyleneglycol]-poly [ethylethylene] tubular 
micelles, much greater than half-life exhibited for the same chemistry in a 
spherical vesicle morphology or indeed for any spherical morphology in the 
literature (Geng et al., 2007). 
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1.10.5 Achieving Specificity 
The previous section described nanoparticle design strategies to evade non-
specific off-target delivery. However, the ultimate goal is to achieve specificity 
for the tissue of interest. The easiest method of developing specificity for a 
therapeutic target is through the enhanced permeability and retention (EPR) 
effect. The vasculature of tumour tissues has a higher permeability than other 
tissues. Furthermore, tumour tissue often lacks the extensive lymphatic 
drainage systems prevalent in other tissues. Therefore, nanoparticles in the 
blood naturally accrue in tumour tissues more favourably than in other tissues. 
The specificity can be achieved by modulating nanoparticle size, an effect 
explored in more detail in Chapter 3 (Bogdanov et al., 1997, Iyer et al., 2006). 
The most common way to achieve specificity for desired tissue is through the 
targeting of unique or overexpressed receptors on the target tissue. 
Nanoparticles, adorned with such targeting moieties, ideally would enter the 
tissue of interest more readily than other tissues. Complications arise in 
finding uniquely expressed receptors and achieving delivery only to tissues 
where the receptor is overexpressed, with some off-target delivery to other 
tissues that express the receptor, even if it’s a comparatively reduced amount. 
The latter has been addressed by the work of the Frenkel group, who 
hypothesised that specific binding of nanoparticles to cells overexpressing a 
specific receptor can be controlled through a combination of high avidity and 
low affinity (Martinez-Veracoechea and Frenkel, 2011). This concept and 
other methods of achieving specific delivery will be explored in Chapter 4 and 
Chapter 5. 
 
1.10.6 Nanotechnology for Central Nervous System Delivery 
The previous sections describe general facets of drug delivery using 
nanoparticles, with particular reference to physical and chemical attributes. 
One of the major applications for this technology is in improving the general 
penetrance of a multitude of potential therapeutics to the CNS. Most 
nanotechnology approaches for CNS delivery focus on crossing the blood-
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brain barrier. Here, some of the existing approaches to crossing the blood-
brain barrier using nanoparticles are discussed. 
The most studied nanoparticle composition for CNS delivery is poly [butyl 
cyanoacrylate] coated with polysorbate 80. Kreuter and colleagues used this 
formulation to deliver the analgesics Dalargin or Loperamide and found a 
greater analgesic response when formulated together than the drug and 
carrier administered together but without direct binding of the drug to 
nanoparticle (Kreuter et al., 1995, Alyautdin et al., 1997). In their later work 
they ascertained the entry of the nanoparticle was dependent on adsorption of 
Apolipoproteins B and E, through a likely mechanism of receptor-mediated 
endocytosis and consequent diffusion of the drug or transcytosis (Kreuter et 
al., 2002, Alyautdin et al., 1997). A similar study by Schröder and Sabel 
validated that this formulation could successfully increase CNS penetrance of 
Dalargin (Schröder and Sabel, 1996). Gao and Jiang used the same 
formulation to test the effect of size on CNS delivery of methotrexate. They 
concluded that delivery of methotrexate was more efficient for nanoparticles of 
70 nm than with 170 nm, 220 nm and 345 nm nanoparticles (Gao and Jiang, 
2006). 
In studies of gold nanoparticle bio-distribution, several groups have reported 
that small nanoparticles of size 10-20 nm accumulate in the brain tissue. Hun 
and colleagues demonstrated that 20 nm gold nanoparticles were able to 
permeate the blood retinal barrier, analogous in function to the blood brain 
barrier, with no toxicity to the retinal tissue (Jeong Hun et al., 2009). De Jong 
and colleagues in bio-distribution studies also found that 10 nm gold 
nanoparticles could be located in the brain, but not 50 nm, 100 nm or 250 nm 
gold nanoparticles, suggesting that size is key to their passage across the 
barrier (De Jong et al., 2008).  
In subsequent studies, focus has shifted to target particular systems of 
transcytosis, most notably the transferrin-receptor mediated and the Lrp-1-
mediated routes. Monoclonal antibodies to the transferrin receptor have been 
found to increase blood-brain barrier penetrance. Ox26 is one such antibody 
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that was shown to increase brain penetrance of methotrexate conjugated to 
the antibody (Pardridge et al., 1991, Friden et al., 1991). Ox26 functionalised 
poly [glycerol]-conjugated poly[lactic-co-glycolic acid] nanoparticles 
encapsulating the analgesic endomorphins had an improved analgesia effect 
in rat models than controls (Bao et al., 2012). Gosk and colleagues used 
Ox26 conjugated to liposomes to increase CNS delivery. However, they 
concluded that these liposomes were co-localised with brain capillary 
endothelial cells, rather than entering the parenchyma itself (Gosk et al., 
2004). Further work by the Zhu group found that an optimal surface density of 
Ox26 improved delivery of poly[ethylene glycol]-poly[ε-caprolactone] 
polymersomes to the CNS, suggesting multiple Ox26-transferrin receptor 
binding events effected transcytosis efficiency. Niewoehner and co-workers 
studied this principle by comparing monovalent and bivalent antibodies to the 
transferrin receptor. They found improved transcytosis efficiency with the 
monovalent antibody. Moreover, the bivalent antibodies were taken through 
the endocytic pathway to the lysosome compartments, further evidence that 
multivalent targeting of the transferrin receptor can reduce delivery 
(Niewoehner et al., 2014). In addition to avidity, affinity has been shown to be 
integral to transcytosis efficiency. It has been demonstrated that high affinity 
antibodies to the transferrin receptor, such as Ox26, co-localised with the 
brain endothelial cells. However, reducing the affinity allowed improved 
transcytosis efficiency into the CNS tissue itself (Yu et al., 2011). The Davis 
group used a combination of size and avidity to fine-tune the interactions of 
gold nanoparticles with the brain endothelium. They concluded that high 
avidity nanoparticles remained attached to the brain endothelium on the CNS 
side, whilst lower avidity nanoparticles can successfully bind on the blood side 
and unbind on the CNS side to improve efficiency (Wiley et al., 2013). In the 
study of transferrin receptor targeted nanoparticles it is clear that efficient 
transcytosis is more complex than simply binding the correct receptor. This 
may be due to triggering different transport mechanisms by cross-linking 
receptors or by strong binding. However this process may be as simple as 
requiring a sufficiently strong initial binding to trigger initial transcytosis, but 
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simultaneously a weak enough binding to allow unbinding on the other side of 
the barrier. The strength of binding of a nanoparticle is regulated through, the 
interfacial contact surface area between nanoparticle and cell (related to size), 
the number of bonds formed (related to ligand and receptor density) and the 
individual strength of each of those bonds (related to affinity). This concept 
will be discussed in more detail in Chapter 4. 
More recently, targeting Lrp1-mediated transcytosis has become an 
increasingly popular mechanism for CNS delivery across the blood-brain 
barrier. Demeule and colleagues identified a family of peptides, called 
Angiopeps, based on the Kunitz protease inhibitor domain of Lrp-receptor 
family substrates. Angiopep-2, particularly, has been shown to stimulate 
highly efficient transcytosis across the blood-brain barrier by Lrp1-receptor 
mediated transcytosis (Demeule et al., 2008b, Demeule et al., 2008a). The 
high expression of Lrp-1 on glial cells has led to the widespread use of this 
peptide to target gliomas with anti-tumour agents. Functionalisation of 
poly[ethylene glycol]−poly[ε-caprolactone]  nanoparticles, PEG-modified 
poly[amidoamine] dendrimers and PEG-modified multi-walled carbon 
nanotubes, with Angiopep-2 was able to increase the delivery and anti-tumour 
activity of drugs including doxorubicin, docetaxel and the TRAIL (tumor 
necrosis factor-related apoptosis-inducing ligand) gene construct against 
gliomas (Gao et al., 2014, Huang et al., 2011, Ren et al., 2012). These studies 
demonstrate that angiopep-2 can successfully improve delivery of a diverse 
range of nanoparticles across the blood-brain barrier for potential therapeutic 
intervention. 
 
1.10.7 Lrp1-Targeted Polymersomes for Central Nervous System 
Delivery 
In the Battaglia group, a pH-sensitive polymersome system has been 
developed for CNS delivery (Tian et al., Submitted). Polymersomes consist of 
amphiphilic diblock copolymers that possess a hydrophilic and hydrophobic 
block. Polymersomes are formed by the self-assembly of these copolymers 
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into vesicle structures in an aqueous environment. The Battaglia group utilise 
a pH-sensitive hydrophobic block, poly[2-(diisopropylamino)ethyl 
methacrylate] (PDPA) that in acidic environments, of pH less than the pKa of 
6.4, is protonated and therefore hydrophilic. At pH 6.5 or above, the PDPA 
block loses its proton, becoming hydrophobic (Lomas et al., 2007). This 
permits control of the self-assembly process by adjusting the pH (See Figure 
1.18).  
 
 
Figure 1.18: Aggregation of PDPA Diblock Copolymers driven by changes in 
pH. The tertiary amine of PDPA is protonated at a pH of below 6.4 (light blue). This 
makes the PDPA block hydrophilic and therefore the monomers are soluble. At a pH 
above 6.4, this proton is lost and the PDPA becomes hydrophobic (orange), in an 
aqueous solution this leads to the formation of bilayer membrane structure formed of 
many aggregated monomers. 
 
Moreover, the pH-sensitivity provides an intracellular cargo release 
mechanism when taken up by cells through endocytosis. The endocytosis 
pathway culminates in endosomal compartments with a characteristic low pH. 
During the progression through the pathway, the acidification leads to the 
disassembly of the polymersomes into many monomers. This creates an 
osmotic shock that induces transient pores within the endosomal membrane, 
thus allowing the cargo to leave the endosome and enter the cell cytoplasm 
for hydrophilic molecules or a membrane for hydrophobic/amphiphilic 
molecules, as summarised in Figure 1.19 (Lomas et al., 2007, Lomas et al., 
2008, Massignani et al., 2009).  
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Figure 1.5 pH-sensitive PMPC-PDPA. 
Self-assembly and disassembly of PMPC-PDPA polymersomes depe ding on pH, 
figure adapted from (Lomas et al., 2007).  
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Figure 1.5 pH-sensitive PMPC-PDPA. 
Self-assembly and disassembly of PMPC-PDPA polymersomes depending on pH, 
figure adapted from (Lomas et al., 2007).  
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Figure 1.19: Cargo Release of pH-sensitive Polymersomes. Polymersomes are 
internalised from a physiological environment of pH of ~7.5 (1), they are trafficked 
through the endocytic pathway characterised by gradual acidification (2). At pH of 
below 6.5, polymersomes start to disassemble into monomers causing an osmotic 
shock (3). Cargo can escape into the cytosol, through transient pores that then reseal 
when back when osmotic balance is restored (4) (Massignani et al., 2010). 
 
In combination with the PDPA hydrophobic block, the Battaglia group utilise 
different hydrophilic blocks, based on their cellular interactions. 
Poly[oligo(ethylene glycol) methyl methacrylate] (POEGMA) is one such 
polymer that contains ethylene glycol oligomers off a methyl methacrylate 
backbone. The ethylene glycol oligomers give POEGMA PEG-like properties 
of immune stealth. In CNS delivery the POEGMA-PDPA polymersomes are 
functionalised with Angiopep-2 to create Ang-POEGMA-PDPA polymersomes 
(Demeule et al., 2008b). These polymersomes have been successfully shown 
to be transcytosed across in vitro transwell models of the blood-brain barrier 
more efficiently than non-functionalised POEGMA-PDPA polymersomes. 
Moreover, the transcytosis event does not involve acidification or any 
apparent co-localisation with traditional markers of the endosomal pathway 
(Tian et al., Submitted). When astrocytes are cultured on the bottom of the 
human dermal fibroblast (HDF) cells exposed to Rhodamine-
loaded polymersomes (0.005 mM) exhibit high levels of fluores-
cence from anywhere within their structure. Indeed, optical
sections obtained by confocal laser scanning microscopy show that
the dye (which otherwise would not gain entry to the cells –see
control data figure 2b, dye control alone) is uniformly distributed
within the cell volume. In these studies it is noteworthy that the cell
lysosomes and DNA were stained with yellow Lysotracker and
green SYTO-9, respectively.
We have reported previously [24–26] that these PMPC-PDPA
polymersomes have no effect on cell viability. Provided that the
fluorescent dye also has no detrimental effect, its combination with
these polymersome allows fluorescence staining of live cells. This is
shown in Figure 3a in which a direct comparison is made with a
Figure 2. Polymersomes intracellular delivery. (a) Mechanism of polymersome-mediated cytosolic delivery. (b) Primary human dermal
fibroblast (HDF) exposed to Rhodamine-loaded (red) polymersomes imaged at different focal levels (0 mm, 5 mm, 10 mm) by confocal laser scanning
microscopy (40x lens, bar 0.02 mm) and compared to untreated cells. The cell lysosomes and DNA were also stained using yellow Lysotracker and
green SYTO-9, respectively. Figure bar 20 mm.
doi:10.1371/journal.pone.0010459.g002
Effective Probes Delivery
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10459
CHAPTER 1: INTRODUCTION 69 
transwell system, Ang-POEGMA-PDPA polymersomes accumulate in the 
astrocytes. This is hypothesised to be through an Lrp1-mediated endocytosis 
mechanism. Furthermore, IgG encapsulated into these polymersomes co-
localises with both the neural marker NeuN and the astrocyte marker Glial 
Fibrillary Acidic Protein (GFAP) when injected intravenously in the mouse tail. 
This demonstrates that Ang-POEGMA-PDPA polymersomes can deliver large 
macromolecules to cells of the CNS across the blood-brain barrier. In 
biodistribution studies, when compared to non-functionalised POEGMA-
PDPA, CNS uptake of Ang-POEGMA-PDPA is indeed improved (Figure 1.20). 
However, the CNS uptake is still much reduced compared to other organs, 
particularly those associated with the RES such as the liver, spleen and bone 
marrow. It is also apparent that some sort of CNS clearance is occurring with 
peak signal at 2 hours, slowly reducing to near baseline levels. It is apparent 
from this work and that of others from section 1.10.6, that CNS delivery can 
be achieved but that it is still highly inefficient and more work is required to 
improve this uptake. 
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Figure 1.20: Biodistribution of Functionalised and non-Functionalised 
POEGMA-PDPA. Uptake of the two formulations of POEGMA-PDPA at 15 minutes, 
30 minutes, 2 hours, 4 hours and 24 hours post intravenous injection into the tail vein 
of mice, obtained through in vivo imaging systems (IVIS) spectrum. Mean ± standard 
error of the mean. (Tian et al., Submitted). 
 
1.11 CHEMOTAXIS 
1.11.1 Chemotaxis 
Chemotaxis is the process whereby a cell or entity is able to detect and 
respond to a concentration gradient by alterations in motility. This motility can 
be towards higher concentrations of a certain stimulus or stimuli 
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(chemoattractants) or away from certain stimuli (chemorepellants). This 
phenomenon is key to bacteria finding favourable environments (Adler, 1966, 
Zigmond, 1977), developmental processes in multicellular organisms and 
immune system function (Zigmond, 1977). More recently, inorganic micro- 
and nano-scale particles with chemotactic properties have been explored. 
Since chemotaxis confers the potential to target particular cells or tissues by 
following concentration gradients of appropriate signals, these particles may 
have interesting applications therapeutically. This section explores the theory 
for designing and optimising such a system for biological applications. 
 
1.11.2 Designing a Nanoscale Chemotactic Particle: Mechanisms of 
Particle Motion 
Although microscale chemotactic systems have been developed, nanoscale 
systems are far more favourable for in vivo applications due to improved 
clearance profiles, particularly between sizes of 40 and 100 nm (as covered 
extensively previously in this chapter). Whilst nanoscale chemotactic particles 
are highly desirable, serious complexities arise when designing particles at 
this scale. “Molecular motors,” appendages or molecular machines that 
generate mechanical force, can actively drive the motion of microscale 
particles. The most famous molecular motor is the bacterial flagellum that 
generates thrust through the proton-driven rotation of a helical appendage 
called a flagellum (Silverman and Simon, 1974). There are a number of other 
molecular motors such as cilia, however they all operate at the microscale. In 
order to produce chemotaxis at the nanoscale, other phoretic mechanisms of 
colloidal movement must be explored. 
Diffusiophoresis is the long known phenomenon that when suspended 
colloidal particles are exposed to a substrate concentration gradient, they 
spontaneously move in a directionally biased manner either towards or away 
from the gradient (See Figure 1.21). This is driven by an unbalanced 
interfacial tension on the particle surface, generating a slip velocity across the 
particle (Derjaguin, 1987). Osmophoresis is similar process, involving a fluid-
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filled vesicle surrounded by a semi-permeable membrane. However, 
osmophoresis is driven by asymmetric osmotic pressure across the particle 
membrane as a result of the difference in substrate concentration (Gordon, 
1981). 
Diffusiophoresis and osmophoresis are both driven by the imposed substrate 
concentration gradient. Self-diffusiophoresis and self-osmophoresis describe 
particles that are able to generate their own local concentration gradient and 
therefore create controlled motion (Golestanian et al., 2007). Local 
concentration gradients can be generated by the asymmetric catalysis of a 
reaction (see Figure 1.21C). 
 
 
Figure 1.21: Motion of Suspended Particles. In a system at equilibrium, 
suspended particles move in a directionally non-biased manner called Brownian 
motion (A). However, when a substrate concentration gradient is applied, suspended 
particles begin to move in a directionally biased manner towards or away from the 
source of substrate, this is known as diffusiophoresis (B).  Distal to the source of 
substrate where the concentration is minimal, suspended particles still move 
according to Brownian motion. Suspended particles that are able to generate their 
own concentration gradients, by catalytic conversion of substrates into products, 
move in directionally biased manner according to the axis of symmetry, called self-
diffusiophoresis (C). Particles not exposed to substrate undergo Brownian motion, 
due to the lack of catalytic activity. 
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In self-diffusiophoretic or self-osmophoretic mechanisms, the direction of 
travel is controlled by the axis of symmetry, rather than the substrate 
concentration gradient. Instantaneously this may result in motion away from 
the source of substrate as direction is assumed random (Ebbens and Howse, 
2010, Golestanian et al., 2005). However, over longer time frames particles 
can undertake controlled chemotaxis by a ‘run and tumble’ mechanism, 
similar to that used by bacteria, as demonstrated in the schematic in Figure 
1.22.  
 
 
Figure 1.22: Run and Tumble Model of Chemotaxis. In these two scenarios, the 
substrate gradient decreases from top to bottom. In scenario A, a particle moves by 
self-diffusiophoresis towards the source of substrate. As the substrate availability 
increases, the catalytic activity increases and this motion is reinforced into a “run”. 
However, in B, the particle moves away from the substrate, therefore catalytic activity 
will decrease and the particle will move slower, tending towards Brownian motion. 
This is called a “tumble” event, which occurs until the particle is randomly orientated 
in such a way that the particle is now driven towards the substrate, in a “run.” 
 
1.11.3 Designing a Nanoscale Chemotactic Particle: Rotational Diffusion 
Suspended particles undertake a process called rotational diffusion, where 
particles rotate in a random and non-directionally biased manner. One of the 
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major complications in the design of chemotactic particles is the contradictory 
requirements of rotational diffusion for successful chemotaxis. Effective 
chemotaxis requires being able to follow a trajectory for a sustained time 
when on a run, whilst being able to rapidly re-orientate during a tumble. For 
the former, a slow rotational diffusion time is desirable because otherwise 
during a run the particle will ‘forget’ its initial trajectory (as demonstrated in 
Figure 1.23).  
 
 
Figure 1.23: Effects of Diffusion Time on Sustaining Direction during a Run 
Schematic of a particle undertaking a run with long (A) and short (B) rotational times. 
 
A fast rotational diffusion time, however, is favourable for reorientation. 
Escherichia coli and other species of bacteria have evolved to solve this 
problem by sustaining a run for only a few seconds before tumbling, 
regardless of concentration gradient (Berg and Brown, 1972). This timescale 
allows it to follow a trajectory up until rotational diffusion times start to become 
significant enough to sufficiently alter the original direction. Furthermore, it is 
possible that rotational times during tumbles are accelerated by switching the 
direction of the flagella rotation, as opposed to stopping rotation altogether. In 
a run, the flagella rotate counter-clockwise (CCW) which, due to the helical 
nature of the flagellum, allows them to come together to form a single rotating 
A B 
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bundle (Figure 1.24A). During a tumble, instead of the stopping rotating 
altogether the flagella rotate in the opposite, clockwise (CW), direction. This 
leads to the bundle falling apart and the flagella re-orientate themselves, as 
seen in Figure 1.24B. The rotation of flagella significantly increases the force 
acting upon the cell, but unlike in a run, this force is symmetrical distributed so 
consequences in little directed translational movement. However it could 
increase the rotational time, allowing for more rapid reorientation for the next 
run stage. 
 
 
Figure 1.24: Chemotaxis of Peritrichous Flagellated Bacteria by Run and 
Tumble. In a run, the flagella rotate in a counter clockwise manner allowing them to 
form a single rotating bundle. In a tumble the flagella rotate in a clockwise manner, 
causing the flagella to separate (Butler and Camilli, 2005). 
 
Nanoscale chemotactic particles are generally considered poor at long-range 
chemotaxis because of their incredibly high rotational diffusion. Rotational 
diffusion (𝑫𝒓) is calculated from the particle size using the equation: 
 𝑫𝒓 = 𝒌𝑩𝑻𝟖𝝅𝜼𝒓𝟑          (1.4) 
 
where 𝒌𝑩  is the Boltzmann constant, 𝑻  is the absolute temperature, 𝜼  is 
viscosity and 𝒓 is the particle radius. As the particle size decreases, the 
a  Peritrichous flagella
Movement
CCW rotation Helical
bundle
b  Monotrichous flagellum
Movement
CCW rotation
Tumbling —
random reorientation CW rotation
Movement (random reorientation)
CW rotation
(S.M.B. and A.C., unpublished data). These data are 
consistent with the absence of strong homology to 
the FliM-binding region in these CheY paralogues 
(I. Kawagishi, personal communication).
As mentioned, multiple chemotaxis systems within 
the s me bacterium are common, and in some cases 
the function of these additional systems is known. The 
soil bacterium Myxococcus xanthus, which initiates a 
developmental programme under starvation conditions 
that culminates in the formation of a fruiting body, has 
four chemotaxis systems. This organism has S-motility, 
which is a form of gliding motility that requires two 
cell-surface components: type IV pili and extracellular 
matrix fibrils. One system of chemotaxis homologues, 
Dif, is involved in fibril biogenesis42, and the Frz and 
Che4 chemotaxis systems control the frequency of 
reversal of gliding direction43,44. The Che3 cluster 
regulates entry into the spore-formation developmental 
programme by controlling developmental gene expres-
sion45. The opportunistic pathogen Pseudomonas aerugi-
nosa uses one set of chemotaxis genes to control flagellar 
motility and another to control twitching motility, which 
is mediated by type IV pili46. As V. cholerae chemotaxis 
operons 1 and 3 are not required for chemotactic con-
trol of flagellar motility, it is possible that genes in these 
operons could regulate flagellum-independent motility 
in this organism. One such mode of motility has been 
observed; however, the requirements for this process 
remain to be determined47.
The role of chemotaxis in virulence
Although the role of motility during infection has 
been examined in several bacterial pathogens, the 
importance of chemotaxis in this process has not been 
as extensively studied48. A priori, chemotaxis would be 
predicted to work hand-in-hand with motility to enable 
bacteria to swim towards preferred colonization sites. 
However, in the case of enteric pathogens, the require-
ment of motility and chemotaxis ranges from being 
crucial to being dispensable for infection TABLE 1. For 
example, Shigella species are non-motile but are highly 
infectious, with an infectious dose as low as 10 cells. 
Clearly, the absence of motility in this organism is not 
an impediment to infection. Among motile bacteria, it 
seems that invasive enteric pathogens might not require 
motility for infection49. Some Shigella, Listeria, Yersinia 
and Salmonella species fall into this category, and each 
of these cross the epithelial barrier by translocation 
through M cells (reviewed in REF. 50), which are spe-
cialized antigen-sampling cells that lack an overlying 
mucus layer51. The ability to invade the epithelium in 
this manner apparently abrogates the need for motil-
ity. By contrast, both flagella and flagellar motility are 
necessary for Yersinia enterocolitica to bind and invade 
enterocytes in tissue culture52.
Alternatively, some non-invasive pathogens, such as 
Helicobacter pylori and Campylobacter jejuni, require 
chemotaxis for infection: neither species are thought 
to attach to the epithelium, but instead use chemotaxis 
to stay within the mucus layer that lines the stomach53 
and caecal crypts54, respectively. Like H. pylori and 
C. jejuni, V. cholerae does not invade the epithelium; 
however, unlike these species, V. cholerae does attach to 
epithelial surfaces, so that it is not clear whether motility 
would be expected to be important for infection.
Chemotaxis and V. cholerae infection. Surprisingly, 
chemotaxis actually inhibits the ability of V. cholerae 
to colonize the small intestine of infant mice. Defined 
non-chemotactic mutants of El Tor biotype strains 
that lack cheY-3 or cheA-2 were shown to out-compete 
the wild-type strain 70-fold in vivo41 TABLE 1. This 
out-competition phenotype correlates with an order-of-
magnitude increase in infectivity, as defined by a 10-fold 
reduction in the number of bacteria that are required to 
cause an infection55. No competitive advantage of these 
mutants is observed during growth in vitro, showing 
that the advantage is specific to the host small intestine. 
This unusual phenotype is explored further below.
Do the other chemotaxis systems present in 
V. cholerae have a role during infection? The answer 
to this question seems to be no. Strains with single 
or combined mutations in each of the cheA and cheY 
paralogues outside of operon 2 retain full virulence 
in competition assays with the wild-type strain in the 
infant-mouse model (S.M.B. and A.C., unpublished 
data). Interestingly, cheA-1 and cheR-1 from operon 
1 were identified as being highly expressed during 
infection in humans56. However, as these genes are 
not required for infection in mice, the significance of 
these data are unclear. At present, it is unclear what 
role, if any, these additional V. cholerae chemotaxis 
systems have in virulence, or for that matter, for life 
in the environment. The expression of two genes that 
encode proteins with homology to MCPs, acfB (access-
ory colonization factor B) and tcpI, is co-regulated with 
virulence genes57,58. However the roles of these proteins 
during infection is unknown.
Figure 2 | Flagellar-based motility. There are many schemes for flagellation in bacteria, of 
which peritrichous flagella and a single polar (monotrichous) flagellum are two types. a | In 
the case of peritrichous flagella, such as those found in Escherichia coli, counter-clockwise 
(CCW) flagellar rotation results in the formation of a helical bundle that propels the cell 
forward in one direction in a smooth-swimming motion (a ‘run’). By contrast, the presence of 
clockwise (CW) rotation causes unbundling of the helical bundle, allowing the bacterium to 
randomly reorient its direction (a ‘tumble’). b | In the case of a single polar flagellum, CCW 
rotati  propels the cell forward in a run, whereas CW rotatio  propels the cell backward 
with a concomitant random reorientation.
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The Gra -negative bacterium Vibrio cholerae, the 
causative agent of the severe diarrhoeal disease 
cholera, is responsible for the deaths of approximately 
120,000 people annually1. Cholera is contracted by 
ingestion of contaminated water or food and is 
therefore associated with inadequate sanitation and 
poverty. As a result, cholera is endemic mainly in the 
developing world, despite the fact that V. cholerae 
is present in temperate zones around the planet. 
Although there are at least 200 known serogroups of 
V. cholerae, cholera has generally been associated only 
with the O1 and O139 serogroups2. The O1 serogroup 
is divided into two major serotypes, Inaba and Ogawa, 
and these can be further divided into two biotypes, 
classical and El Tor. Throughout history, cholera has 
been associated with explosive epidemics and, since 
the nineteenth century, pandemics.
Humans are the only known vertebrate host for 
V. cholerae and following ingestion, the organism 
must survive passage through the gastric barrier of 
the stomach. V. cholerae is not particularly resistant to 
low pH3, and this is believed to contribute to the rela-
tively high infectious dose that is required to produce 
infection in healthy human volunteers4. However, 
V. cholerae can adapt to mildly acidic pH, and these 
acid-adapted bacteria have a huge competitive 
adva ta e during experimental infection when 
compared with unadapted V. cholerae5. Following 
passage through the stomach, the bacteria then enter 
the small intestine, which is the main site of infec-
tion. After reaching the small intestine, chemotaxis 
could conceivably be required to locate the appropriate 
intestinal niche for colonization and virulence-factor 
expression, an idea that will be explored in this review.
Two well characterized virulence factors of 
V. cholerae are cholera toxin and the toxin co-regulated 
pilus (TCP). The TCP is required for colonization in 
both humans and animal models of infection6,7, and 
these pili are believed to mediate microcolony forma-
tion on the intestinal epithelium8. Cholera toxin is a 
ribosylating enterotoxin9 that is responsible for the 
profuse watery diarrhoea associated with cholera, 
known as rice-water stool. The genes that encode 
these virulence factors are tightly regulated, so that 
expression does not occur inappropriately, such as 
during extra-intestinal growth in rich media10,11. By 
eliciting diarrhoea, V. cholerae cells are shed from the 
host and back into the environment in the rice-water 
stool. It is estimated that cholera patients can shed 
as many as ten trillion V. cholerae cells per day12, and 
these shed V. cholerae are highly motile, as observed 
by microscopy13. There are two possible fates for 
GOING AGAINST THE GRAIN: 
CHEMOTAXIS AND INFECTION 
IN VIBRIO CHOLERAE
Susan M. Butler and Andrew Camilli
Abstract | Chemotaxis is the process by which motile cells move in a biased manner both 
towards favourable and away from unfavourable environments. The requirement of this 
process for infection has been examined in several bacterial pathogens, including Vibrio 
cholerae. The single polar flagellum of Vibrio species is powered by a sodium-motive force 
across t e inner membra e, and can rotate to prod ce speeds of up to 60 cell-body l ngths 
(~60µm) per second. Investigating the role of the chemotactic control of rapid flagellar motility 
during V. cholerae infection has revealed some unexpected and intriguing results.
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rotational diffusion coefficient increases relative to the radius to the power of 
three. Figure 1.25 demonstrates the relationship between nanoparticle size 
and rotational diffusion coefficient for a spherical particle. 
 
Figure 1.25: Relationship between Particle Diameter, Rotational and 
Translational Diffusion Coefficients. T=310K, η=0.0017 Pa.s. Pictures (left to 
right): Micelle ~10 nm, polymersome ~50-150 nm, bacteria ~1-2 μm and neutrophils 
~10-15 μm. Image of primary neutrophils provided by James Robertson. Micelle and 
vesicle images provided by Silvia Bianco. 
 
The rotational diffusion of nanoscale particles, of 100 nm in size, means that a 
particle will be essentially randomly orientated in ~0.4 ms. Therefore, 
nanoparticles cannot sustain effective chemotaxis over long time scales 
unless either a change occurs in rotational times or without other 
considerations coming into play. The Golestanian group have recently 
suggested that chemotactic particles actively align to the substrate 
concentration gradient, thus reducing the apparent rotational times (Saha et 
al., 2014). They have also previously observed such a reduction in rotational 
times for platinum-coated microscale polystyrene Janus particles (Howse et 
al., 2007). If such an alignment could be replicated at the nanoscale, it raises 
the intriguing possibility of being able to regulate both translational and 
rotational mobility to produce strong chemotaxis. The Golestanian group also 
propose a number of other mechanisms of chemotaxis in addition to the 
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alignment effect. They postulated that particles would naturally accrue in 
areas of low enzymatic activity, as they would be eventually driven away from 
highly concentrated regions due to the consequent high enzymatic activity, 
this they refer to as the “polar run and tumble”. However, they also describe 
the net motion of such a particle towards a substrate by the traditional run and 
tumble method, referred to as “apolar run and tumble.” In any population of 
particles a combination of the alignment, polar run and tumble, apolar run and 
tumble and diffusiophoresis/osmophoresis may be acting simultaneously 
giving complex phoretic behaviour in response to a substrate concentration 
gradient. Moreover, through interactions of multiple particles moving by such 
mechanisms, emergent collective behaviour may occur (Saha et al., 2014). 
 
1.11.4 Chemotactic Polymersomes 
In recent work within the Battaglia group, the aforementioned principles were 
used in the design and testing of chemotactic polymersomes. In order to 
generate the asymmetry required for self-diffusiophoresis or self-
osmophoresis to occur, polymersomes were made from blending two different 
copolymers, poly[(2-methacryloyl)ethyl phosphorylcholine]-poly[2- 
(diisopropylamino)ethyl methacrylate]  (PMPC-PDPA) and poly[ethylene 
oxide]-poly[butylene oxide] (PEO-PBO). The polymers within the hybrid 
polymersomes, over time, phase separate into distinct domains (LoPresti et 
al., 2011). The phase separation of these two copolymers creates 
“mushroom-like” polymersomes at a ratio of 9:1 PMPC-PDPA to PEO-PBO, 
as demonstrated in Figure 1.26 (Cecchin et al., Submitted). 
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Figure 1.26: Structure of a 9:1 Ratio PMPC-PDPA/PEO-PBO Hybrid 
Polymersome.  Transmission electron micrograph of a hybrid PMPC-PDPA/PEO-
PBO polymersome forming the indicated mushroom domain of PEO-PBO (A). 
Schematic of the hybrid polymersome with PMPC-PDPA as blue and PEO-PBO as 
yellow (B). Micrograph taken from (Cecchin et al., Submitted). Graphic produced by 
Silvia Bianco. 
 
The PEO-PBO copolymer forms more permeable membrane structures than 
PMPC-PDPA (Battaglia et al., 2006). Consequently, the efflux of products 
from an enzymatic reaction, performed in the aqueous core, will occur more 
favourably through the PEO-PBO domain, thus generating the concentration 
gradient required for self-diffusiophoresis or self-osmophoresis, as 
summarised in Figure 1.27. 
 
A B 
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Figure 1.27 Proposed Mechanism of Propulsion for a Hybrid PMPC-PDPA/PEO-
PBO Polymersome. Hybrid polymersomes that encapsulate a catalytic enzyme 
favourable expel the additional products from the reaction through the more 
permeable PEO-PBO domain, thus generating a concentration gradient across the 
polymersome for self-diffusiophoresis and self-osmophoresis (Cecchin et al., 
Submitted). 
 
The PMPC-PDPA/PEO-PBO polymersomes have been demonstrated to be 
chemotactic in several tests, using different enzyme-substrate combinations 
(Cecchin et al., Submitted). The two enzyme-substrate combinations used 
were catalase enzyme with hydrogen peroxide substrate and glucose oxidase 
enzyme with glucose substrate. When assayed for single particle chemotaxis, 
by Nanosight® tracking analysis, the hybrid polymersomes demonstrated clear 
directional propulsion towards the substrate source, with no directional bias 
observed in symmetric pristine PMPC-PDPA polymersomes, symmetric 
pristine PEO-PBO polymersomes, or asymmetric hybrid polymersomes minus 
enzyme. Furthermore, long-range chemotaxis behaviour was observed in a 
bulk chemotaxis assay that measured movement of the nanoparticle 
population by fluorescence intensity across a 10 cm Petri dish. Moreover, the 
strength of chemotaxis to glucose could be increased by co-encapsulation 
glucose oxidase and catalase, which forms a cascade reaction, as hydrogen 
peroxide is a product of glucose oxidase. This demonstrates that hybrid 
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polymersomes are chemotactic in response to different substrates across 
length scales orders of magnitude greater than the polymersome. 
Furthermore, the chemotactic activity over long distances and time scales and 
calculated rotational times of up to 10000 times slower than expected would 
suggest that this system is able align itself to the external concentration 
gradient as discussed in the previous section (Cecchin et al., Submitted). 
 
1.12 AIMS AND OBJECTIVES 
Increasingly, nanoparticles are being utilised as novel delivery vectors across 
the blood brain barrier. Generally, these approaches are limited by their still 
relatively poor and non-specific delivery. Therefore, the overall aim of this 
work is to utilise computational methodologies to investigate methods to 
ultimately improve the general and specific delivery of nanoparticles across 
the blood brain barrier.  Incorporated in this overall aim are a number of key 
aims: 
 
Aim: To produce an agent-based model of nanoparticle behaviour under 
blood flows. 
Hypothesis: It is hypothesised that by combining FLAME’s agent-based 
modelling framework and CFD methods, a highly flexible model of 
nanoparticle behaviour under blood flow can be developed that can be used 
for further study of nanoparticle interaction with the blood-brain barrier at both 
the individual particle and system levels. 
 
Aim: To demonstrate how modification of receptor-ligand mediated 
nanoparticle-endothelial interactions can result in improved general and 
specific transcytosis efficiency across the blood-brain barrier. 
Hypothesis: Manipulating nanoparticle properties such as size, ligand 
density (avidity) and receptor-ligand affinity can alter the nanoparticle-
endothelial interaction. Tailoring these interactions for certain scenarios such 
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as different receptor expression and different shear flows can improve general 
and specific delivery across the blood-brain barrier. 
 
Aim: To determine whether chemotactic nanoparticles are able to improve 
delivery to target cells and delivery across the blood-brain barrier 
Hypothesis: Chemotactic nanoparticles are able to follow gradients of 
specific chemical stimuli. Fine-tuning and use of chemotactic nanoparticles 
will allow nanoparticles to follow appropriate chemical signals to the cell or 
tissue that releases them. Furthermore, this may also be utilised to introduce 
greater dispersive activity of nanoparticles within the blood stream that may 
increase delivery. 
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2.1 THE FLEXIBLE LARGE-SCALE AGENT-BASED MODELLING 
ENVIRONMENT 
FLAME is an open source software package written in C. The FLAME 
framework is not an agent-based modelling application itself but generates an 
agent-based executable for serial or parallel architectures from user input 
files. FLAME consists of two major components, the parser executable, 
(Xparser) and the message board communication libraries (Libmboard). The 
source code for these were downloaded from the FLAME website 
(www.flame.ac.uk). 
The FLAME framework requires three input files for an executable model: 
Ø Model.xml: This file is written in XMML using the FLAME XMML 
schema located at http://flame.ac.uk/schema/xmml_v2.xsd. This file 
declares agents, memory variables for each agent, functions to 
undertake by each agent, the process order for each function, input 
and output messages required for each function, messages and 
memory variables for each message. 
Ø Functions.c: This file is written in the C language, it must include all the 
functions declared in the Model.xml file. The functions have full read 
and write capabilities for the given agent’s memory variables. It may 
also read or write message board variables if declared appropriately as 
an input or output within the relevant function in the Model.xml file. 
Ø 0.xml: This file is an XMML file containing the information for the initial 
states of the model. It declares the memory variables for each agent at 
time 0 in the given simulation. 
The FLAME Xparser uses the Model.xml and Functions.c files to generate the 
simulation code using the FLAME XMML schema templates. The compiler 
then is used to generate the executable using the Libmboard library. The 
executable requires an input of initial states (0.xml) to run the simulation. A 
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diagrammatic summary of producing an agent-based model using FLAME is 
demonstrated in Figure 2.1. 
 
 
Figure 2.1: Creating an Agent-based Application using FLAME. Illustration of the 
two phases of creating a FLAME executable from user input files. Parsing, creating 
the simulation code from the XMML and C input files. Compilation and linking, 
compilation of the simulation code into the final executable model (Chin et al., 2012).  
 
2.1.1 FLAME: Generating Initial States 
The initial states, 0.xml, files were created using MATLAB® and Statistics 
Toolbox Release 8.2.0.701 (2013b), The MathWorks, Inc., Natick, 
Massachusetts, United States. Software license number 910950. 
 
2.1.2 FLAME: Serial Compilation and Execution 
FLAME, by default, creates serial applications for execution on a single CPU. 
Simulation scripts were written and compiled, in serial, for testing using 
Xcode® 5 and executed on a MacBook Pro running OS X 10.8. 
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2.1.3 FLAME: Parallel Compilation and Execution 
FLAME can generate parallel applications by the inclusion of the argument ‘-p’ 
during parsing. Applications were compiled and executed, in parallel, on the 
Iceberg high performance computing facility 
(https://www.shef.ac.uk/wrgrid/iceberg) based at the University of Sheffield. 
Iceberg runs a 64-bit Redhat-based Linux operating system with 1544 CPUs 
that run at a collective performance of ~15 teraflops (Floating-point 
Operations Per Second). Parallel applications on Iceberg were compiled using 
the GNU compiler collection with OpenMPI 1.8.3 and run across multiple 
Intel® cores using an InfiniBand® interconnect. 
Parallel models must partition data across the available cores. Achieving 
maximum speed-up ideally locates communicating agents on the same core. 
FLAME offers in-built methods for partitioning agents when executed in 
parallel, round robin or geometric partitioning: 
Round robin Partitioning: This is the simplest partitioning method that 
distributes one agent at a time to each core in turn. It is implemented by the 
inclusion of a ‘-r’ argument to the simulation executable. Although this method 
is the simplest, it does not consider the function of the agent, which may 
impact model performance 
Geometric Partitioning: This partitioning method considers the spatial 
variables (𝑥, 𝑦 and 𝑧 co-ordinates) of each agent to allocate agents to cores 
based on similar location. It is implemented by the inclusion of ‘-g’ argument 
to the simulation executable. This method is based on the rationale that 
spatially proximal agents are more likely to communicate than distal agents. 
Therefore, partitioning using this method often improves the speed up of 
parallelisation. 
Geometric partitioning offers a greater speed up for simulations where 
changes in 𝑥 , 𝑦  and 𝑧  co-ordinates are consistent between agents and 
sufficiently small. However, in the simulations presented in this thesis, 
generally, this is not the case. Furthermore, geometric partitioning can give 
CHAPTER 2: MATERIALS AND METHODS 85 
unbalanced loading between nodes, reducing performance. Therefore, round 
robin partitioning is used throughout this work. 
 
2.1.4 FLAME: Data Processing and Visualisation 
Data processing of model output was performed using self-designed C scripts 
or visualised using the FLAME visualiser developed previously by Dr Simon 
Coakley (downloadable from www.flame.ac.uk). State graphs and process 
order graphs, generated in the dotty language by FLAME, were visualised 
using the open-source software Graphviz, available from 
http://www.graphviz.org. 
 
2.2 POLYMERSOME ANALYSIS FOR AGENT-BASED MODELLING 
This section is dedicated to the conversion of the physical chemistry of 
nanoparticles, particularly polymersomes, into usable data within agent-based 
models.  
 
2.2.1 Size Analysis 
The models presented in this thesis are based around spherical 
nanoparticles. Therefore the major physical variable of these particles is size. 
In many in silico studies, size populations are given homogeneously as 
particles of a given size. However, most samples contain a distribution of 
sizes, known as a polydisperse population. These can be further filtered and 
separated into different sized subpopulations. These are then analysed by a 
number of different methods. The most commonly employed analytical 
techniques used within the Battaglia laboratory are dynamic light scattering 
(DLS), transmission electron microscopy (TEM) and Nanosight tracking 
analysis (NTA). TEM and NTA give particle-by-particle measurements of 
particle size and therefore can be directly used to create simulated particles of 
the measured sizes. However this can be limiting when simulating larger or 
smaller populations than that measured. DLS does not use individual particle 
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measurements, but rather measures scattering patterns of the population. The 
correlation of scatter patterns with the original measurement changes over 
time according to the rate of movement (Brownian motion) of the particles. 
This is then used to determine the size distribution through the Stokes-
Einstein equation that relates size to particle diffusion (Einstein, 1905). 
DLS distribution curves are generated by the sorting of particle size into size 
classes by the Zetasizer® software package. In order to achieve a single 
method for generating nanoparticle populations from size data, simple tools to 
place NTA and TEM data into the same size classes as output by Zetasizer® 
have been developed using MATLAB. The resultant size distributions are then 
used to generate simulated samples that fit the given distribution. First, the 
simulated nanoparticle agents are assigned to a size class based on 
probabilities calculated from the cumulative frequency data (See Figure 2.2A 
and 2B). The absolute size is then assigned by weighting the probability of 
sizes within the class by the neighbouring classes. Figure 2.2 demonstrates 
distributions of different sized polydisperse nanoparticles from DLS analysis 
(Figure 2.2C) and their respective simulated distributions (Figure 2.2D). 
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Figure 2.2: Simulation of DLS Distributions. Distribution of a nanoparticle 
population obtained by DLS analysis (A). Bar graph of probability of a given particle 
being within each size class (B). Distributions of multiple nanoparticle populations 
obtained from DLS analysis (C). and their simulated equivalent populations (D). DLS 
distribution data provided by Dr James Robertson and Dr Milagros Avila-Olias of the 
University of Sheffield, based on size separation of PMPC25-PDPA70 polymersomes. 
 
2.2.2 Calculating Polymer Number from Polymersome Size 
An estimate of the number of polymers (𝑵𝒂𝒈𝒈) per polymersome can be 
calculated from the hydrated particle radius (𝒓), monomer molecular weight 
(𝑴𝒘𝑷𝑶𝑳𝒀𝑴𝑬𝑹), polymer chain lengths (𝑳𝑷𝑶𝑳𝒀𝑴𝑬𝑹), polymer density (𝝆𝑷𝑶𝑳𝒀𝑴𝑬𝑹), 
particle membrane thickness (𝑴𝑵𝑷) and the particle brush length (𝑩𝑵𝑷). The 
membrane and brush are demonstrated in the anatomy of a polymersome in 
Figure 2.3. 
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Figure 2.3: Anatomy of a Polymersome. The graphic that this figure is adapted 
from was provided by Silvia Bianco. 
 
Density (𝝆) 
The density of polymers in an aqueous environment is difficult to determine 
due to the association with water in a hydrated form. Packing of the 
membrane and the pH-sensitive nature of PDPA polymer further complicate 
this. This is because the hydrophilic properties of PDPA are governed by its 
ionisation state. Given that the densities of polymers are usually similar to 
water, they can be estimated as having a density tending towards that of 
water (1.0 g·cm-3). Therefore density for PMPC and PDPA are considered as: 
 𝝆𝑷𝑴𝑷𝑪 = 1.0 g·cm-3 (1000.0 kg·m-3) 𝝆𝑷𝑫𝑷𝑨 = 1.0 g·cm-3 (1000.0 kg·m-3) 
 
Molecular Volume (𝑴𝒗𝑷𝑶𝑳𝒀𝑴𝑬𝑹) 
The molecular volume of a polymer can be calculated from the polymer 
density and the molecular weight of the polymer: 
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𝑴𝒗𝑷𝑶𝑳𝒀𝑴𝑬𝑹 = 𝑴𝒘𝑷𝑶𝑳𝒀𝑴𝑬𝑹𝝆𝑷𝑶𝑳𝒀𝑴𝑬𝑹𝑵𝑨𝑽𝑨𝑮𝑨𝑫𝑹𝑶          (2.1) (Battaglia and Ryan, 2005, Smart et 
al., 2009) 
 
MPC and DPA have a molecular weight of 295.5 g·mol-1 and 213.3 g·mol-1 
respectively. Therefore, for a standard formulation of PMPC25-PDPA70 (𝑳𝑷𝑴𝑷𝑪 
= 25 and 𝑳𝑷𝑫𝑷𝑨 = 70), you obtain the following molecular volumes: 
 𝑴𝒗𝑷𝑴𝑷𝑪 = 1.23×10!!" cm3 𝑴𝒗𝑷𝑫𝑷𝑨 = 2.36×10!!" cm3 
 
For the purpose of the later calculations, it is easier to convert the units to nm3 
by multiplying by 1021. 
 𝑴𝒗𝑷𝑴𝑷𝑪 = 12.3 nm3 𝑴𝒗𝑷𝑴𝑷𝑪 = 23.6 nm3 
 
Membrane Thickness (TNP) and Brush Length (BNP) 
The membrane thickness and brush length have been previously measured 
for polymersomes from transmission electron microscope (TEM) images and 
small angle x-ray scattering (SAXS) (Smart et al., 2009, Pearson et al., 2013) 
Battaglia JACS 2005). It was demonstrated that the membrane thickness 
scales with the molecular mass according to a power law with a 2/3 exponent: 
 𝑴𝑵𝑷 = 𝟎.𝟑𝟓𝟗(𝑳𝑷𝑫𝑷𝑨)𝟐𝟑          (2.2) 
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The constant 0.359 is derived from the membrane thickness (𝑴𝑵𝑷) of 6.1 nm 
measured for an 𝑳𝑷𝑫𝑷𝑨  of 77 in Pearson and colleagues by !.!!!!! = 0.359 
(Pearson et al., 2013). 
The hydrophilic brush thickness scales linearly with the number of repeating 
units in the hydrophilic block, according to a dense brush configuration. For 
PMPC25-PDPA70 polymersomes, the membrane thickness can be 
experimentally measured using TEM to be 6.1 nm. The POEGMA brush can 
be calculated assuming a fully stretched configuration, where a C-C bond is 
0.247 nm, giving a brush length of 6.187 nm (from 25×0.247).  
 
Polymer Chains per Polymersome (Nagg) 
The number of polymer chains per vesicle of radius 𝒓 can be calculated by 
first calculating the membrane volume (𝑴𝒗𝑵𝑷): 
 𝑴𝒗𝑵𝑷 = 𝟒𝟑𝝅((𝒓𝑵𝑷 − 𝑩𝑵𝑷)𝟑 − 𝒓− 𝑩𝑵𝑷 −𝑴𝑵𝑷 𝟑)          (2.3) 
 
Assuming a packing factor of 1, Equation 2.3 can be divided by the molecular 
volume of PDPA, thus giving: 
 
𝑵𝒂𝒈𝒈 = 𝟒𝟑𝝅((𝐫𝑵𝑷!𝑩𝑵𝑷)𝟑! 𝒓!𝑩𝑵𝑷!𝑴𝑵𝑷 𝟑)𝑴𝒗𝑷𝑫𝑷𝑨           (2.4). 
 
This is the method presented by Wang and colleagues (Wang et al., 2012). 
This is similar to the method presented by Massignani and colleagues, 
however their calculation is based on the surface area of the vesicle and area 
per molecule of the hydrophilic block as opposed to the volume (Massignani 
et al., 2009). 
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2.2.3 Calculating Ligand Density from Polymersome Size 
The number of polymer chains in the outer leaflet, particularly in smaller 
vesicles, is expected to be greater than in the inner leaflet. This can be 
explained by the ratio (𝑹𝑺𝑨) of the exterior membrane surface area (𝑬𝑺𝑨) and 
the interior membrane surface area (𝑰𝑺𝑨): 
 𝑹𝑺𝑨 = 𝑬𝑺𝑨𝑰𝑺𝑨           (2.5) 
 
For a vesicle this is equal to: 
 𝑹𝑺𝑨 = (𝒓!𝑩𝑵𝑷)𝟐(𝒓!𝑩𝑵𝑷!𝑴𝒃𝑵𝑷)𝟐          (2.6) 
 
As the polymersome size increases and 𝒓 becomes larger, this ratio tends 
towards 0. To estimate the difference in the number of chains between the 
inner and outer leaflet, a similar calculation was made using the inner volume 
of the membrane and the outer volume of the membrane, therefore: 
 
𝑵𝒂𝒈𝒈!𝒊𝒏𝒏𝒆𝒓 = 𝟒𝟑𝝅((𝒓!𝑩𝑵𝑷!𝑴𝑵𝑷𝟐 )𝟑! 𝒓!𝑩𝑵𝑷!𝑴𝑵𝑷 𝟑)𝑴𝒗𝑷𝑫𝑷𝑨           (2.7) 
 
𝑵𝒂𝒈𝒈!𝒐𝒖𝒕𝒆𝒓 = 𝟒𝟑𝝅((𝒓!𝑩𝑵𝑷)𝟑! 𝒓!𝑩𝑵𝑷!𝑴𝑵𝑷𝟐 𝟑)𝑴𝒗𝑷𝑫𝑷𝑨           (2.8) 
 
Ligands are covalently attached to the end of the polymer chains. The 
percentage of polymers used in formation is known from chemical analysis by 
high performance liquid chromatography (HPLC) and controlled by blending 
functionalised and non-functionalised polymers. Therefore using the estimate 
of the number of polymer chains in the outer leaflet (𝑵𝒂𝒈𝒈!𝒐𝒖𝒕𝒆𝒓) and the 
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percentage of functionalised polymer (𝑷%), the ligand density (𝑳𝑫) can be 
estimated: 
 
𝑳𝑫 = 𝑵𝒂𝒈𝒈!𝒐𝒖𝒕𝒆𝒓× 𝑷%𝟏𝟎𝟎%𝟒𝝅𝒓𝟐            (2.9) 
 
2.3 COMPUTATIONAL FLUID DYNAMICS 
2.3.1 Incompressible Form of the Navier-Stokes Equations 
The Navier-Stokes equations refer to three coupled partial differential 
equations (PDEs) with the vector equation for the conservation of momentum 
being: 
 𝝆 𝝏𝒖𝝏𝒕 + 𝒗 ∙ 𝜵𝒗 = −𝜵𝒑+ 𝜵 ∙ 𝝉+ 𝑭          (2.10) 
 
where ρ is the density, t is time, 𝜵 is the del operator, 𝒗 is the velocity, 𝒑 is the 
pressure, 𝝉  is the total stress tensor and F is the force. 
The continuity equation describing the conservation of mass can be 
expressed as: 
 𝝏𝝆𝝏𝒕 + 𝜵 ∙ 𝝆𝒖 = 𝟎          (2.11) 
 
while the equation for conservation of energy is: 
 𝝆𝑪𝒑 𝝏𝑻𝝏𝒕 + 𝒗.𝜵 𝑻 = − 𝜵.𝒒 + 𝝉:𝑺− 𝑻𝝆 𝝏𝝆𝝏𝑻 |𝒑 𝝏𝒑𝝏𝒕 + 𝒗.𝜵 𝒑 + 𝑸          (2.12) 
where Cρ is the specific heat capacity at constant pressure, T is the absolute 
temperature, q is the heat flux vector, S is the rate of strain tensor and Q is 
the heat sources.  
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In order to simplify the solutions to the Navier-Stokes equations, RBCs are 
treated as separate objects that influence flow by creating transient moving 
wall boundaries. Acellular blood (plasma) is a Newtonian fluid and therefore 
the fluid flow has been treated as Newtonian. Blood flow is incompressible, 
thus meaning the density of the fluid remains unchanged, such that: 
 𝝏𝝆𝝏𝒕 = 𝟎           (2.13) 
 
Therefore, by substituting Equation 2.13 into Equation 2.10 and Equation 2.11 
the incompressible Newtonian form for the conservation of momentum 
(Equation 2.14) and incompressible form of the continuity equation (Equation 
2.15) is achieved: 
 𝝆 𝝏𝒗𝝏𝒕 + 𝒗 ∙ 𝜵𝒗 = −𝜵𝒑+ 𝜼𝜵𝟐𝒗+ 𝑭          (2.14) 
 
where 𝜼  is the dynamic viscosity and 𝜵𝟐  is the Vector Laplacian. The 
incompressible form of the continuity equation is: 
 𝝆𝛁 ∙ 𝒗 = 𝟎           (2.15). 
 
Equation 2.13 also leads to decoupling of the energy Equation 2.12 from 
Equation 2.14 and Equation 2.15.  
 
2.3.2 Execution of the Galerkin/Least Squares Method in Comsol 
Multiphysics 
In order to find a solution to the Navier-Stokes equations the laminar flow 
package in the Comsol® Multiphysics software (License number 7074209) 
was used. Comsol Multiphysics uses a Galerkin/Least Squares (GLS) method 
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to resolve the Navier-Stokes equations. The GLS method is a variation of the 
FEM. The next section describes how the model was produced in Comsol. 
 
2.3.3 Geometry 
The vessel geometry was created using a regular cylinder of specified radius 
and height (Figure 2.4). 
 
  
Figure 2.4: Creating the Vessel Geometry in Comsol Multiphysics. 
 
The RBCs were placed at intervals dictated by the haematocrit, as cylinders 
with a radius and height of a RBC in a parachute conformation (Figure 2.5).  
 
CHAPTER 2: MATERIALS AND METHODS 95 
 
Figure 2.5: Creating the Red Blood Cell Geometry in Comsol Multiphysics. 
 
The vessel and RBCs are declared as separate entities by the 'difference' 
setting (Figure 2.6). 
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Figure 2.6: Setting the Difference in Geometry in Comsol Multiphysics. 
 
The resulting geometry is visualised in Figure 2.7. 
 
 
Figure 2.7: The Vessel Geometry in Comsol Multiphysics. A shortened section of 
the geometry in Comsol Multiphysics. 
 
2.3.4 Meshing 
In order to produce the finite elements within the geometry, the tetrahedral 
meshing setting was used with a 'fine' mesh setting, giving approximately 45 
elements·μm-3 depending on haematocrit levels (Figure 2.8). 
 
CHAPTER 2: MATERIALS AND METHODS 97 
 
Figure 2.8: Meshing the Geometry in Comsol Multiphysics. 
 
The resulting meshed geometry was visualised as Figure 2.9. 
 
 
Figure 2.9: Meshed Geometry in Comsol Multiphysics. 
 
2.3.5 Fluid Properties 
Blood plasma was treated as a Newtonian fluid with a variable viscosity 
related to the haematocrit and a density of 1060 kg·m-3 (Figure 2.10). 
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Figure 2.10: Setting Blood Material Properties in Comsol Multiphysics. 
 
The Navier-Stokes equations were applied to the fluid domain or blood 
plasma using the vessel and RBCs to create boundary conditions (Figure 
2.11). 
 
 
Figure 2.11: Setting the Material in which to Solve Laminar Flow in Comsol 
Multiphysics. 
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2.3.6 Boundary Conditions 
There are four main boundaries used within the laminar flow model presented 
in this thesis. The vessel walls were declared as non-slip boundaries with a 
velocity of 0 (Figure 2.12).  
 
 
Figure 2.12: Setting the No Slip Boundary in Comsol Multiphysics. 
 
The RBC walls were treated as moving boundaries at a rate of 60 μm·s-1 for 
normal conditions and 80 μm·s-1 for functional hyperaemia conditions (Figure 
2.13).  
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Figure 2.13: Setting the Moving Boundaries in Comsol Multiphysics. 
 
One end of the vessel was designated the inlet (Figure 2.14) and the other the 
outlet (Figure 2.15). The inlet and outlet were specified by pressure values. 
 
 
Figure 2.14: Setting the Inlet Conditions in Comsol Multiphysics. 
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Figure 2.15: Setting the Outlet Conditions in Comsol Multiphysics. 
 
Comsol Multiphysics uses the weak form of the Navier-Stokes equation and 
the generalised minimal residual method (GMRES) to solve flow within the 
defined geometry. GMRES is an iterative method of obtaining an approximate 
solution to the given problem (Figure 2.16). 
 
 
Figure 2.16: Configuring the Stationary Iterative Solver in Comsol Multiphysics 
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2.3.7 Execution of a Laminar Flow Model in FLAME 
The meshing from the Comsol Multiphysics solution for the Navier-Stokes 
equations was exported with co-ordinates (𝑥, 𝑦, 𝑧), velocity in all three planes 
(𝑉!, 𝑉!, 𝑉!), total velocity (𝑉!"#$%) and the shear stress (𝜏!). The MATLAB initial 
states generator used these values to build the mesh as a FLAME XMML file 
for implementation. In order to allow RBCs to move and not require re-
meshing, the nodes updated their location each iteration by the same distance 
traversed by the RBCs. This allowed a simple parallelisation of an FEM 
solution for laminar flow. 
Nanoparticle motion was given by Newton’s second law according to the 
velocity of the nearest element: 
 𝒎 𝝏𝟐𝒙𝝏𝒕𝟐 = 𝑭(𝒕,𝒙, 𝝏𝒙𝝏𝒕)          (2.16) 
 
where m is the mass, 𝝏𝟐𝒙𝝏𝒕𝟐  is the acceleration in 𝑥, 𝑭 the force, t the time and 𝑥 
the 𝑥-coordinate.  
 
2.4 SIMULATION OF BROWNIAN MOTION 
A simulation of the random walk, known as Brownian motion, can be achieved 
from environmental and particle specific properties as outlined by Andrews 
and Bray (Andrews and Bray, 2004). Using the Stokes-Einstein equation the 
diffusion coefficient (𝑫𝒄) can be calculated by: 
 𝑫𝒄 = 𝒌𝑩𝑻𝟔𝝅𝜼𝒓          (2.17) 
 
where 𝒌𝑩 is the Boltzmann constant, 𝑻 is the absolute temperature, 𝜼 is the 
dynamic viscosity and 𝒓  is the particle radius. 
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Andrews and Bray described methods to convert the diffusion coefficient into 
a standard deviation (σ) that can be used to plot a normalised distribution: 
 𝝈 ≡ 𝟐𝑫𝒄𝚫𝒕          (2.18) 
 
where 𝚫𝒕 is the time step. Thus giving the Gaussian for probability (𝑷) of a 
change in 𝑥-coordinate of 𝜟𝒙: 
 
𝑷 ≡ 𝟏𝝈 𝟐𝝅 𝒆(!𝜟𝒙𝟐𝟐𝝈𝟐)          (2.19) 
 
Then by generating random numbers that fit the normalised distribution, a 
random walk in the 𝑥-plane can be achieved. Random numbers that fit to a 
normalised distribution can be given by the Box-Muller transformation and 
variations of this method (Box and Muller, 1958). The polar method presented 
below is an adaptation of this method by Bell and Knop (Knop, 1969). It has 
advantages in its improved computational efficiency and robustness when 
used for stochastic modelling. Firstly two random numbers (𝒅𝟏 and 𝒅𝟐) are 
generated that satisfy the following: 
 −𝟏 ≤ 𝒅𝟏 ≤ 𝟏 
and −𝟏 ≤ 𝒅𝟐 ≤ 𝟏 
and  𝟎 ≤ 𝒅𝟏𝟐𝒅𝟐𝟐 ≤ 𝟏 
 
Then two numbers (𝑮𝟏 and 𝑮𝟐) are generated that satisfy a normal distribution 
with mean of 0 and standard deviation of 1 by the following: 
 
𝑮𝟏 = 𝒅𝟏 !𝟐𝒍𝒏  (𝒅𝟏𝟐𝒅𝟐𝟐)(𝒅𝟏𝟐𝒅𝟐𝟐)           (2.20) 
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𝑮𝟐 = 𝒅𝟐 !𝟐𝐥𝐧  (𝒅𝟏𝟐𝒅𝟐𝟐)(𝒅𝟏𝟐𝒅𝟐𝟐)            (2.21) 
 
These numbers can be converted to fit the given distribution by the following 
translation: 
 ∆𝒙 = 𝑮𝝈+ 𝝁          (2.22) 
 
where 𝝈 is the standard deviation previously calculated and 𝝁 is the mean, 
which for the random walk should be 0. The resulting value is then used as 
the change in 𝑥-coordinate. The repeating of this for the 𝑦- and 𝑧- coordinates 
then gives a 3D simulation of the random walk. Simple example codes of this, 
in C and in FLAME, are given in the Appendix II and III respectively. 
The random walk (𝑭𝑩) can be combined with the laminar flow (𝑭𝑳) model 
presented in the previous section by the addition of the movement vectors to 
give the total movement force (𝑭𝑻𝒐𝒕𝒂𝒍): 
 𝑭𝑻𝒐𝒕𝒂𝒍 = 𝑭𝑳 + 𝑭𝑩          (2.23). 
 
2.5 SIMULATION OF ROTATIONAL DIFFUSION 
A simulation of rotational diffusion can be achieved by similar methods to 
translational diffusion as described in the previous section. Firstly the 
rotational diffusion coefficient (𝑫𝒓) is calculated: 
 𝑫𝒓 = 𝒌𝑩𝑻𝟖𝝅𝜼𝒓𝟑           (2.24) 
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where 𝒌𝑩 is the Boltzmann constant, 𝑻 is the absolute temperature, 𝜼 is the 
dynamic viscosity and 𝒓  is the particle radius. Then the standard deviation 𝝈 
of Gaussian distribution is calculated: 
 𝝈 ≡ 𝟐𝑫𝒓𝚫𝒕           (2.25) 
 
where 𝚫𝒕 is the time step. The probability (𝑷) of a change in angle of theta 
(𝜟𝜽) can then be calculated by: 
 
𝑷 ≡ 𝟏𝝈 𝟐𝝅 𝒆(!𝜟𝜽𝟐𝟐𝝈𝟐)          (2.26). 
 
Random numbers can be generated to fit this distribution by the polar form of 
the Box-Muller transformation described in the previous section.  
Rotational diffusion is used to determine the location of points on the outer 
surface of the nanoparticle, such as receptors or an asymmetric patch. The 
new location of the point (𝒙′, 𝒚′) can be calculated from the original point (𝒙, y) 
and the angle of rotation (𝜽) by the rotation matrix: 
 𝒙′𝒚′ = 𝒙𝒚 𝒄𝒐𝒔𝜽 − 𝒔𝒊𝒏𝜽𝒔𝒊𝒏𝜽 𝒄𝒐𝒔𝜽            (2.27) 
 
therefore: 
 𝒙! =   𝒙 𝐜𝐨𝐬𝜽− 𝒚 𝐬𝐢𝐧𝜽           (2.28) 𝒚! =   𝒙 𝐬𝐢𝐧𝜽+ 𝒚 𝐜𝐨𝐬𝜽           (2.29). 
 
To achieve rotational diffusion, three angles are generated from the rotational 
diffusion coefficient, the angle around the 𝑧-axis (𝜽), around the 𝑥-axis (𝝋) and 
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around the 𝑦 -axis (𝝓 ). The 𝑥 , 𝑦  and 𝑧  co-ordinates of a point are then 
sequentially rotated around each angle to get the new co-ordinates. 
 
2.6 SIMULATION OF A DIRECTIONALLY BIASED NANOPARTICLE 
To simulate a directionally biased propelled particle, a point is assigned on the 
nanoparticle surface to act as the point of the asymmetric patch 
(𝑥!""#$,   𝑦!""#$,   𝑧!""#$), with propulsion occurring in the opposite direction to 
that point. This is in order to fit with the hypothesis of action of the formulation 
designed within the Battaglia group (Cecchin et al., 2014), as demonstrated in 
Figure 2.17. 
 
 
Figure 2.17: Schematic of a Chemotactic Polymersome. Graphic of a 
polymersome with an asymmetric patch (A) and a simple schematic of a modelled 
asymmetric point (B). 
 
Rather than updating the 𝑥-, 𝑦- and 𝑧- coordinates of the asymmetric patch 
every iteration, the patch is originally set to (0, -𝒓, 0), where 𝒓 is the particle 
radius. The angles of rotation (𝜃, 𝜑 and 𝜙) of the whole particle are held within 
the memory and updated each iteration, the location of the patch is then 
calculated from these only when required using the original point in order to 
maximise computational efficiency.  
(x,$y) (xAssym,$yAssym)
A B 
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The propulsion is then set in the opposite direction to the patch. The 
propulsion is given as a value in the positive 𝑦-direction (𝜑), thus given a 
propulsion vector of: 
 𝟎𝑷𝟎  . 
 
This is rotated sequentially around the angles of rotation to give the final 
propulsion vector (𝑭𝑷). This is then added to the Brownian motion vector (𝑭𝑩) 
to give a total movement vector (𝑭𝑻𝒐𝒕𝒂𝒍): 
 
 𝑭𝑻𝒐𝒕𝒂𝒍 = 𝑭𝑩 + 𝑭𝑷          (2.30). 
 
Similarly the propelled particle simulation can be combined with the laminar 
force model by adding the laminar force vector: 
 𝑭𝑻𝒐𝒕𝒂𝒍 = 𝑭𝑳 + 𝑭𝑩 + 𝑭𝑷          (2.31). 
 
2.7 CONSIDERATION OF BOUNDARIES 
Motile particles will encounter boundaries due to the compartmentalised 
nature of biological systems. There are a number of ways to approach the 
interaction of particles and boundaries. The most common is the reflective 
boundary, particles that cross the plane of the boundary are simply reflected 
back into the compartment, as seen in Figure 2.18. 
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Figure 2.18: Reflective Boundaries. Particle reflections at a straight (A) and curved 
(B) boundary. The initial trajectory of the particle (blue line) is reflected in the line of 
incidence (black dashed line) that is set at a distance of the particle radius (r) from 
the boundary (black solid line) for A or from the tangent (black dotted line) at the 
point of intersection for B. 
 
The reflective boundary is the most common type used within the simulations 
presented in this thesis, however the sticky boundary and deleting boundary 
are also used. Any particles that cross a sticky boundary are immobilised at 
the point of collision and can be quantitfied. The deleting boundary 
automatically deletes any agent that crosses it and is used at the exit of the 
vessel. 
 
2.8 SIMULATION OF RECEPTOR BINDING 
The binding and unbinding of a receptor was based on the model presented 
by Decuzzi and Ferrari with adaptations for agent-based modelling (Decuzzi 
and Ferrari, 2006). The probability (𝑷𝒇𝒐𝒓𝒎)  of a ligand binding to a receptor is 
given by: 
 𝑷𝒇𝒐𝒓𝒎 ≃ 𝟏− 𝒆!𝑹𝑫𝑳𝑨𝒄𝒌𝒂𝟎𝚫𝒕           (2.32) 
 
where 𝑹𝑫 is the receptor density on the cell surface, 𝒌𝒂𝟎  is the association 
constant at zero load per receptor-ligand pair, 𝑳𝑨𝒄 is the contact area for a 
r
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ligand on the cell surface and 𝚫𝒕 is the time step. The contact surface area for 
an individual ligand is given by: 
 𝑳𝑨𝒄 = 𝝅(𝑩𝑳𝟐 − 𝜹𝑳𝟐)      (2.33) 
 
where 𝜹𝑳  is the distance from the ligand nanoparticle surface, to the cell 
surface. 
The probability of a receptor-ligand bond rupturing (𝑷𝒃𝒓𝒆𝒂𝒌), when no shear 
flow is present is given by: 
 𝑷𝒃𝒓𝒆𝒂𝒌 ≃ 𝟏− 𝒆!𝒌𝑫𝚫𝒕           (2.34) 
 
where 𝒌𝑫 is the dissociation constant, given as the inverse of the association 
constant. 
In the presence of shear flow the probability of bond rupture can be given by: 
 
𝑷𝒃𝒓𝒆𝒂𝒌 ≃ 𝟏− 𝒆!𝒌𝑫𝚫𝒕𝒆𝑩𝑳𝑭𝒅𝒊𝒔𝑲𝑩𝑻𝑩𝑵            (2.35) 
 
where 𝑩𝑳 is the characteristic bond length, 𝑭𝒅𝒊𝒔 is the dissociating force, 𝒌𝑩 
is the Boltzmann constant, 𝑻 is the temperature and 𝑩𝑵  is the number of 
bonds. 
The total dissociating force is given by the addition of the drag force (𝑭𝒅) and 
half the torque force (𝑻𝒒): 
 
 𝑭𝒅𝒊𝒔 = 𝑭𝒅 + 𝑻𝒒𝟐            (2.36) 
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The drag force acting upon a spherical particle is related to the wall shear 
stress (𝑺𝝁), force as a function of aspect ratio (𝑭𝑺), the particle radius (𝒓) and 
the distance from the vessel wall and centre of nanoparticle mass (𝒍): 
 𝑭𝑫 = 𝟔𝝅𝒓𝒍𝑺𝝁𝑭𝑺           (2.37). 
 
The force as a function of aspect ratio is given as: 
 𝑭𝑺 = 𝟏+ 𝟏.𝟕𝟑𝟔− 𝟎.𝟏𝟑𝟖𝜸+ 𝟎.𝟏𝟐𝟖𝜸𝟐 + 𝟎.𝟎𝟗𝜸𝟑 𝒆!𝜸           (2.38) 
 
where 𝜸 is the aspect ratio of the nanoparticle (Pozrikidis, 1994). A spherical 
nanoparticle has an aspect ratio of 1, therefore: 
 𝑭𝑺 = 𝟏.𝟔𝟔𝟖           (2.39) 
 
and thus the drag force can be estimated as: 
 𝑭𝑫 = 𝟏𝟎𝝅𝒓𝒍𝑺𝝁          (2.40). 
 
The torque forces acting upon a nanoparticle can be similarly expressed as: 
 𝑻 = 𝟒𝝅𝒓𝟑𝑺𝝁𝑻𝑺           (2.41) 
 
where 𝑻𝑺  is the force as a function of the aspect ratio, given as: 
 𝑻𝑺 = 𝟏+ (−𝟐𝟎.𝟓+ 𝟒𝟔.𝟓𝜸− 𝟑𝟓.𝟏𝜸𝟐 + 𝟖.𝟗𝟓𝜸𝟑)𝒆!𝜸          (2.42) (Pozrikidis, 
1994). 
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For a spherical nanoparticle (𝜸 = 𝟏), this gives: 
 𝑻𝑺 = 𝟎.𝟗𝟒𝟓           (2.43) 
 
and a simplified approximation of the torque as: 
 𝑻 = 𝟑.𝟕𝟖𝝅𝒓𝟑𝑺𝝁          (2.44). 
 
The bond length in these studies was based on the bond length of the Lrp1-
angiopep-2 interaction. There is limited availability of structural data for the 
Lrp1 protein, therefore the bond length was estimated from the molecular 
weight (𝑴𝒘) of the extracellular Lrp1β chain (85 kDa) and Angiopep-2 (2.3 
kDa) as 6.5 nm using the methods presented by Erickson (Erickson, 2009, 
Martin et al., 2008). This method assumes that most proteins have a similar 
density of approximately 1.37 g·cm-3. The density can be used to find the 
partial specific volume (𝑷𝒓𝑺𝑷𝑽 ) of proteins. The average partial specific 
volume is given as 0.73 cm3·g-1. This is then used to calculate the volume 
(𝑷𝒓𝑽𝒐𝒍) from the density: 
 𝑷𝒓𝒗𝒐𝒍(𝒏𝒎𝟑) = 𝑷𝒓𝑺𝑷𝑽(𝒄𝒎𝟑·𝒈!𝟏)×𝟏𝟎𝟐𝟏(𝒏𝒎𝟑·𝒄𝒎!𝟑)𝟔.𝟎𝟐𝟑×𝟏𝟎𝟐𝟑(𝑫𝒂·𝒈!𝟏)            (2.45) 
 
which simplifies to: 
 𝑷𝒓𝒗𝒐𝒍 𝒏𝒎𝟑 = [𝟏.𝟐𝟏𝟐×𝟏𝟎!𝟑 𝒏𝒎𝟑 ·𝑫𝒂!𝟏 ]×𝑴𝒘(𝑫𝒂)          (2.46). 
 
Assuming the protein is a globular protein (spherical) this would give a length 
(𝑩𝑳) of: 
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𝑩𝑳 ≈ 𝟐× 𝟑𝑷𝒓𝒗𝒐𝒍𝟒𝝅𝟑            (2.47). 
 
This method gives a rough estimate of the length of Lrp1 as 5.8 nm and 
Angiopep-2 as 0.87 nm. Therefore the bond length was estimated at 6.5 nm. 
However, it would be expected that the bond length would be larger than this 
as it is unlikely that a receptor protein is also globular. However there would 
also be some expected overlap of the ligand and receptor in order to form a 
bond. Although this method is a relatively crude estimation of the bond length, 
other studies have used arbitrary values ranging from 1 nm to 20 nm, which 
can significantly influence the results. 
 
2.9 SIMULATION OF CELL TRAFFICKING 
After initial binding, nanoparticle endocytosis, trafficking and exocytosis was 
performed using the timings elucidated by Xiaohe Tian. After binding, 
nanoparticles that remained bound to the apical membrane for 10 s were 
endocytosed. Endocytosed particles were unable to bind for a further 10 s, 
before being exocytosed on to the basolateral membrane (Tian and Battaglia, 
unpublished). 
 
2.10 SIMULATION OF FENESTRATIONS 
Fenestrations were treated as uniform cylindrical channels of 500 nm in length 
and 60 nm in diameter for normal tissue or 240 nm for tumour tissue. 
Fenestrations agents were added into simulations by randomly distributing the 
agents to a density of 16 μm-2 on the outside of the vessel in line with data 
obtained from the endothelium of the pancreas (Milici et al., 1985), ensuring 
that no two agents were within 60 nm or 240 nm, for normal or tumour models 
respectively, from the nearest fenestration. Entry into the fenestration pore 
was treated as a passage event for simplicity.  
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2.11 STATISTICAL ANALYSIS 
Correlation of simulated and expected particle displacement was analysed 
through the two-tailed Pearson’s rank coefficient. All other tests for 
significance were analysed by the t-test using the Holm-Sidak method. 
Significance analysis was performed in Prism version 6.0f for Macintosh OS 
X, GraphPad Software, La Jolla California USA, www.graphpad.com. 
In Chapter 4, where ratios are calculated using the mean of nanoparticle 
binding events, the total error can be calculated as follows. When the ratio is: 
 𝑹 = 𝑵𝒙𝒚𝒛𝑵𝒒𝒓𝒔           (2.48) 
 
where 𝑵𝒙𝒚𝒛  is the mean of values 𝒙, 𝒚 and 𝒛 and 𝑵𝒒𝒓𝒔  is the mean of the 
values 𝒒,  𝒓 and  𝒔. The total error 𝑬 is calculated as: 
 
𝑬 = 𝑹 𝝈𝒙𝒙 + 𝝈𝒚𝒚 + 𝝈𝒛𝒛 + 𝝈𝒒𝒒 + 𝝈𝒓𝒓 + 𝝈𝒔𝒔            (2.49). 
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CHAPTER 3: RESULTS AND DISCUSSION I 
AGENT-BASED MODELLING OF NANOPARTICLE 
BEHAVIOUR UNDER BLOOD FLOW: INSIGHTS INTO 
DISTRIBUTION AND TARGETING TUMOURS 
 
3.1 INTRODUCTION 
3.1.1 Blood Flow in Capillaries 
Blood flow in the microvasculature affects the ability of blood-borne molecules 
to be distributed to the vessel walls and cross the endothelial wall into the 
tissue. Blood flow through capillaries is driven by the pressure difference 
between the pre-capillary pressurised arterioles and the post-capillary low-
pressure venules. Capillary flow is laminar, as defined by the Reynold’s 
number (𝑹𝒆), the ratio between viscous and inertial forces: 
 𝑹𝒆 = 𝝆𝒗𝑫𝑯𝜼           (3.1) 
 
where 𝝆 is the density, 𝒗 is the mean velocity, 𝑫𝑯  is the hydraulic diameter 
and 𝜼 the dynamic viscosity. Capillaries have a Reynold’s number of 0.001, 
well below the range of transient flow of ~2400, due to their small length 
scales and high viscosity (Cho and Cho, 2011). Laminar flow is characterised 
by flow in parallel layers with no mixing. Flow at the vessel wall is vastly 
reduced due to friction with the stationary vessel wall, called a non-slip 
boundary, with the velocity increasing towards the centre of the vessel in a 
parabolic manner, as seen in Figure 3.1.  
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Figure 3.1: Laminar Flow in a Pipe. Longitudinal cross-section of laminar flow 
along a pipe. 
 
3.1.2 Blood Flow and Brownian Motion in Capillaries 
In addition to laminar forces, other forces also act upon nanoparticles within 
the blood. In particular, thermal fluctuations, also known as Brownian motion, 
cause random movement of particles in relation to the thermal energy of the 
system. The displacement of particles is related to the diffusion coefficient 
(𝑫𝒄), calculated from the system thermal energy and the Stokes’ drag of the 
particles, by the Stokes-Einstein equation: 
 𝑫𝒄 = 𝒌𝑩𝑻𝟔𝝅𝜼𝒓           (3.2) 
 
where 𝒌𝑩 is the Boltzmann constant, 𝑻 is the absolute temperature and r is 
the particle radius. 
 
3.1.3 Red Blood Cells and Blood Flow 
The blood contains a high density of blood cells and cell fragments, including 
RBCs, white blood cells and platelets. RBCs are the most numerate blood 
cell, constituting 38-46% of the volume of blood, a measure referred to as the 
haematocrit. White blood cells make up about 1% of blood volume and 
platelets <0.5% of blood volume. In capillaries, the haematocrit is reduced to 
10-12%, reflecting the hydrostatic pressure (McWhirter et al., 2011). In its 
resting form, the RBC is a biconcave disk measuring ~7.8 μm in diameter, 
comparable to the size of capillaries. However, RBCs deform under shear 
stress into numerous conformations favourable for reduced resistance to flow 
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in restricted geometries (Skalak and Branemar.Pi, 1969, McWhirter et al., 
2009). The presence of RBCs creates complications in obtaining accurate 
solutions to the Navier-Stokes equations. RBCs confer non-Newtonian 
properties to the fluid. This means that the viscosity will alter under shear 
stress in a non-predictable way. This can be explained by the dependence of 
viscosity on shear-rate, haematocrit, RBC conformation, RBC aggregation 
and plasma viscosity (Schmid-Schönbein et al., 1969, Wells and Merrill, 
1962). These properties are also simultaneously related to the viscosity, 
therefore making complete solutions very difficult to obtain.  
 
3.1.4 Transport at the Vessel Wall 
At the vessel surface, nanoparticles can interact and traverse the endothelial 
layer in numerous ways. In many tissues, pores, called fenestrations, 
punctuate the microvasculature, which allows free exchange of many 
substrates. The structure, size and density of fenestrae differ from tissue to 
tissue depending on the function of the tissue itself. In early electron 
microscopy studies it was demonstrated that in the fenestrated endothelium of 
the pancreas, intestinal mucosa and kidneys, fenestrations were ~60 nm in 
diameter (Milici et al., 1985). Furthermore, these fenestrations can be 
considerably larger in vessels supplying tumours, with fenestrations reported 
from 200-1200 nm in size (Hobbs et al., 1998) (Alexis et al., 2008). However, 
in other tissues including at the blood-brain barrier, the vasculature is 
characterised by the lack of fenestrations (Abbott et al., 2010). The 
endothelial cells themselves can also regulate the exchange of numerous 
substrates between blood and tissue by receptor-mediated transport 
mechanisms and cellular trafficking. 
 
3.2 AIMS AND OBJECTIVES 
The aim of the work presented in this chapter was to implement an agent-
based model, using FLAME, of blood flow within a capillary encompassing 
thermal fluctuations. The design of this model must be able to take advantage 
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of FLAME’s intrinsic parallelisation optimisation to allow flexible addition and 
removal of specific functions in order to answer specific research questions, 
on top of the core blood flow functions. It is hypothesised that through the use 
of this model a further understanding of the fundamental role of capillary blood 
flow in distribution and uptake of nanoparticles can be gained. This model can 
then later be used to answer specific research questions related to 
nanoparticle transport at the blood-brain barrier. 
 
3.3 RESULTS AND DISCUSSION 
3.3.1 Building an Agent-based Model of Blood Flow 
Agent-based modelling has previously proven to be a powerful tool for 
predictive biological modelling. Its integration with more classic CFD 
approaches allows great potential for testing the blood flow dependent 
behaviour of nanoparticles. Blood flow dynamics in capillaries is integral for 
distribution and subsequent uptake of blood-borne molecules. It was aimed to 
create a simple core model that simulates blood flow with the intention of 
studying a variety of other processes, including but not limited to, nanoparticle 
distribution studies, receptor binding dynamics, the effect of ligand density, 
and cellular trafficking, plus the effect of varying flow conditions on all of the 
aforementioned (Chapters 4 and 5).  A summary of this is provided in the 
schematic in Figure 3.2. In this work, it was decided to use FLAME as the 
agent-based modelling platform. This was because of the ease of FLAME’s 
scalability onto high performance computing systems. This is due to a number 
of factors, discussed in detail in Chapter 1, in summary the programming in C 
that is ideal for high performance computing architectures. Furthermore, the 
lack of required MPI coding from user allows increasing accessibility of the 
model to less specialised programmers. Finally, FLAME’s ability to add and 
remove functions with ease to a core model with inherent speed up 
capabilities is a useful feature for the modelling work required in the whole of 
this thesis. 
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Figure 3.2: Flow Diagram of Model Functions. The flow diagram demonstrates the 
progression of functions in the model. Core functions that are conserved in all 
variations of the model are shown in blue, whilst optional functions that can be 
included in the model, at the user’s discretion, are shown in green. The optional 
functions can be added in a variety of combinations into the core model, to allow 
flexibility in modelling approach to reflect the experimental question. The functions 
within the dashed box are performed iteratively, where a single iteration is equivalent 
to the discrete passage of a set time-step 𝜹𝒕. 
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In the microvasculature, where RBC and capillary diameter are comparable, 
RBCs severely influence the fluid dynamics of blood flow. White blood cells 
and platelets are also present in the microvasculature; however, the reduced 
number of both cells compared to RBCs and the small size of platelets limits 
the influence of these cells. Therefore, this model concentrates on RBCs as 
the major driver of fluid dynamical changes in the microvasculature. Whilst 
inclusion of RBCs is important to flow modelling, direct modelling of RBC 
behaviours, such as deformation and aggregation, has been largely omitted. 
Previous studies have utilised several techniques, most notably immersed 
finite element methods, to incorporate RBC deformation and RBC interactions 
within flow models (Zhang et al., 2008a, Kaoui et al., 2009, Fedosov et al., 
2014). Although a similar approach could be utilised within the model 
described, the additional computational burden required would limit the 
capabilities of the model to include much of the desired additional 
functionality. In these theoretical studies and experimental observations, a 
number of RBC conformations have been described, including, the slipper-
like, the parachute, bullet-like and disk conformations. A number of these 
papers also produced phase-diagrams relating the conformation to other 
properties of the flow, such as shear stress, confinement and haematocrit 
(Fedosov et al., 2014, Kaoui et al., 2009). The slipper phase, according to the 
work of Fedosov and colleagues, occurs when both shear rates and 
confinement are low, however the shear rates and confinement parameters of 
these simulations favour the parachute conformation. Therefore the parachute 
conformation was adopted in consequent simulations. 
Several studies have demonstrated that both specific and non-specific 
interaction with proteins can affect the nanoparticle residency in the blood 
(Cedervall et al., 2007, Lundqvist et al., 2008). Protein interactions are 
dictated by the surface chemistry and charge. A common solution to this is to 
use a coating that reduces protein adsorption such as PEG or similar (Vittaz 
et al., 1996). This generally improves the systemic half-life and reduces 
immune cell interaction properties, thus increasing the potential therapeutic 
load at target tissues (Otsuka et al., 2003, Owens and Peppas, 2006). 
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However, as discussed in Chapter 1, PEGylation is unable to completely 
prevent protein absorption leading to potential alterations in nanoparticle 
properties, including size, surface charge and immunogenicity. Furthermore, 
other factors such as PEG length and nanoparticle shape are also important 
in protein absorption to nanoparticles. However for simplicity, in subsequent 
simulations it is assumed that nanoparticles will be inert. In previous studies, it 
has been demonstrated that certain compositions of nanoparticles can 
interact with both themselves and RBCs, with varying effects on distribution 
and cellular interactions (Chambers and Mitragotri, 2007). However, these 
properties are likely to be individual to the nanoparticle formulation used and 
therefore have been omitted from the model, except for a simple rule that 
neither can occupy the same space. However, specific interactions are easily 
implementable within the model at a later stage if appropriate. 
The laminar flow was evaluated by the Garlerkin/Least Squares FEM, using 
RBCs as moving boundaries at a rate of 60 μm.s-1. A diagrammatic summary 
of the model built is provided in Figure 3.3. A table of variables for the model 
is included in Table 3.1. 
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Figure 3.3: Model Summary Schematic.  The model focuses on a single capillary 
(ii) taken from the capillary bed (i). The model includes the effect of laminar flow (A) 
on RBCs in their native biconcave disk shape (B), causing the deformation of RBCs 
into a parachute conformation (C). This subsequently affects distribution and fluid 
dynamics of particles in the fluid-phase of the blood, which will in turn affect 
interactions at the vessel wall (D). At the interface of blood and vessel wall (iii), 
particles proximal to the vessel wall can pass through cellular junctions between cells 
or fenestrations, if present, within cells and therefore freely exchange with the 
interstitial fluid according to the diffusion gradient (E). Particles may bind 
corresponding proximal receptors on the endothelial cells (F), they may then be 
released or internalised and subjected to various cellular trafficking systems (G).
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Variable Description Symbol Typical Value 
Vessel Radius Radius of the Capillary 𝑽𝒓 4 μm 
Vessel Length Length of the Capillary 𝑽𝒍 800 μm 
RBC Radius Radius of RBC 𝑹𝑩𝑪𝒓 3.9 μm 
RBC Width Width of RBC 𝑹𝑩𝑪𝒘 2.5 μm 
Haematocrit % RBCs/Blood (v/v) 𝑯% 10-12 % 
RBC Number Number of RBC Agents to 
Reflect Haematocrit 
𝑹𝑩𝑪𝒏  
Nanoparticle 
Radius 
Radius of Nanoparticle 𝒓 10-200 nm 
Arteriole 
Pressure 
Pressure at Arteriole End of 
Capillary 
𝒑𝒂 1500-3000 Pa 
Venule 
Pressure 
Pressure at Venule End of 
Capillary 
𝒑𝒗 1000 Pa 
Pressure 
Difference 
Pressure difference from 
arteriole to venule end of 
the capillary 
𝒑∆ 500-2000Pa 
Dynamic 
Viscosity 
 𝜼 See Figure 3.10 
Temperature Absolute Temperature 𝑻 310 K 
Boltzmann 
Constant 
 𝒌𝑩 1.381E-23 m2 kg s-2 K-1 
Cartesian 
Coordinates 
 𝒙,𝒚, 𝒛  
Time Step Time step per iteration 𝚫𝒕 0.0001 (laminar) and 
0.000001 (Brownian 
motion) 
Velocity Absolute velocity [in 𝒙  𝒚  𝒛] 𝒗  [𝒗𝒙,𝒗𝒚,𝒗𝒛]  
Density Density of Fluid 𝝆 1060 kg m-3 
Stress Sensor Shear Stress 𝝉  
Force Force [Laminar, Brownian] 𝑭[𝑭𝑳,𝑭𝑩]  
Dispersion 
Factor 
Dispersion Factor, Average 
Dispersion Factor 
𝝑𝑫,𝝑𝑫 0 to 1 
Element 
Number 
Number of Elements for 
Finite Element Method 
𝑬𝒏  
Mass Nanoparticle Mass 𝒎  
Diffusion 
Coefficient 
 𝑫𝒄  
Table 3.1: Names, Denotations and Typical Values of Key Values with the 
Model. Typical values are given, where appropriate, from information available in the 
literature. 
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3.3.2 Agent-based Modelling of Brownian Motion 
Flow in capillaries is influenced by both laminar forces and thermal 
fluctuations referred to as Brownian motion. In order to create a model of the 
random walk characteristic of Brownian motion, the methods described by 
Andrews and Bray were used (Andrews and Bray, 2004). These methods 
utilise the diffusion coefficient of a particle to generate a Gaussian curve that 
describes the probability of a particle displacing a certain distance in a single 
plane in a discrete time step. The random walk in 1D can be achieved by 
generating random numbers that fit to the given Gaussian using the polar form 
of the Box-Muller transformation (Box and Muller, 1958, Knop, 1969). 
Repeating this for the extra dimensions can create 2D and 3D random walks 
(More details of this are included within Chapter 2.). To validate this method, 
1000 random numbers that fit a Gaussian of mean 0 and standard deviation 1 
were generated using the polar form of the Box-Muller transformation.  This 
was used to generate the observed frequency of number ranges and plotted 
against the expected Gaussian, as seen in Figure 3.4. This demonstrated that 
this implementation of the polar form of the Box-Muller gave a highly 
significant agreement with the expected Gaussian, with a calculated 
Pearson’s correlation coefficient (rP) of 0.9998 and a P value of <0.0001. 
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Figure 3.4: Testing the Implementation of the Polar Box-Muller Transformation. 
The frequency probabilities of the expected Gaussian curve of mean 0 and standard 
deviation 1 and that observed from the given implementation of the polar Box-Muller 
transformation. 
 
This demonstrated that the Box-Muller transformation implementation could 
then be used to generate random normally distributed numbers for simulation 
of the random walk. To confirm that this method was suitable, the mean 
squared displacement (MSD) of particles over time (𝒕) was calculated using 
the equation: 
 𝑴𝑺𝑫 𝒕 = 𝒒 𝒕 − 𝒒(𝟎) 𝟐 (3.3) 
 
where 𝒒 𝒕  is the position of the particle at time 𝒕 and 𝒒(𝟎) is the position of 
the particle at time 0. The MSD is related to the diffusion coefficient through 
the relationship: 
 𝑴𝑺𝑫 = 𝒌𝑫𝒄 (3.4) 
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where 𝒌 is a constant of dimensionality of 2 for 1D, 4 for 2D or 6 for 3D. 
Therefore the calculated MSD can be compared to the expected displacement 
based on the particles diffusion coefficient, as demonstrated in Figure 3.5. 
 
 
Figure 3.5: Validation of the Random Walk in 3D. The mean squared deviation of 
simulated particles of different diameters, compared to the expected mean squared 
deviation from the diffusion coefficient. All samples are significant as tested by the 
Pearson’s rank correlation coefficient; the coefficient for each size is indicated (rP). 
 
Figure 3.5 demonstrates that, for all sized particles tested, an excellent 
correlation is apparent between expected and observed mean squared 
deviations with correlation coefficients of all >0.9995 and P values < 0.0001. 
Furthermore, to demonstrate that the simulation of the random walk produced 
by the model is reflective of that of actual nanoparticles, particle traces were 
compared with those from similarly sized nanoparticles from Nanosight® 
tracking analysis, provided by Anna Puiggalí Jou (Figure 3.6). 
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Figure 3.6: Nanoparticle Traces of Simulated Nanoparticle and Tracked 
Nanoparticle Motion. Comparison of simulated nanoparticles of different diameters 
with equivalent sized nanoparticles tracking using Nanosight Tracking Analysis. 
Scale bar=2 μm, 𝒕=1.17 s, 𝚫𝒕=0.039 s, 𝜼=0.00069 Pa. s, 𝑻=310 K. 
 
Figure 3.6 demonstrates a good concordance of traces from the nanosight 
tracking analysis with the simulations of the random walk. Generally the 
distance travelled in each time step and across the whole time period gets 
shorter as particle size increases, due to the increased Stokes’ resistance of 
the larger particles. The direction of each step is random in both the 
simulations and the tracking analysis, demonstrating that this method can be 
used for simulating the random walk. 
 
3.3.3 Parallelisation of the Capillary Blood Flow Model 
In order to test the parallelisation of the capillary model built using FLAME, a 
number of test simulations were run across different numbers of cores on the 
White Rose Grid Iceberg High Performance Computing Cluster at the 
University of Sheffield. Iceberg was chosen due to the ease of access, its use 
in developing FLAME and the extensive previous use of FLAME applications 
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on Iceberg (Kiran et al., 2011). It should be noted, however, that FLAME has 
also been tested on a large number of other architectures including SCARF, 
HAPU, NW-Grid, HPCx and bglogin2 (Chin et al., 2012). The runtimes were 
plotted in Figure 3.7A and demonstrates that the speed up is good up until 8-
12 cores, thereafter the simulation time plateaus. Moreover, whilst the core 
hours used is efficient with a small number of cores (up to 16), thereafter the 
number of core hours used rises steadily until it is using 4.4-times the number 
of core hours for 16 cores and 5.7-times the number of core hours for 32 
cores (Figure 3.7B). Therefore, all simulations were run across eight cores 
hereafter to obtain the lowest simulation time using the least computational 
resources. Furthermore, the use of 8 cores compared to ≥10 cores also 
reduced queuing time through the Son of Grid Engine queue system 
employed on Iceberg. 
 
 
Figure 3.7: Parallelisation of the Capillary Blood Flow Model. The runtime of 
simulations (A) and the core hours (B) against the number of cores are plotted in blue 
(solid). The hypothetical runtime (A) and core hours (B) of simulations with maximum 
speed up is demonstrated in black (dashed). Each data point represents the mean ± 
standard deviation of three simulations (n=3). 
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3.3.4 Brownian Forces become the Dominant Force at the Vessel Wall 
Interface 
To validate the correct operation of the finite element method used, heat maps 
were produced of flow velocity in longitudinal (Figure 3.8A) and latitudinal 
(Figure 3.8B and 3.8C) vessel slices at a physiologically relevant haematocrit 
of 10.7% (McWhirter et al., 2011). The heat maps demonstrate a clear 
relationship between proximity to the vessel wall and a decrease in flow 
velocity (Figure 3.8B). In regions containing RBCs, flow velocity is increased 
around the cells as they move at slower rates than the fluid phase (Figure 
3.8C).  
 
 
Figure 3.8: Heat Mapping of Laminar Forces. Longitudinal cross-section (A) 
demonstrating velocity of blood flow along the vessel, with latitudinal cross-sections 
proximal to the red blood (B) cell and distal to the RBC (C). 
 
Next, a comparison of the various influences of Brownian motion and laminar 
flow on final nanoparticle movement was made in different regions of the 
vessel. Typical nanoparticle traces for Brownian motion (Figure 3.9A and 
3.9B) alone, laminar flow alone (Figure 3.9C and 3.9D) and laminar flow with 
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Brownian motion (Figure 3.9E-H) are shown for a 100 nm nanoparticle at the 
centre of the vessel and the edge of the vessel. At the centre of the vessel, 
laminar forces are expected to be high (𝑣 = 5500  𝜇𝑚  𝑠!!) as it is furthest 
away from the non-slip boundary. The relative impact of Brownian forces 
(Figure 3.9A) is therefore consequently very small, relative to the laminar 
forces (Figure 3.9C), leading to only minor fluctuations from laminar flow 
(Figure 3.9E and 3.9G). However at the vessel wall (Figure 3.9D), the flow 
velocity is vastly reduced (𝑣 = 440  𝜇𝑚  𝑠!! ), thus making Brownian forces 
more significant to the displacement of the particle (Figure 3.9B, 3.9F and 
3.9H). This is summarised by the relative contributions of Brownian and 
laminar forces to the total MSD of nanoparticles at low and high shear flow 
(Figure 3.9I). At low laminar forces, Brownian forces contribute almost equally 
to laminar forces in the displacement of the particle, where as the relative 
contribution of Brownian forces at high laminar forces is negligible. The 
dominance of Brownian forces and reduction in laminar forces allows 
maximum contact time between potential substrates and the vessel wall 
interface. It also allows nanoparticles proximal to the vessel wall but not within 
binding range to diffuse closer to the vessel wall, thereby permitting binding. 
Although not included in the current model, the significance of Brownian 
forces at the vessel wall is likely to be further increased by the presence of a 
gel-like layer at the cell wall called the glycocalyx. This layer consists of 
glycosylated proteins (glycoproteins) and lipids (glycolipids) that can project 
200-500 nm within the vessel. It can also regulate accessibility of various 
blood components to the wall based on particle properties such as charge and 
size (van den Berg et al., 2003). 
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Figure 3.9: Balance of Brownian to Laminar Forces. 100 nm nanoparticle traces 
under only Brownian motion (A and B), only laminar flow (C and D) and both 
Brownian and laminar forces (E and F [single nanoparticle], G and H [ten 
nanoparticles]) at the edge (B, D, F and H) and centre (A, C, E and G) of the vessel. 
The relative contribution of laminar (FL) and Brownian (FB) forces to the mean 
squared displacement at low laminar and high laminar force is demonstrated (I). 
(Time = 0.003 s, Δt = 0.0001 s). Each data point represents the mean ± standard 
deviation of 10 simulations (n=10). 
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3.3.5 Red Blood Cells enhance Nanoparticle Dispersion 
In order to see the effect that RBCs have on flow dynamics and subsequent 
nanoparticle dispersion, the behaviour of nanoparticles at varying 
haematocrits was studied. State and process order graphs, produced by 
FLAME, for the parallel execution of these simulations are provided in Figure 
3.10.  
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Figure 3.10: FLAME State and Process Order Graphs of the Core Model. The 
state graph (A) demonstrates the dependency of functions on both previous functions 
and messages for parallelisation of the core model. The process order graph (B) 
shows the order in which FLAME prioritises the functions to reduce the lag from using 
the message passing interface. 
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The haematocrit range used was from acellular (0%) to whole blood (45%), 
including a high density of simulations at the physiologically relevant range for 
a capillary (10-12%). The viscosity used in resolving the Navier-Stokes 
equations was related to the haematocrit in order to account for the non-linear 
increase in viscosity usually observed with higher haematocrit (Figure 3.11). 
 
 
Figure 3.11: The Relationship between Haematocrit and Viscosity. The viscosity 
used in the models is given by a relationship between haematocrit and viscosity. 
Capillary and whole blood haematocrits are indicated. 
 
Figure 3.12A shows the average position of a nanoparticle relative to the 
centre of a 4000 nm vessel, as a function of haematocrit. At haematocrits of 
0%, an even dispersion of nanoparticles would be expected, giving a 
theoretical average of ~2700-2800 nm with a nanoparticle diameter of 100 
nm. However, it would be expected that this value would increase due to 
volume exclusion with increasing number of RBCs located towards the centre 
of the vessel, as observed in Figure 3.12A. Furthermore, to correlate this with 
likelihood of increased delivery, the percentage of all nanoparticles that would 
be within a binding range of the vessel wall (Figure 3.12B), given as 20 nm 
from the proximal edge of the nanoparticle to the vessel wall, was quantified. 
A marked increase is observed with increasing haematocrit, particularly 
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across the physiologically relevant range, further demonstrating that RBCs aid 
the dispersion of nanoparticles to the vessel wall.  
 
 
Figure 3.12: The Effect of Haematocrit on Nanoparticle Distribution. The 
increased dispersion of nanoparticles to the vessel edge as a function of increasing 
haematocrit is demonstrated by, the average distance from the centre of a 4000nm in 
radius capillary (A) and percentage of nanoparticles within 20 nm of the vessel wall 
(B). Capillary and whole blood haematocrit ranges are indicated. Each data point 
represents the mean ± standard deviation of three simulations (n=3). 
 
The increase in haematocrit also had an effect on the average velocity of 
nanoparticles across the whole vessel (Figure 3.13A) and for nanoparticles 
within 20 nm of the vessel wall (Figure 3.13B). It can be expected that this 
would influence both the motion of particles at the vessel wall, as it alters the 
laminar-Brownian force ratio, and their subsequent transport at the vessel 
surface, due to increased wall shear stress.  
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Figure 3.13: The Effect of Haematocrit on Nanoparticle Velocity. The average 
velocity of, all nanoparticles within the vessel (A) and only nanoparticles within 20 nm 
of the vessel wall (B), as a function of haematocrit. Mean ± standard deviation, n=3. 
 
Similar conclusions, demonstrating improved nanoparticle distribution with 
higher haematocrit, were made by Tan and colleagues using both simulations 
and microfluidics as a method of validation (Tan et al., 2012). Whilst their 
conclusions are similar, they focus on scenarios in the presence or absence 
of RBCs, using a haematocrit of 38% (in silico) and 36% (microfludic 
experiments), which is considerably higher than the 10-12% expected in 
capillaries. Therefore, it is unclear from this work whether this observation 
would be as significant in more physiological conditions. Furthermore, the 
vessels used in their study were bigger than that described here (20 μm and 
11 μm compared to 8 μm), making immediate comparison of data difficult.  
To further study the flow dynamics with differing haematocrits, an average 
dispersion factor was calculated for vessels with varying haematocrit. The 
dispersion factor is the ratio between radial velocity (towards the vessel edge) 
and the longitudinal velocity (towards the end of the vessel) at a given 
element, with the radial velocity (𝑽𝒓) being: 
 
𝑽𝒓 = 𝑽𝒙𝟐 + 𝑽𝒚𝟐         (3.5)  
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where 𝑽𝒙 is the velocity in the 𝑥-direction, 𝑽𝒚 is the velocity in the 𝑦-direction. 
The Dispersion Factor (𝝑𝑫) can be thus defined as: 
 𝝑𝑫 = 𝑽𝒓𝑽𝒛         (3.6)  
 
where 𝑽𝒛 is the velocity in the 𝑧-direction, similarly the average dispersion 
factor (𝝑𝑫) can be given as: 
 𝝑𝑫 = 𝝑𝑫𝑬𝒏          (3.7) 
 
where 𝑬𝒏 is the number of elements.  
A dispersion factor of 0 would indicate that flow is parallel to the vessel wall, 
giving no dispersion, whereas, any increase in dispersion factor would show 
the presence of trajectories away from parallel to the vessel wall. Figure 3.14 
demonstrates an initial increase in the average dispersion factor as a function 
of haematocrit. However, above haematocrits of 20-25%, this then falls and 
tends back towards 0. This would indicate that an intermediate range of 
haematocrit could be better for allowing maximum dispersion of nanoparticles 
towards the edge of the vessel.  
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Figure 3.14: The Effect of Haematocrit on Dispersion. The average dispersion 
factor is shown as a function of increasing haematocrit. Capillary and whole blood 
haematocrit ranges are indicated. Each data point represents the average dispersion 
factor calculated from a single Comsol simulation (n=1). 
 
To understand why the average dispersion factor shows increased dispersion 
from lower haematocrits to higher, further observation of flow dynamics was 
performed using heat mapping of the dispersion factor at individual elements. 
Figures 3.15A, 3.15B and 3.15C are schematics of the three dominant flow 
streamlines observed throughout the simulations imposed on heat maps of 
the velocity in the y-axis (perpendicular to the vessel). In Figure 3.15A, in the 
absence of RBCs, flow can be considered to be a Poiseuille’s flow and will 
result in an expected and observed average dispersion factor of 0. Figure 
3.15B demonstrates that flow, in the presence of an intermediate haematocrit, 
will manoeuvre around the RBCs and will lead to the observed increase in 
average dispersion factor. However, at higher haematocrits, the space 
between RBCs is significantly reduced, and as such, two separate phases are 
formed (Figure 3.15C). A cellular-phase is formed where, due to the reduced 
space between RBCs, flow between RBCs occurs at the same velocity as that 
of the RBCs. A separate cell-free phase is created at the edge of the vessel; 
the flow of this phase occurs such that the cellular-phase resembles flow past 
a cylinder moving at a rate equal to the RBC velocity. Interaction between the 
two phases becomes minimal as the space between RBCs is reduced, 
consequently resulting in the decline of average dispersion factor observed 
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with increasing haematocrit above 20-25% in Figure 3.14. A similar but less 
defined pattern in flow is also apparent in the work of Tan and co-workers and 
McWhirter and colleagues (Tan et al., 2012, McWhirter et al., 2009). 
 
 
Figure 3.15: The Effect of Haematocrit on Fluid Dynamics in a Capillary. 
Streamlines of different types of flow observed and heat maps of the velocity in the y-
plane are shown with respect to haematocrit, at no haematocrit (H% = 0) a one phase 
Poiseuille’s flow (A), at 10.7% representative of intermediate haematocrits (0 < H% < 
20) an interacting flow between cellular and cell-free layers (B) and at a haematocrit 
of 38% representative of high haematocrits (H% > 20) separate cellular and cell-free 
layers (C). 
 
The consequence of a low average dispersion factor is that only nanoparticles 
already proximal to the vessel edge can be transported across the vessel 
wall. However with higher average dispersion factors, nanoparticles at the 
centre of the vessel will be transiently dispersed from the centre to the vessel 
edge and vice versa with flow. This permits a greater number of nanoparticles 
the opportunity to be transported at the vessel wall. 
The effect of haematocrit on uptake from the blood hasn’t been studied 
directly in vivo. However, in perfusion studies of the rat liver with different 
haematocrits both oxygen uptake and galactose elimination were reduced 
(Keiding et al., 1980). Though the reduction in the uptake of oxygen could be 
expected given the role of red blood cells in oxygen transport, the reduction in 
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galactose elimination may suggest that with reduced haematocrit there is 
reduced uptake of galactose from the blood, in line with the results of our 
simulations. However, it is important to note that as oxygen is important in 
metabolism, the galactose elimination reduction could be a secondary effect 
of the reduced oxygen uptake. 
 
3.3.6 Nanoparticle Size Selectively Targets Delivery to Tumour Tissues 
In order to demonstrate the flexibility and efficacy of the model in aiding the 
design of nanoparticles, the ability to increase specificity of nanoparticles for 
tumours was tested. A key factor in nanoparticle efficacy is their ability to 
selectively target the tissue of interest, whilst avoiding potential off-target 
effects at other tissues. The design of these simulations was to test the ability 
of different sized nanoparticles to traverse fenestrations with pore size 
corresponding to both normal vessels and tumour vessels. In line with the 
work of Milici and co-workers, a fenestration size of 60 nm for normal tissue 
was used and a relatively conservative size of 240 nm was used for tumours, 
in line with the values reported by Hobbs and colleagues (Figure 3.16) (Hobbs 
et al., 1998, Milici et al., 1985). It should be noted that tumour fenestrations 
can be considerably larger than that used in these simulations, however due 
to the heterogeneous nature of tumour fenestrations it was believed prudent 
to use a fenestration size towards the lower end of the range reported for this 
proof-of-principle study. In future work, use of more exact ranges for particular 
tumour types and the ability to account for heterogeneity in fenestration size 
could be included within the model. 
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Figure 3.16: Morphology of Fenestrations in Normal and Tumour Vessels. 
 
The core model described previously was utilised using a haematocrit of 
10.7%, with the inclusion of a fenestration agent and function to add 
fenestrations to the vessel wall. The relevant state and process order graphs, 
generated by FLAME, for this model can be seen in Figure 3.17. 
 
240 nm 60 nm 
Normal Vessel Tumour Vessel 
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Figure 3.17: FLAME State and Process Order Graphs of the Fenestration 
Model. The state graph (A) demonstrates the dependency of functions on previous 
functions and messages for parallelisation of the fenestration model. The process 
order graph (B) shows the precise order in which FLAME prioritises the functions to 
reduce the lag from using the message passing interface. 
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Nanoparticle sizes used were 10 nm, 20 nm, 50 nm, 70 nm, 80 nm, 100 nm 
and 160 nm. Polydisperse samples were also generated to correspond to 
nanoparticle populations measured using dynamic light scattering analysis 
(see Figure 3.18).  
 
 
Figure 3.18: Simulating Polydisperse Nanoparticle Distributions from Dynamic 
Light Scattering Data. Size distributions from DLS Zetasizer software (A) and their 
corresponding simulated distributions (B) analysed and plotted in the same manner. 
 
Polydisperse populations with an average diameter corresponding to 20 nm, 
50 nm, 70 nm, 100 nm and 160 nm (Figure 3.19) were chosen to compare 
with the equivalent monodisperse samples and more importantly, with data 
expected from corresponding biological experiments.  
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Figure 3.19: Polydisperse Nanoparticle Populations. Polydisperse nanoparticle 
populations generated from DLS size data were used alongside monodisperse 
populations of the average sizes, fenestration sizes are indicated by dashed lines. 
 
Figure 3.20 demonstrates that across all size ranges, delivery across tumour 
vessel fenestrations is vastly increased compared to normal capillaries. 
Furthermore efficient delivery is still achieved with nanoparticles at 50 nm, 70 
nm, 80 nm and 100 nm, where little or no delivery is achieved across normal 
fenestrations, suggesting that this size range can improve specific delivery to 
tumour tissue.  
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Figure 3.20: Uptake of Nanoparticles across Normal and Tumour Capillaries. 
The percentage uptake after 0.5 s is compared between normal fenestrations and 
tumour fenestrations for monodisperse (Md) and polydisperse (Pd) nanoparticle 
populations. Each data point represents the mean ± standard deviation of three 
simulations (n=3). 
 
This concept, called the EPR effect or passive-targeting, has been proven 
previously in many studies (Bogdanov et al., 1997, Iyer et al., 2006). In these 
studies an important feature was the half-life of the nanoparticle, which is 
related to size, shape and surface chemistry. The EPR effect has been used, 
to good effect, to increase the tumour penetration of several well-known anti-
cancer drugs including doxorubicin and Taxol. Gradishar and colleagues 
demonstrated that in Stage III clinical trials, administration of albumin-based 
130 nm nanoparticles bound to Taxol performed signficantly better than Taxol 
controls (Gradishar et al., 2005). Sabbatini and co-workers, likewise, 
demonstrated an improved response in patients subjected to the higher 
molecular weight poly-L-glutamic acid conjugated Taxol (~80000Da) 
(Sabbatini et al., 2004). Vasey and colleagues used N-2-
(hydroxypropyl)methacrylamide conjugated doxorubicin (Mw= 30000 Da) and 
demonstrated anti-tumour activity in Phase I studies (Vasey et al., 1999). 
Doxil® is a commercially available liposome-encapsulated doxorubicin of size 
87 nm. It is a PEGylated particle giving a half-life of 50-60 hours in human 
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blood (Soundararajan et al., 2009). A general feature of these studies was to 
raise the molecular weight above the rate of blood extravasation, thus 
improving blood circulation times, giving enhanced uptake in tumours in 
agreement with the data shown in this chapter. Generally sizes between 40-
100 nm have previously been demonstrated to persist in the blood due to 
reduced loss caused by blood extravasation and filtration by the 
reticuloendothelial systems of the liver, spleen and kidneys (Maeda et al., 
2000, Fang et al., 2011, Alexis et al., 2008). The results for specific delivery to 
a tumour fall within this range, thus making the data more significant with 
respect to translation from simulation to experimental data.  
A comprehensive systematic study of the EPR effect, looking at 
characteristics such as size, shape and surface chemistry is lacking. 
However, the work of Meng and co-workers did look at factors including size 
and surface chemistry by studying the uptake of three composition of 
mesoporous silica nanoparticles, NP1, NP2 and NP3 (Meng et al., 2011). NP1 
is a 100 nm nanoparticle that aggregates into large agglomerates in saline 
(520 nm) and media (306 nm in DMEM). NP2 is a smaller PEGylated 
nanoparticle of 70 nm that again aggregated in saline (597 nm). NP3, 
however, was a 77 nm nanoparticle that only swelled to 110 nm in saline. It 
was demonstrated that NP3, also based on PEG, accumulated significantly 
better in tumours in vivo than NP1 or NP2, reaching ~12% of injected dose. 
NP1 was sequestered, predominantly by the liver and spleen, consistent with 
removal of large particles by the RES. NP2 and NP3, however, demonstrated 
increased circulatory half-life, likely a result of the surface modification with 
PEG. NP2 demonstrated a reduced uptake in the tumour tissue, which may 
suggest that the large aggregates reduced these particles from crossing 
tumour fenestrations. 
It should be noted that whilst irregular and larger fenestrations have been 
reported at tumour vasculature, fenestration density changes, irregular flow 
and poor cellular junction formation are also characteristic of tumour 
vasculature, inevitably influencing overall uptake into tumour tissues (Fang et 
al., 2011). As a consequence of the leaky vasculature and reduced lymphatic 
CHAPTER 3: RESULTS AND DISCUSSION I 146 
system in tumour tissue, interstitial fluid pressure (IFP) is increased in tumour 
tissue. In normal tissue a convection flow occurs from the pressurised vessel 
to the non-pressurised tissue. However, the rise in IFP prevents this 
convective flow from the blood to tumour tissue, reducing extravasation to by 
diffusion only and as such partly negates the beneficial delivery of the EPR 
effect, causing a significant hurdle in cancer therapy (Jain and Stylianopoulos, 
2010, Heldin et al., 2004, Wiig and Swartz, 2012). In the simulations 
presented in this chapter, convective flow across fenestrations is not 
considered, but would likely increase the uptake of nanoparticles into normal 
tissue, below the fenestration cut off, where the lack of IFP encourages 
uptake. This highlights the importance of using nanoparticles above the cut off 
range normal fenestrations but below that of tumour tissues. In future work, 
consideration for the IFP could be included within the model. However, as 
most of the work considered in this thesis focuses on the blood-brain barrier, 
where free exchange is vastly reduced, it has not been included in the model 
presented to reserve computational power for other functions. 
In the analysis of polydisperse nanoparticle uptake, a marked difference in 
size between those entering fenestrations and those in the vessel was 
observed (Figure 3.21), with smaller sizes being taken up more readily as 
would be expected from the filtration effect observed in Figure 3.20.  
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Figure 3.21: Filtration Effect of Fenestrations and Polydisperse Nanoparticles. 
A comparison was then made between the average size of the nanoparticles within 
fenestrations and those within the vessel for the polydisperse populations. Each data 
point represents the mean ± standard deviation of three simulations (n=3). 
 
To quantify a potential effect of this on cargo delivery the number (Figure 
3.22A) and volume of nanoparticles (Figure 3.22B) delivered was then 
compared between the polydisperse samples and their respective 
monodisperse samples, based on the assumption that the volume of a 
nanoparticle is directly related to the amount of cargo it can carry. Whilst a 
similar effect was demonstrated using both monodisperse and polydisperse 
populations, delivery of larger sizes, by number, was significantly (P < 0.01) 
reduced in the polydisperse samples, likely reflecting the presence of a 
minority of nanoparticles of greater size than the tumour vessel fenestrations 
as can be seen in the distributions in Figure 3.19. In parallel, in polydisperse 
populations corresponding to 70 nm, a small but critical increase is observed 
in the delivery to normal tissue (P=0.00007), reflecting presence of particles 
below the 60 nm cut off. Therefore, polydispersity is a key consideration in the 
design of nanoparticles for improved specificity using the EPR effect. 
Furthermore, across all samples, the polydisperse populations delivered 
significantly less volume across the fenestrations (as much as 66% reduction 
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for the 160 nm population). This demonstrates that monodisperse 
nanoparticle populations, often used in computational simulations, may give 
poor correlation with observed experimental results, where delivery 
quantification will be directly related to the volume of the nanoparticle itself or 
the related volume of cargo. Whilst here the effects of polydispersity and size 
are considered for a specific scenario in nanoparticle delivery, size and 
therefore polydispersity also influence general nanoparticle properties such as 
immune system interaction, clearance, tissue penetration and diffusion rates. 
 
 
Figure 3.22: Uptake of Mono versus Poly -disperse Populations by Number and 
by Volume. Polydisperse populations (Pd) are compared to their size-matched 
monodisperse populations (Md) for uptake, by number, in fenestrations at 0.5 s; a 
dashed baseline for normalised monodisperse populations is included (A). The 
relative volume of nanoparticle mass delivered across fenestrations was then 
compared between polydisperse populations and their equivalent monodisperse 
population at 0.5 s; a dashed baseline for normalised monodisperse populations is 
included (B). Significance tested by the Holm-Sidak t-test, * P < 0.01, ** P < 0.005, 
*** P < 0.001. Each data point represents the mean ± standard deviation of three 
simulations (n=3). 
 
Recently, the size cut off properties of fenestrations has gained new interest. 
It has been demonstrated that the fenestrations themselves, though sized 
around 60-65 nm, have a markedly lower size cut off (Sarin, 2010). For 
example, diaphragmed fenestrae such as those seen in glands have a cut off 
of 6-12 nm and non-diaphragmed fenestrae as seen in the kidney glomeruli 
has cut off of 15 nm. The low cut off kidney fenestrae is partially attributed to 
the actions of the glycocalyx layer, which has a pore size of ~20 nm (Squire et 
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al., 2001, Weinbaum et al., 2003). Interestingly, changes in the glycocalyx of 
tumour tissues has been reported and furthermore has been suggested to be 
important in the spread (metastasis) of cancer cells (Pavelka and Roth, 2010). 
The change in glycocalyx in tumours is important in understanding how the 
glycocalyx may influence the EPR effect, something not addressed within 
these simulations but a potential avenue for future study. The work of Sarin 
and others suggests that the permeability of fenestrated endothelium to ~60 
nm macromolecules is attributable to vesicular-vacuolar organelles 
(Simionescu et al., 1974, Dvorak et al., 1996, Sarin, 2010). Furthermore, the 
work of Dvorak demonstrated the vesicular-vacuolar organelles transport 
more macromolecules in murine ovarian carcinoma models than in normal 
endothelium, suggesting a mechanism by which the EPR effect may occur 
independently of fenestrae (Dvorak et al., 1996). It is clear from this that the 
EPR effect may not be fully understood and better understanding of it may be 
used to improve future simulations. 
The data provided in this section concentrates on the effect of size and 
polydispersity on simulated uptake of nanoparticles in tumour tissue 
compared to normal tissue. Although generally trends within this data match 
up well with the data provided in the literature, such as an increase in size 
improves specific tumour delivery, the simplicity of the model does not allow 
easy direct comparisons between the simulations and in vivo data. However, 
future further extrapolation to larger-scale simulations may address this issue.  
 
3.4 CONCLUSIONS 
In conclusion, a successful implementation of an agent-based model of 
nanoparticle behaviour under physiological blood flow has been 
demonstrated. This model has been designed to allow the facile inclusion of 
cellular interactions and trafficking. This model gives insight into the integral 
role of RBCs in the distribution of nanoparticles to the vessel walls. 
Furthermore, the model’s successful application to aid nanoparticle design 
has been demonstrated by showing how larger size nanoparticles can 
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specifically target tumour tissues and how polydispersity is a key criterion to 
control delivery of nanoparticles. In the following chapters, this model is 
further adapted to study uptake of nanoparticles into the CNS across the 
blood-brain barrier. 
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CHAPTER 4: RESULTS AND DISCUSSION II 
MODELLING NANOPARTICLE BINDING AT THE BLOOD-
BRAIN BARRIER: INSIGHTS INTO IMPROVING GENERAL AND 
SPECIFIC DELIVERY TO THE CENTRAL NERVOUS SYSTEM 
 
4.1: INTRODUCTION 
4.1.1 Controlling Transcytosis Efficiency by Affinity 
The blood-brain barrier is able to regulate the entry of large macromolecules, 
including certain proteins and lipoproteins, by transcytosis. Receptor-
mediated transcytosis induces such a transport mechanism through the 
binding of a ligand to a receptor. In previous drug delivery approaches across 
the blood-brain barrier, hijacking this mechanism has been utilised to aid 
nanoparticle delivery to the CNS. However, methods to improve both the 
general delivery across the blood-brain barrier and specific delivery at 
different regions of the blood-brain barrier are needed to prevent off-target 
effects and improve therapeutic load. Delivery to specific regions of the CNS 
requires the targeting of heterogeneity in the blood-brain barrier. This concept 
is explored in this chapter by studying the process of transcytosis with 
different levels of receptor expression and different blood flows.  
One of the most striking findings in studies of transcytosis across the blood-
brain barrier was that low affinity antibodies to the transferrin receptor 
demonstrated improved transcytosis efficiency (Yu et al., 2014, Yu et al., 
2011). Transcytosis involves five major stages, receptor binding, endocytosis, 
trafficking, exocytosis and receptor dissociation, as summarised in Figure 4.1.  
 
CHAPTER 4: RESULTS AND DISCUSSION II 152 
 
Figure 4.1: Stages of Transcytosis. Unbound cargo (A), upon receptor binding (B) 
can stimulate the endocytosis process that involves invagination (C), wrapping and 
fission (D) of a transport vehicle. The transport vehicle is trafficked across the cell (E) 
to the abluminal membrane where it is primed for exocytosis (F) and fuses with the 
membrane (G). The bound cargo is then released from the receptor into the 
abluminal compartment (H). Part B and H are both dependent on the same 
equilibrium reaction, 𝑹 + 𝑳 ↔ 𝑹𝑳. In transcytosis, part B requires the forward reaction 
and part H requires the reverse reaction. 
 
It was hypothesised that the improved performance of lower affinity antibodies 
was a direct result of the need for both effective receptor binding and 
unbinding (Yu et al., 2011, Yu et al., 2014). High affinity antibodies are highly 
effective in receptor binding but highly ineffective at unbinding and therefore 
would fail to detach from endothelial cells. On the other hand, despite the 
improved unbinding capabilities of low affinity antibodies, the ability to form 
and maintain a stable bond for long enough to induce transcytosis is 
diminished, thus reducing transcytosis efficiency. Therefore, a balance is 
required to form and maintain sufficiently strong bonds to enable binding and 
endocytosis but also a sufficiently weak bond to allow unbinding and release, 
as seen in Figure 4.2. 
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Figure 4.2: Effect of Binding Affinity on Transcytosis Efficiency. As affinity 
decreases and the dissociation constant (𝒌𝒅) increases, the binding rate declines 
and simultaneously the unbinding rate increases. Transcytosis efficiency is optimal 
when both these rates are in balance at an intermediate dissociation constant. 
 
4.1.2 Controlling Nanoparticle Affinity 
Whilst similar principles may apply to nanoparticles, nanoparticle affinity is 
much more complex. Nanoparticles can form multiple receptor-ligand binding 
events between themselves and the interacting cell. Therefore, absolute 
binding affinity is dictated not only by the affinity of each receptor-ligand pair, 
but also by the number of bonds between the particle and host. The interfacial 
contact surface area (𝑨𝒄), the receptor density (𝑹𝑫) and the ligand density 
(𝑳𝑫) dictate the number of bonds (𝑩𝑵) between the particle and a cell. The 
target cell determines the receptor density whilst ligand density is an 
adaptable property of the nanoparticles. The interfacial surface area is the 
surface area of the nanoparticle that is within a set binding distance from the 
cell. The characteristic length of the receptor-ligand bond (𝑩𝑳) dictates this 
distance. The interfacial surface area is thus dictated by the nanoparticle 
position, relative to the membrane, the size of the nanoparticle, the bond 
length and the curvature of the nanoparticle. In consequence, the interfacial 
surface area can be manipulated by altering the bond length, nanoparticle 
shape and nanoparticle size, as demonstrated in Figure 4.3. 
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Figure 4.3: Controlling the Interfacial Surface Area by Changing Size and 
Morphology. The interfacial surface is dictated by the bond length ( 𝑩𝑹𝑳 ), 
nanoparticle size (A), nanoparticle shape (B and C) and the closest distance of the 
nanoparticle relative to the cell (𝜹𝒆𝒒). 
 
The ligand density affects the likelihood of new bond formation, with a higher 
density assumed to increase the probability of formation, as can be seen in 
Figure 4.4. 
 
 
Probability Adhesion (!!): !! ≃ !!!!!!!!!!(!!!"!!"!!! )  
 
 !! is the receptor density on the cell surface, !!!is the ligand density on 
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Figure 4.4: Effect of Ligand Density on Nanoparticle-Cell Adhesion. In A, the 
low ligand density reduces the number of bonds formed compared to B and C, where 
ligand density and number of bonds increases. 
 
In addition to ligand density, receptor density is also important, as 
demonstrated in Figure 4.5. The probability of a spherical nanoparticle 
adhering (𝑷𝒂) to the cell membrane, in the absence of shear stress, can be 
given as: 
 𝑷𝒂 ≃ 𝑹𝑫𝑳𝑫𝒌𝒂𝟎𝑨𝒄      (4.1) 
 
where 𝒌𝒂𝟎  is the association constant at zero load per receptor-ligand pair 
(Decuzzi and Ferrari, 2006). 𝒌𝒂𝟎 can also be expressed as: 
 
𝒌𝒂𝟎 = 𝒌𝒇𝟎𝒌𝒓𝟎      (4.2) 
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where 𝒌𝒇𝟎 and 𝒌𝒓𝟎 are the forward and reverse reaction rates at equilibrium 
distance respectively. Therefore, nanoparticle binding may be tailored for 
specific receptor expression levels by manipulation of the receptor-ligand 
bond strength (affinity), ligand density and nanoparticle size. 
 
 
Figure 4.5: Effect of Receptor Density on Nanoparticle-Cell Adhesion. In A, the 
low receptor density reduces the number of bonds formed compared to B, where 
receptor density is greater. 
 
4.1.3 Shear Flow and Nanoparticle-Cell Binding 
Receptor binding of nanoparticles in the blood is affected by the blood flow. 
Blood flow creates a shearing force at the vessel walls that strains the 
receptor-ligand bonds and therefore increases the chances of bond rupture. 
However, multiple bonds help stabilise adhesion of nanoparticles to the 
endothelial wall. Nanoparticles adhered to the cell wall are subject to two 
major forces that will effect bond strain. The drag force (𝑭𝑫) is the force 
exerted on the nanoparticle in the direction of flow, as seen in Figure 4.6A. 
The torque (𝑻) is rotational force acting upon the nanoparticle, as seen in 
Figure 4.6B. 
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Figure 4.6: Forces acting on Nanoparticles under Shear Flow. There are two 
major forces acting on nanoparticles, the drag force (A) in the direction of flow and a 
rotating force called the torque (B). 
 
The drag force and torque forces are both related to the particle radius (𝒓), 
particle aspect ratio (𝜸) and wall shear stress (𝑺𝝁). The drag force can be 
defined as: 
 𝑭𝑫 = 𝟔𝝅𝒓𝒍𝑺𝝁𝑭𝑺       (4.3) 
 
where 𝒍 is the distance from the particle centre of mass to the cell membrane 
and 𝑭𝑺 is the force as a function of aspect ratio which is equal to: 
 𝑭𝑺 = 𝟏+ 𝟏.𝟕𝟑𝟔− 𝟎.𝟏𝟑𝟖𝜸+ 𝟎.𝟏𝟐𝟖𝜸𝟐 + 𝟎.𝟎𝟗𝜸𝟑 𝒆!𝜸       (4.4) (Decuzzi and 
Ferrari, 2006, Bentley et al., 2008). 
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The torque can be given as: 
 𝑻 = 𝟒𝝅𝒓𝟑𝑺𝝁𝑻𝑺      (4.5) 
 
where 𝑻𝑺 is the torque force as a function of aspect ratio, given as: 
 𝑻𝑺 = 𝟏+ (−𝟐𝟎.𝟓+ 𝟒𝟔.𝟓𝜸− 𝟑𝟓.𝟏𝜸𝟐 + 𝟖.𝟗𝟓𝜸𝟑)𝒆!𝜸       (4.6) (Decuzzi and 
Ferrari, 2006, Bentley et al., 2008). 
 
Therefore nanoparticle-cell adhesion is dependent on the fluid dynamics 
within the blood, in addition to the affinity, ligand-receptor densities, size and 
shape considerations from the previous section.  
The fluid dynamics in the cerebrovasculature are generally maintained at a 
relatively constant level by autoregulation. However, transient local increases 
in blood flow, called functional hyperaemia, occur by the neurovascular 
coupling response. Functional hyperaemia is a natural mechanism for 
increasing the uptake of key molecules into the required area of the CNS, in 
response to local neural stimulation. Through a variety of techniques, 
particularly fMRI, we have been able to associate different parts of the CNS 
with their function. The knowledge of the function of distinct CNS regions 
means it may be possible to induce neural activity within a region of interest. 
For example, in rodents it is possible to reproducibly stimulate neural activity 
and consequent functional hyperaemia within the barrel cortex by whisker 
stimulation. Whilst, functional hyperaemia mechanism is mainly to increase 
access of important nutrients for ATP production, such as glucose and 
oxygen, it could be utilised to increase drug uptake into stimulated regions of 
the CNS. The increase of blood flow increases the overall number of 
nanoparticles that access the area, but may affect overall binding due to the 
increase in wall shear stress. Moreover, the size of a nanoparticle is 
significantly larger than a single glucose molecule (~1.5 nm). Therefore, given 
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the size components within Equations 4.3 and 4.5, it is apparent that the 
dislodging force will be significantly larger for a nanoparticle than a glucose 
molecule. However, a composition of nanoparticle could be designed to bind 
effectively under such conditions, allowing us to harness the inducible 
localised increase in blood flow in functional hyperaemia to give specific, 
controllable enrichment of nanoparticles delivered to distinct regions of the 
CNS.  
 
4.2 AIMS AND OBJECTIVES 
In this chapter, an agent-based model of nanoparticle-cell binding is built, 
based on the transwell in vitro models of the blood-brain barrier. This model 
will then be used to investigate how adapting the 𝒌𝒂𝟎 , ligand density and 
nanoparticle size can alter transcytosis efficiency. This will be used to 
establish optimal nanoparticle properties for different levels of receptor 
expression. These studies will be then extended to investigate the binding 
efficiency of nanoparticles under different shear flow conditions using the 
model from Chapter 3. 
 
4.3 RESULTS AND DISCUSSION 
4.3.1 Building a Transwell Model of Nanoparticle Transcytosis 
Nanoparticles designed for their ability to cross the blood-brain barrier by 
receptor-mediated transcytosis are routinely pre-screened using in vitro 
transwell models of the blood-brain barrier. Therefore, to improve the 
translational utility of in silico approaches, an agent-based model was 
designed based on the geometry of the transwell insert used in the Battaglia 
laboratory (Figure 4.7). 
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Figure 4.7: Dimensions of a Polycarbonate Transwell. The agent-based model 
was based on the polycarbonate transwell insert for a 6-well plate, using a media 
volume of 300 μl. 
 
Cells were simulated as a uniform 2-μm thick layer at the bottom of the insert. 
Nanoparticles were randomly seeded within the aqueous phase in the starting 
states. Nanoparticles in the aqueous phase moved according to Brownian 
motion using the methods provided in Chapter 3 with a time step (𝚫𝒕) of 
0.00005 s. The dynamic viscosity was given as 0.00078 Pa·s, the viscosity of 
the cell medium Dulbecco’s Modified Eagle Medium (DMEM) at a standard 
culture temperature of 37°C (310 K) (Bacabac et al., 2005). The boundaries of 
the transwell, the top of the aqueous phase and the edge of the cell layer 
were treated as reflective boundaries. 
The Battaglia group’s CNS-targeting nanoparticle is based on functionalising 
POEGMA-PDPA polymersomes with Angiopep-2 that targets the Lrp1 
receptor (Tian et al., 2015). The characteristic length for Lrp1-Angiopep-2 was 
estimated as 6.5 nm based on the molecular weight of Lrp1β, the extracellular 
chain that forms part of the Lrp1 heterodimer, using the methods of Erickson 
(Alyaudtin et al., 2001, Schröder and Sabel, 1996). Nanoparticles in close 
enough proximity to the top of the cell layer (𝜹𝒆𝒒 < 𝑩𝑳) are able to form bonds 
with the cell. Temporary ligand agents were created randomly on the outside 
of these nanoparticles to the required density. It was adjudged that this 
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method would be computationally less expensive than adding in rotational 
diffusion and updating the positions of the ligands each iteration. Moreover, 
for the time step used for receptor binding (0.01 s) and the radii of the 
nanoparticles, the contact surface area is effectively randomised each 
iteration by rotational diffusion, so that re-creation of the ligands would not 
adversely effect the robustness of the model compared to incorporating full 
rotational diffusion.  
Therefore this method was adapted to give a simulation of binding and 
unbinding across discrete steps. Decuzzi and Ferrari investigated the binding 
of nanoparticles in a static linear flow. They gave the probability of a 
nanoparticle adhering as: 
 
𝑷𝒂 ≃ 𝑹𝑫𝑳𝑫𝒌𝒂𝟎𝑨𝒄𝒆(!𝑩𝑹𝑳𝑭𝑹𝑳𝑲𝑩𝑻 )       (4.7) 
 
where 𝑹𝑫𝑳𝑫𝒌𝒂𝟎𝑨𝒄  represents the likelihood of bond formation and (− 𝑩𝑳𝑭𝑹𝑳𝑲𝑩𝑻 ) 
represents the total dislodging force. 𝑭𝑹𝑳 is the dislodging force per receptor-
ligand pair. This is calculated from the total dislodging force divided by an 
approximation of bond number, derived from the receptor density and the 
contact surface area: 
 𝑭𝑹𝑳 = 𝑭𝒅𝒊𝒔𝑹𝑫𝑨𝑪       (4.8) 
 
The method Decuzzi and Ferrari does not have the capability to allow 
reversible binding and unbinding of nanoparticles, nor does it consider the 
exact number of bonds each particle makes. Therefore, this method was 
adapted to give a dynamic model of nanoparticle binding, where each 
available ligand is considered separately. A nanoparticle is bound if at least 
one ligand-receptor bond is formed. Therefore, adhesion occurs if: 
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𝑩𝑵 ≥ 𝟏       (4.9) 
 
where  𝑩𝑵 is the number of bonds which is equal to: 
 𝑩𝑵 = 𝑩𝑵 + 𝑩𝑭 − 𝑩𝑹       (4.10) 
 
where 𝑩𝑭 is the number of bonds formed and 𝑩𝑹 is the number of bonds 
ruptured in a discrete passage of time (𝚫𝒕). For every individual ligand within 
bonding distance, the probability of forming a bond in a discrete passage of 
time was given as: 
 𝑷𝒇𝒐𝒓𝒎 ≃ 𝟏− 𝒆!𝑹𝑫𝑳𝑨𝒄𝒌𝒂𝟎𝚫𝒕           (4.11) (Decuzzi and Ferrari, 2006, Hammer and 
Apte, 1992). 
 
The contact surface area for an individual ligand (𝑳𝑨𝒄) is calculated by: 
 𝑳𝑨𝒄 = 𝝅(𝑩𝑳𝟐 − 𝜹𝑳𝟐)      (4.12) 
 
where 𝜹𝑳  is the distance from the ligand nanoparticle surface, to the cell 
surface. In the absence of wall shear stress from flow, the probability of a 
ligand unbinding can be given from the dissociation constant (𝒌𝑫), the inverse 
of the association constant (𝒌𝒂𝟎). The probability of a bond rupturing in a 
discrete passage of time is given as: 
 𝑷𝒃𝒓𝒆𝒂𝒌 ≃ 𝟏− 𝒆!𝒌𝑫𝚫𝒕           (4.13) 
 
A bond is formed or ruptured accordingly if a randomly generated number is 
less than the calculated probability. 
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Timing of transcytosis remains a largely unexplored area, however timing of 
endocytosis has been much better studied, both theoretically and 
experimentally. Gao and colleagues used theoretically modelling to identify an 
optimal particle radius and wrapping time for particles. The optimal particle 
size was 54-60 nm in diameter, with an optimal wrapping time of 2-58 s (Gao 
et al., 2005). The timing of entry is dictated also in part by the pathway of 
entry and optimal size for each entry route. The most likely routes of entry for 
a nanoparticle to take are clathrin-mediated, caveolin-mediated or clathrin and 
caveolin-independent endocytosis. The optimal size of cargo for each route is 
120 nm, 60 nm and 90 nm respectively (Conner and Schmid, 2003). Caveolin-
mediated endocytosis is a slow process with a half-life of >20 minutes. 
However, clathrin and other caveolin-independent endocytosis mechanisms 
can be substantially quicker of the order of tens of seconds to minutes. In 
neural synapses a clathrin and caveolin-independent endocytosis mechanism 
has been timed of the order of milliseconds, much quicker than clathrin-
dependent endocytosis (Watanabe et al., 2013, Artalejo et al., 2002). In 
addition to size, shape was also shown to be important in endocytosis 
mechanics as demonstrated by the work of Decuzzi and Ferrari. They 
demonstrated that with non-spherical particles, such as cylindrical particles or 
ellipsoid particles, the wrapping time is often slower, ranging from 41 s for an 
aspect ratio of nearly 1 and radius perpendicular to the cell membrane of 50 
nm to 2105 s for an aspect ratio of 0.32 and radius perpendicular to the cell 
membrane of 500 nm (Decuzzi and Ferrari, 2008). In previous work in the 
Battaglia laboratory, based on live cell imaging of Lrp1-mediated transcytosis 
of polymersomes through B.End3 brain endothelial cells, the timing of cellular 
trafficking has been tracked. Endocytosis occurs within 10 s from initial 
binding of polymersomes to the apical edge of the endothelial cell, within the 
realms of a clathrin-mediated or caveolin and clathrin-independent 
endocytosis process. Previously, LDLs and the transferrin receptor have been 
identified to utilise clathrin-mediated endocytosis but it is also possible other 
mechanisms could operate at the blood-brain barrier in place of or in 
conjunction with clathrin-mediated endocytosis (Schmid, 1997, Kibbey et al., 
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1998). Trafficking and exocytosis is complete by 20 s after initial binding (Tian 
and Battaglia, unpublished). In the simulations of transcytosis similar timings 
were used. Bonds could be formed for 10 s after initial binding of the 
nanoparticle to the cell. Nanoparticles then entered a trafficking stage where 
no bonds were ruptured or formed for a further 10 s. Nanoparticles then 
undertook exocytosis and were placed on the basolateral side of the cell, 
where bonds can rupture once more (Figure 4.8). The state graph and 
process order graph for running the simulation of transwell nanoparticle 
binding, in parallel, is given in Figure 4.9. 
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Figure 4.8: Simulation of Transcytosis States. Nanoparticles on the apical side 
are given the state variable 0. They are free to move by Brownian motion. When in 
close proximity to the vessel wall, state 0 nanoparticles can bind to the apical side of 
the cell. Successfully bound nanoparticles are given the state variable 100. They may 
form and break bonds, but are not subject to Brownian motion. If all bonds are 
broken the nanoparticle reverts to state 0. If it remains in state 100 for 10 s, then it is 
assigned the state variable 102. State 102 nanoparticles are unable to form or break 
bonds and are dormant for a further 10 s before entering state 101. State 101 
nanoparticles are bound to the cell on the basolateral side, they may break bonds 
with the cell. If all bonds are broken, the nanoparticle is given a state variable of 1 
and is released into the basolateral compartment. 
 
Apical (Blood) 
Basolateral (CNS) 
State_0 
State_100 
State_102 
State_101 
State_1 
10 s 
10 s 
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Figure 4.9: FLAME State and Process Order Graphs of the Transwell Receptor 
Binding Model. The state graph (A) demonstrates the dependency of functions on 
both previous functions and messages for parallelisation of the transwell receptor 
binding model. The process order graph (B) shows the order in which FLAME 
prioritises the functions to reduce the lag from using the message passing interface. 
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The simulation of transcytosis makes several assumptions. Firstly, that bond 
rupture does not occur during cellular trafficking. In transcytosis of transferrin, 
the receptor is usually recycled during the cellular trafficking in the early 
endosome, suggesting that most of the receptor unbinding occurs during this 
stage (Maxfield and McGraw, 2004). However, work within the Battaglia 
laboratory has determined that Lrp1 does not co-localise with endosomal 
markers and therefore receptor unbinding is less likely to occur at this stage in 
Lrp1-mediated transcytosis (Tian et al., 2015). Secondly, the simulations 
assume that no new binding events occur on the basolateral side. Lrp1 is 
expressed on both the apical and basolateral sides of the cell, this may allow 
binding to occur on the basolateral side and even basolateral to apical 
transcytosis events (Herz and Marschang, 2003). This has been omitted from 
the simulations and instead the simulation is performed for just 5 minutes, to 
discount the likelihood of basolateral to apical transcytosis events occurring in 
corresponding in vitro experiments. This method also assumes that each 
receptor-ligand binding event and each nanoparticle-cell binding event is 
independent. Steric effects can affect multiple receptor-ligand binding events. 
Multiple nanoparticle binding events have been demonstrated to effect events 
such as membrane wrapping and endocytosis (Abhishek et al., 2011). In 
observations of transcytosis in live cells, the lag time from when a particle 
binds to the apical membrane, until transport occurs, is correlated with an 
increased intensity in fluorescence from the nanoparticles (Tian and Battaglia, 
unpublished). This suggests that multiple particles are accrued and 
transported simultaneously, something not explored within these simulations.  
 
4.3.2 Improving Specificity by Adapting Nanoparticle Properties  
In order to test for optimal nanoparticle design, nanoparticles with different 
sizes, ligand densities and receptor-ligand affinities were evaluated in the 
transwell model of the blood-brain barrier. The nanoparticles were modelled 
as 40 nm and 100 nm spheres. This was in keeping with the optimal range for 
longevity in the blood. A number of different ligand densities were used in 
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simulations, these were 1014 m-2, 5×1014 m-2, 1015 m-2, 2×1015 m-2 and 4×1015 
m-2. In previous studies of receptor-ligand binding for nanoparticle binding or 
in leukocyte rolling, a wide-range of 𝒌𝒇𝟎 and 𝒌𝒓𝟎 values has been used (Haun 
and Hammer, 2008, Mehta et al., 1998, Smith et al., 1999b, Tan et al., 2013). 
Substituting these values into Equation 4.2 gives a range for 𝒌𝒂𝟎 as 1-100000, 
therefore 𝒌𝒂𝟎  values of 10, 100, 200, 500 and 1000 were used within the 
simulations. All the different combinations of nanoparticle composition were 
then trialled with receptor densities of 1015 m-2 and 5×1014 m-2. 1015 m-2 was 
used in line with the work of Decuzzi and Ferrari. 5×1014 m-2 was used as it 
represents half the expression level of 1015 m-2 (Decuzzi and Ferrari, 2006). 
In order to demonstrate the relative binding properties of each composition, 
20000 nanoparticles were distributed in the transwell model and simulated for 
5 minutes. Nanoparticles were permitted to bind and unbind, but transport 
was initially omitted, in order to study just the binding properties to the apical 
side of the barrier. Figure 4.10 demonstrates that generally increasing the 
ligand density, receptor density and 𝒌𝒂𝟎  improves nanoparticle binding. In 
Figures 4.10C and D, there is evidence of a plateau with high ligand densities 
and high 𝒌𝒂𝟎. This is suggestive that binding becomes limited by the lower 
mobility of 100 nm nanoparticles compared to the 40 nm nanoparticles (Figure 
4.10A and B) where such a plateau is less apparent. This limitation means 40 
nm particles have the potential to perform better, reaching a maximum of 
1.9% binding compared to ~1.5% for 100 nm nanoparticles. However binding 
at lower values of 𝒌𝒂𝟎  and lower ligand densities is improved for 100 nm 
particles, demonstrating that their increased size gives stronger binding, likely 
due to the subsequent increased contact surface area between the 
nanoparticle and the cell membrane. 
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Figure 4.10: Nanoparticle Binding in an in silico Transwell Model of the Blood 
Brain Barrier without Transport. The percentage of nanoparticles bound to the 
barrier after 5 minutes for 40 nm particles with a receptor density of 5×1014 m-2 (A) or 
1015 m-2 (B) and 100 nm particles with a receptor density of 5×1014 m-2 (C) or 1015 m-2 
(D). Each data point represents the mean ± standard deviation of three simulations 
(n=3). 
 
Generally there is an increase in the binding of nanoparticles to the higher 
density of receptor (Figure 4.10B and D) as compared to the lower density 
(Figure 4.10A and C). However, the difference is more distinct when the 
overall binding strength is reduced. For example, for a 40 nm particle with a 
ligand density of 4×1015 m-2, a 𝒌𝒂𝟎 of 1000 gives a nominal 1.1-fold increase in 
binding to the higher receptor density, where as a 𝒌𝒂𝟎 of 100 gives a 1.7-fold 
increase. To investigate this further, the binding ratio of the mean binding to 
the higher density against the mean binding to the lower density was 
calculated for each nanoparticle formulation, along with the total error 
(calculated as described in Section 2.11), and plotted in Figure 4.11. Where 
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the total error was calculated to be >30% of the mean, the points were 
omitted: 
 
 
Figure 4.11: Specificity of Nanoparticle Binding in an in silico Transwell Model 
of the Blood Brain Barrier without Transport. The ratio of nanoparticles bound to 
the barrier with a receptor density of 1015 m-2 against binding to a barrier with a 
receptor density of 5×1014 m-2 for 40 nm (A) and 100 nm (B) nanoparticles. Data 
points with a percentage error of >30% were omitted. Each data point represents the 
mean ± standard deviation of three simulations (n=3). Significance calculated using 
the Holm-Sidak t-test, * P < 0.05, ** P < 0.01, *** P < 0.005 
 
Figure 4.11A demonstrates that the greatest improvement for uptake by the 
higher receptor density occurs when the 𝒌𝒂𝟎 value is low and the ligand density 
is high or alternatively when the 𝒌𝒂𝟎 value is high but the ligand density is low. 
The Frenkel group have likewise demonstrated the latter, where a high ligand 
density with a low binding affinity gave super-selective behaviour for 
increased receptor expression (Gosk et al., 2004). However, their ligand 
densities were higher than in the simulations in this chapter, in order to 
guarantee that each available receptor can choose between multiple ligands, 
giving increased binding strength through entropy effects. The method 
presented here works in the limit of comparable ligand to receptor density, 
therefore it is difficult to replicate such findings with this method, even if there 
is broad agreement with their findings. Overall, this demonstrates that the 
binding specificity is dictated by the collective binding strength of a 
nanoparticle. Figure 4.11B demonstrates that a low 𝒌𝒂𝟎  value is consistently 
better for improving binding specificity, with a reduction in specificity as ligand 
0 10 20 30 40
0
1
2
3
Ligand Density (×1014 m-2)
R
at
io
Specificity-Apical-40nm(error)
Ka=10
Ka=100
Ka=200
Ka=500
Ka=1000
*** ***
* **
*** *** ***
** *** *
0 10 20 30 40
0
1
2
3
Ligand Density (×1014 m-2)
R
at
io
Specificity-Apical-100nm(error)
Ka=10
Ka=100
Ka=200
Ka=500
Ka=1000
* * *** ***
* * ** *
*** **
**
NS NS
NS NS NS
0.000 0.001 0.002 0.003 0.004
0.0
0.5
1.0
1.5
2.0
2.5
Ligand Density (nm-2)
%
 B
ou
nd
40nm-Apical-0.001
Ka=10
Ka=100
Ka=200
Ka=500
Ka=1000
A B 40 nm 100 nm 
%
 B
ou
nd
!!! !!!! !!!! !!!! !!!! !
=10 
=100 
=200 
=500 
=1000 
CHAPTER 4: RESULTS AND DISCUSSION II 171 
density is increased. It can be concluded from this that weakening the 
absolute binding affinity of nanoparticles improves specificity for a higher 
receptor expression. The increased receptor density may aid binding by 
increasing the likelihood of multiple receptor-bond formations, thus increasing 
stability of inherently weak interactions, or by simply improving the likelihood 
of an initial receptor-bond forming.  
To investigate whether different nanoparticle compositions and receptor 
expression levels affected the bond density, the average number of bonds per 
particle was plotted (Figure 4.12). Simulations with less than 5 bound particles 
were omitted due to the high error attributed to these simulations. Increasing 
the ligand density increased the number of bonds per particle across all 
simulations. This effect was greater for larger particles (Figures 4.12C and D) 
as compared to smaller particles (Figure 4.12A and C). This demonstrates 
that the number of bonds is highly related to the absolute number of ligands 
that can form bonds, dictated by the contact surface area and the ligand 
density. An increased 𝒌𝒂𝟎  also appeared to increase the number of bonds 
formed, although this effect is more negligible at 40 nm (Figure 4.12A and B), 
particularly for a high density of receptor (Figure 4.12B). Interestingly, the 
number of bonds per receptor is consistently lower with a higher receptor 
density. This suggests that the major route for the improved binding to the 
higher receptor density is caused by the increasing probability of forming an 
initial bond, as opposed to increasing the stability of the nanoparticle-cellular 
interaction through multiple bonds. However, it is likely that both contribute to 
the overall improved binding. 
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Figure 4.12 Number of Bonds per Nanoparticle for Binding in an in silico 
Transwell Model of the Blood Brain Barrier without Transport. The average 
number of bonds per nanoparticle bound to the barrier after 5 minutes for 40 nm 
particles with a receptor density of 5×1014 m-2 (A) or 1015 m-2 (B) and 100 nm 
particles with a receptor density of 5×1014 nm-2 (C) or 1015 nm-2 (D). Simulations with 
less than 5 bound particles were omitted. Each data point represents the mean ± 
standard deviation of three simulations (n=3). 
 
4.3.3 Improving Transcytosis Efficiency by Adapting Nanoparticle 
Properties  
To model transcytosis efficiency of nanoparticles, the same compositions of 
nanoparticle were modelled for 5 minutes, but with cell trafficking and 
unbinding into the basolateral compartment included. The percentage of 
particles that have successfully bound, undergone cell trafficking and been 
released on the basolateral side was plotted in Figure 4.13.  40 nm 
nanoparticles (Figure 4.13A and B) demonstrate that with strong overall 
binding, due to the collective influence of high ligand density and high 𝒌𝒂𝟎, 
there is a reduction in the efficiency of transcytosis. Lower affinities (𝒌𝒂𝟎 = 10, 
100 or 200) demonstrate improved transcytosis efficiency with increased 
0 10 20 30 40
0
1
2
3
4
5
Ligand Density (×1014 m-2)
B
on
ds
/P
ar
tic
le
100nm-BondNorm-0.0005
Ka=10
Ka=100
Ka=200
Ka=500
Ka=1000
0 10 20 30 40
0
1
2
3
4
5
Ligand Density (×1014 m-2)
B
on
ds
/P
ar
tic
le
100nm-BondNorm-0.001
Ka=10
Ka=100
Ka=200
Ka=500
Ka=1000
0 10 20 30 40
0
1
2
3
4
5
Ligand Density (×1014 m-2)
B
on
ds
/P
ar
tic
le
40nm-BondNorm-0.0005
Ka=10
Ka=100
Ka=200
Ka=500
Ka=1000
0 10 20 30 40
0
1
2
3
4
5
Ligand Density (×1014 m-2)
B
on
ds
/P
ar
tic
le
40nm-BondNorm-0.001
Ka=10
Ka=100
Ka=200
Ka=500
Ka=1000
0.000 0.001 0.002 0.003 0.004
0.0
0.5
1.0
1.5
2.0
2.5
Ligand Density (nm-2)
%
 B
ou
nd
40nm-Apical-0.001
Ka=10
Ka=100
Ka=200
Ka=50
Ka=10
A B 
C D 
%
 B
ou
nd
!!! !!!! !!!! !!!! !!!! !
=10 
=100 
=200 
=500 
=100  
40 n , RD = 5×1014 m-2 40 nm, RD = 1015 m-2 
10  , RD = 5×1014 m-2 100 nm, RD = 1015 m-2 
CHAPTER 4: RESULTS AND DISCUSSION II 173 
ligand density. A similar pattern is also observed for 100 nm nanoparticles 
(Figure 4.13C and D), but with the decline in efficiency occurring with lower 
ligand densities and with lower 𝒌𝒂𝟎 values. This reflects the steeper increase in 
the number of bonds per particle that occurs with larger nanoparticles, as 
observed in the previous section. The increased number of bonds increases 
the stability of the binding and provides a greater energetic barrier for release. 
Generally transcytosis efficiency was increased at the higher receptor density 
(Figures 4.13B and D) as compared to the lower density (Figures 4.13A and 
C). This reflects both the increased initial binding of the particles but also 
accounts for the reduction in the number of bonds per nanoparticle observed 
at the higher receptor densities in the previous section. Thus, more particles 
are present with lower energetic barriers to overcome for release. 
 
 
Figure 4.13: Nanoparticle Transcytosis in an in silico Transwell Model of the 
Blood Brain Barrier. The percentage of nanoparticles transcytosed across the 
transwell barrier after 5 minutes for 40 nm particles with a receptor density of 5×1014 
m-2 (A) or 1015 m-2 (B) and 100 nm particles with a receptor density of 5×1014 nm-2 (C) 
or 1015 nm-2 (D). Each data point represents the mean ± standard deviation of three 
simulations (n=3). 
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In order to confirm that the lack of free basolateral nanoparticles at higher 
values of 𝒌𝒂𝟎 and ligand densities was due to failure to unbind the basolateral 
membrane, the percentage of basolaterally bound nanoparticles was plotted 
(Figure 4.14). Figure 4.14 demonstrates that nanoparticles at high 𝒌𝒂𝟎  and 
ligand density are indeed sequestered on the basolateral membrane. 
Furthermore at low values of 𝒌𝒂𝟎 (𝒌𝒂𝟎 = 10), there is virtually no binding to the 
basolateral membrane, suggesting that almost all transport results in rapid 
release on the basolateral side. Interestingly, the levels are much lower than 
that bound to the apical membrane without transport. This may reflect the lack 
of binding potential on the basolateral side of the simulations, suggesting 
apical binding is only maintained by rapid and dynamic bond formation and 
bond rupture, as opposed to forming more stable bonds.  
 
 
Figure 4.14: Nanoparticle Binding to the Basolateral Side of an in silico 
Transwell Model of the Blood Brain Barrier. The percentage of nanoparticles 
bound to the basolateral side of the barrier after 5 minutes for 40 nm particles with a 
receptor density of 5×1014 m-2 (A) or 1015 m-2 (B) and 100 nm particles with a receptor 
density of 5×1014 m-2 (C) or 1015 m-2 (D). Each data point represents the mean ± 
standard deviation of three simulations (n=3). 
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The relative unbinding efficiency of the different nanoparticle compositions 
was estimated by calculating the total number of unbound basolateral 
nanoparticles across three replicate simulations as a percentage of the total 
bound and unbound basolateral nanoparticles across the same three replicate 
simulations (Figure 4.15). A number of compositions had too few basolateral 
nanoparticles across all three replicate simulations to accurately calculate the 
unbinding efficiency, due to overall poor and unstable binding on the apical 
side, therefore these points were omitted from Figure 4.15. Nanoparticles with 
a 𝒌𝒂𝟎 of 10 had an unbinding efficiency of >95%. Where as nanoparticles with 
a 𝒌𝒂𝟎 of 1000 had an unbinding efficiency of <5% at higher ligand densities. As 
expected nanoparticle unbinding efficiency declined as the 𝒌𝒂𝟎  or ligand 
density was increased. 
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Figure 4.15: Nanoparticle Release in an in silico Transwell Model of the Blood 
Brain Barrier. The efficiency of nanoparticle release on the basolateral side of the 
barrier as a percentage of all transcytosed nanoparticles after 5 minutes for 40 nm 
particles with a receptor density of 5×1014 m-2 (A) or 1015 m-2 (B) and 100 nm 
particles with a receptor density of 5×1014 m-2 (C) or 1015 m-2 (D). Points with too few 
basolateral particles were omitted. Each data point represents the unbinding 
efficiency calculated from the total number of nanoparticles released across three 
simulations and the total number of nanoparticles transcytosed across three 
simulations. 
 
4.3.4 Building a Capillary Model of Nanoparticle Binding 
To give a simulation of nanoparticles binding under shear flow, the simulation 
of nanoparticles undergoing binding to the blood-brain barrier was combined 
with the simulation of blood flow from Chapter 3. Furthermore, the dislodging 
forces calculated from the drag and torque forces were integrated into 
Equation 4.13. The aspect ratio (𝜸) of spherical particles is equal to 1, 
therefore by applying this Equation 4.4 and Equation 4.6, Equation 4.3 
reduces to: 
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𝑭𝑫 = 𝟏𝟎𝝅𝒓𝒍𝑺𝝁       (4.14)    
 
and Equation 4.5 reduces to: 
 𝑻 = 𝟑.𝟕𝟖𝝅𝒓𝟑𝑺𝝁      (4.15). 
 
The dislodging force ( 𝑭𝒅𝒊𝒔 ) is calculated as the force acting on the 
nanoparticle shared over the number of bonds (𝑩𝑵). It can be assumed that 
whilst the drag force (Equation 4.2) affects all bonds equally, the torque force 
(Equation 4.4) will mainly affect bonds in the trailing half of the nanoparticle, 
therefore: 
 𝑭𝒅𝒊𝒔 = 𝑭𝒅 + 𝑻𝒒𝟐       (4.16) (Decuzzi and Ferrari, 2006). 
 
In the work of Decuzzi and Ferrari, the number of bonds was estimated as 
being related to the contact surface area and the receptor density. However, 
as the number of bonds is known in these simulations, the probability of bond 
breakage under shear flow can be given as: 
 
𝑷𝒃𝒓𝒆𝒂𝒌 ≃ 𝟏− 𝒆!𝒌𝑫𝚫𝒕𝒆𝑩𝑳𝑭𝒅𝒊𝒔𝑲𝑩𝑻𝑩𝑵       (4.17) 
 
where 𝒌𝑩  is the Boltzmann constant and 𝑻  is the temperature. Cellular 
trafficking was omitted in these simulations. This is because a typical 
simulation of blood flow will simulate 0.5-2 s, much lower than the measured 
20 s for transport. Moreover, it can be expected that cellular trafficking times 
will be reduced in vivo as endothelial cells in the blood-brain barrier can be as 
little as 500 nm in distance from the apical to basolateral side, compared to 
several microns in in vitro cultured cells. Nanoparticles in capillaries were 
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simulated with a time step of 0.00005 s for Brownian motion and 0.0001 s for 
laminar flow and receptor binding. The state graph and process order graph 
for parallel execution of the capillary model of nanoparticle binding is given in 
Figure 4.16. 
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Figure 4.16: FLAME State and Process Order Graphs of the Capillary Receptor 
Binding Model. The state graph (A) demonstrates the dependency of functions on 
both previous functions and messages for parallelisation of the capillary receptor 
binding model. The process order graph (B) shows the order in which FLAME 
prioritises the functions to reduce the lag from using the message passing interface. 
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The dislodging force is dependent on particle size. In order to evaluate the 
relative dislodging force of different molecules under shear flow, the 
dislodging force was plotted against particle size (Figure 4.17). Figure 4.17 
demonstrates that the dislodging force increases with particle size in an 
exponential manner. Moreover, the size of key endogenous molecules 
including glucose, proteins and LDLs is indicated as a comparison to the size 
of nanoparticles. It is apparent that the relative size of nanoparticles compared 
to glucose leads to an increase in dislodging force by 150-1000 times. 
Furthermore, the dislodging force of nanoparticles is 2-13 times greater than 
LDL molecules, the typical substrate for the Lrp-1 receptor. Stronger binding 
to the vessel wall may therefore be required for nanoparticles to be 
transported. Forming more bonds and/or stronger individual bonds could 
provide this stronger binding. Therefore, it is important to find a nanoparticle 
composition that can bind under such conditions. 
 
 
 
Figure 4.17: Dislodging Force as a Function of Particle Size. The dislodging 
force is demonstrated as function of particle size when 𝑺𝝁 = 𝟎.𝟐𝟓  𝑷𝒂  and 𝜹𝒆𝒒 =𝟑  𝒏𝒎.  
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4.3.5 The Effect of Functional Hyperaemia on Nanoparticle Binding 
In order to evaluate whether functional hyperaemia negatively affects the 
efficiency of nanoparticle binding and transcytosis, the model presented in 
Chapter 3 was adapted to model increasing shear flows. Functional 
hyperaemia can increase overall blood velocity by approximately 20-30% 
(Zheng et al., 2002). In order to model functional hyperaemia, RBC velocity 
was increased by one-third to 80 μm·s-1. Functional hyperaemia is, at least 
partially, mediated by an increase of blood flow through the arteriole. 
Therefore, blood flow velocity at the inlet was increased by one-third and then 
blood flow was resolved according to the methods in Chapter 3. The relative 
shear stress under normal and functional hyperaemia flow is shown in Figure 
4.18. Figure 4.18 demonstrates that shear stress is highest proximal to RBCs. 
The wall shear stress, distal to the RBCs, is higher under functional 
hyperaemia conditions (Figure 4.18B) than under normal flow (Figure 4.18A). 
Therefore, under functional hyperaemia the unbinding probability should be 
higher. The aim of this section is to establish what effects functional 
hyperaemia has on distribution and binding of nanoparticles to the endothelial 
blood-brain barrier. 
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Figure 4.18: Shear Stress under Normal Flow and Functional Hyperaemia. The 
shear stress is demonstrated in longitudinal and latitudinal cross-sections of the 
vessel under normal flow (A) and functional hyperaemia (B). Latitudinal slices are 
taken distally from the RBCs. 
 
Firstly, the number of nanoparticles that passaged through each vessel in 0.5 
s was quantified. The normalised number of nanoparticles, in Figure 4.19, 
demonstrates that there is 1.3-fold increase in the number of nanoparticles 
that passes through a vessel under functional hyperaemia compared to 
normal flow. 
 
 
Figure 4.19: Normalised Number of Particles Transiting through a Vessel 
under Normal Flow and Functional Hyperaemia. The number of particles 
transiting through a vessel is normalised against normal flow. Each bar represents 
the mean ± standard deviation of three simulations (n=3). 
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Therefore if nanoparticle binding efficiency is maintained under functional 
hyperaemia, or is only marginally decreased, due to the increase access of 
nanoparticles to the area overall, delivery will be improved by inducing 
functional hyperaemia. Nanoparticle compositions used in the previous 
sections were placed within the two blood vessels with different receptor 
densities and their binding was analysed at 0.5 s (Figure 4.20). Generally, 
under flow in Figure 4.20, there appears to be a greater specificity for the 
higher density of receptor expression. This effect is observable even with 
higher levels of flow. The increased wall shear stress under functional 
hyperaemia does seem to reduce the percentage of nanoparticles bound in 
Figure 4.20, as expected. This difference appears greater at lower receptor 
densities, ligand densities, 𝒌𝒂𝟎  values and sizes, likely reflecting both the 
decreased number of bonds and decreased stability of bonds compared with 
higher values. 
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Figure 4.20: Efficiency of Nanoparticle Binding in a Capillary Model of Normal 
Flow and Functional Hyperaemia. Nanoparticles were simulated for 0.5 s under a 
normal flow (left, A, C, E and G) and functional hyperaemia (right, B, D, F and H). 
The percentage of nanoparticles bound to the apical side of the barrier was 
calculated for each composition of nanoparticle. Each data point represents the 
mean ± standard deviation of six simulations (n=6). 
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To investigate whether the lower binding efficiency was offset by the 
increased number of nanoparticles transiting the vessel, giving an increased 
number of bound particles under functional hyperaemia, the ratio of mean 
binding events under functional hyperaemia conditions compared to normal 
flow was compared after 0.05 s (Figure 4.21). Ratios with a cumulative error 
of >20% were excluded from these graphs. Figure 4.21 demonstrates that for 
certain compositions of nanoparticle, there is an increased number of bound 
particles under functional hyperaemia. These compositions generally correlate 
with a higher overall binding affinity due to increased size, 𝒌𝒂𝟎, ligand density 
and receptor density. Intriguingly, at 40 nm, several nanoparticle formulations 
bind at a ratio of <1 at a lower receptor density (Figure 4.21A), but above it at 
higher receptor density (Figure 4.21B). Therefore, induction of functional 
hyperaemia with these compositions should only give improved binding if the 
receptor density is increased. This may be a useful tool for specifically 
targeting the blood-brain barrier when the level of receptor expression can’t be 
ascertained. 
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Figure 4.21: Effect of Functional Hyperaemia on Nanoparticle Binding. The ratio 
of nanoparticle binding under functional hyperaemia against normal flow for 40 nm (A 
and B) and 100 nm nanoparticles (C and D) with a receptor density of 5×1014 m-2 (A 
and C) or 1015 nm-2 (B and D). Points with a >20% error were excluded. Each data 
point is calculated from the mean ± standard error of the mean of binding under 
functional hyperaemia from six replicate simulations (n=6) and normal flow conditions 
conditions from six replicate simulations (n=6). Each point represents the ratio ± 
cumulative error. Significance calculated using the Holm-Sidak t-test, * P < 0.05, ** P 
< 0.01, *** P < 0.005, arrows represent a significant increase or decrease. 
 
Next, the specificity for the higher receptor expression was studied. Figure 
4.22 demonstrates similar patterns to as seen in the transwell model, where 
specificity is generally increased with reduced overall binding affinity, either 
through low 𝒌𝒂𝟎 and high receptor density or high 𝒌𝒂𝟎 and low receptor density. 
The increases in specificity were generally slightly higher than in the transwell 
model. This may reflect the increased vulnerability under shear flow of 
nanoparticles that form fewer bonds.  
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Figure 4.22: Specificity of Nanoparticles for increased Receptor Expression 
under Shear Flow. The ratio of binding between a receptor density of 1015 m-2 and 
5×1014 m-2 for 40 nm (A and B) and 100 nm (C and D) nanoparticles under normal (A 
and C) or functional hyperaemia (B and D) flows. Points with a >20% error were 
excluded. Each data point is calculated from the mean ± standard error of the mean 
of binding under functional hyperaemia from six replicate simulations (n=6) and 
normal flow conditions conditions from six replicate simulations (n=6). Each point 
represents the ratio ± cumulative error. Significance calculated using the Holm-Sidak 
t-test, * P < 0.05, ** P < 0.01, *** P < 0.005 
 
To investigate whether functional hyperaemia had an effect on the bond 
number, the average number of bonds per particle was plotted under normal 
flow and functional hyperaemia (Figure 4.23). Figure 4.23 demonstrates that 
functional hyperaemia, on the whole, gives a marginal decrease in the 
number of receptor bonds. The increased shear stress is likely to make 
nanoparticles bound with very few bonds detach, which would give an overall 
increase in the average number of bonds per particle. However, it is also likely 
to uniformly increase the rate of bond rupture, thus giving an expected 
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decrease in the average number of bonds. These two effects working in 
tandem may result in making the difference in bond number smaller. 
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Figure 4.23: Average Number of Bonds per Nanoparticle in a Capillary Model 
of Normal Flow and Functional Hyperaemia. Nanoparticles were simulated for 0.5 
s under a normal flow (left, A, C, E and G) and functional hyperaemia (right, B, D, F 
and H). The average number of bonds per bound nanoparticle was calculated for 
each composition of nanoparticle. Each data point represents the mean ± standard 
deviation of six simulations (n=6). 
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Finally, the ratio was calculated for nanoparticle binding under functional 
hyperaemia at receptor density of 1015 m-2 to normal flow with a density of 
5×1014 m-2 (Figure 4.24). This demonstrated that combining the two methods 
to obtain specificity gave an improved targeting effect for some nanoparticle 
compositions than either method alone. 
 
 
Figure 4.24: The Combined increased Specificity from induction of Functional 
Hyperaemia and increased Receptor Density. The ratio of binding under 
functional hyperaemia with a receptor density of 1015 m-2 compared to normal flow 
with a density of 5×1014 m-2 for 40 nm (A) and 100 nm particles (B). Points with a 
>20% error were excluded. Each data point is calculated from the mean ± standard 
error of the mean of binding under functional hyperaemia from six replicate 
simulations (n=6) and normal flow conditions conditions from six replicate simulations 
(n=6). Each point represents the ratio ± cumulative error. Significance calculated 
using the Holm-Sidak t-test, * P < 0.05, ** P < 0.01, *** P < 0.005 
 
The models here are limited by the lack of cellular trafficking and release. In 
line with previous data, it can be expected that unbinding is less efficient with 
stronger overall binding of nanoparticles. However, there are several other 
factors, not considered here that may also impact unbinding efficiency. A key 
characteristic of these models is that binding and unbinding are related 
opposite processes. Cell intrinsic mechanisms to aid receptor-ligand 
detachment are excluded; these include changes in pH in the endosomal 
pathway, salt concentration and the presence of enzymes. Furthermore, a key 
function of the blood-brain barrier is to allow the CNS to have a different ionic 
composition compared to the blood (Abbott et al., 2010, Touitou and Barry, 
2006); changes in ion concentration and pH can affect receptor-ligand 
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interactions, therefore altering the kinetics from one side of the barrier to the 
other. Furthermore, the impact of constituent molecules within culture media 
and blood are neglected in our simulations. As discussed in Chapter 3, protein 
fouling is often observed when nanoparticles come into contact with serum. 
This can cause particle swelling changing size parameters and potentially 
altering the binding dynamics of nanoparticles to the cell surface. Whilst a 
number of strategies may be employed to reduce this effect, such as 
PEGylation as discussed in Chapter 1, it can’t be discounted that this would 
affect in vitro and in vivo validation of the data presented in this chapter. 
The model is based on a number of previously unknown parameters, 
including the Lrp1-Angiopep-2 bond length, the 𝒌𝒂𝟎  of the Lrp1-Angiopep-2 
interaction and the receptor density of the Lrp-1 receptor on the blood-brain 
barrier. In their absence, a range of values from the literature and values 
calculated from existing data has been used. In studies of nanoparticles 
targeting the blood-brain barrier, size, receptor-ligand affinity and ligand 
density have not been considered together. However, ligand density has been 
considered alongside size in the work of Wiley and co-workers (Wiley et al., 
2013). They used gold nanoparticles of different sizes and conjugated them to 
varying levels of transferrin. They demonstrated both a size and ligand density 
affect on the overall binding of the nanoparticles to Neuro2A cells. The overall 𝒌𝑫 of their nanoparticles decreased with increasing size and increasing ligand 
density, representing a similar effect to that seen within this chapter. The 
ligand densities of their formulations varied from 0.001 nm-2 to 0.007 nm-2, 
covering similar ranges to that covered in the simulations. The 𝒌𝑫  of 
monoferric transferrin has previously been estimated to be 10-6 M, 
corresponding to a 𝒌𝒂𝟎  of 100000, several orders of magnitude above that 
covered in the simulations (Sawyer and Krantz, 1986). Ligand densities for 
other nanoparticle formulations are available from the literature and also 
conform to the ranges investigated in this study. The Kreuter group used 
loperamide-loaded human serum albumin nanoparticles functionalised with 
the Ox26 or R17217 transferrin receptor antibodies, of ~166-168 nm, at ligand 
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densities of 0.003 nm-2 and 0.002 nm-2 to achieve anti-nociceptive effect in 
rats (Ulbrich et al., 2009). 
The work by Yu and colleagues, did not directly calculate the 𝒌𝑫  of their 
candidate antibodies, however they used Elisa inhibition studies to calculate 
IC50 values that can approximate the 𝒌𝑫 (Yu et al., 2011). They created an 
anti-TfR antibody (TfRA) and three variants of increasing IC50 value. This 
gave IC50 values of 1.7 nM (TfRA), 6.9 nM (TfRB), 65 nM (TfRC) and 111 nM 
(TfRD). When administered in trace doses, brain uptake was increased with 
increasing affinity. However, this trend was reversed with higher therapeutic 
doses with the lowest affinity performing best, hypothesised to be due to the 
rate-limiting step of unbinding. This demonstrates both the underlying 
importance of binding affinity but also blood concentration. The latter of which 
will be affected by blood clearance properties, underlying the need for 
consideration of properties including size and PEGylation on nanoparticle 
clearance.  
A number of techniques exist to find the binding kinetics of proteins, including 
surface plasmon resonance (SPR), dual-polarisation interferometry (DPI), bio-
layer interferometry (BLI), microscale thermophoresis (MT) and isothermal 
titration calorimetry (ITC). Surface Plasmon Resonance (SPR) and Dual-
Polarisation Interferometry (DPI) both use an immobilised receptor and a flow 
system to calculate the association and dissociation properties. In SPR, 
binding of the receptor-ligand pair causes a change in the reflective angle, 
altering the signal (Pattnaik, 2005). DPI measures conformational changes 
that occur during a receptor-ligand interaction (Cross et al., 2008). Bio-layer 
interferometry is an optical technique that uses immobilised protein on a tip to 
detect binding and calculate binding properties (Rich and Myszka, 2007). ITC 
and MT do not require immobilising the receptor. ITC measures specific 
changes in temperature to follow the kinetics of a protein-protein interaction 
(Velázquez-Campoy et al., 2001). MT is able to detect changes in size, 
charge and hydration shell. It uses this data to follow the course of a reaction 
and ascertain the kinetics of the reaction (Wienken et al., 2010). 
CHAPTER 4: RESULTS AND DISCUSSION II 193 
Whilst the literature does contain references to ligand density, receptor-ligand 
affinity and size, receptor density is rarely considered in blood-brain barrier 
delivery. In recent work, Chen and colleagues, established a technique to find 
the receptor density of live cells using fluorescence correlation spectroscopy 
and fluorescently labelled aptamers that bind specific cell surface receptors 
(Chen et al., 2009). They used this technique to look at the receptor density of 
protein tyrosine kinase 7 (PTK7) on two different cell lines and found densities 
of 5×1014 and 1.3×1015, similar to the two values used in this study. It cannot 
be discounted also that differences in receptor expression will be found 
between species and different cell lines, which may affect the translation of 
results from in vitro to in vivo models. 
Future work to ascertain these values would aid refinement of these methods. 
Furthermore, better integration of biological imaging techniques, such as 
fMRI, into more complex blood flow models may allow development of 
personalised treatment strategies. This could consider other aspects of 
changes in blood flow, including changes in neurovascular coupling and blood 
flow associated with disease.  
One additional effect of nanoparticle binding strength that we have not studied 
is the effect of strong binding on nanoparticle penetration throughout the 
entire tissue. Frieboes and colleagues demonstrated that particles that bind 
rapidly and strongly to the vessel walls in tumour models gave a depletion 
effect throughout the remaining downstream vasculature network (Frieboes et 
al., 2013). This limits the potential for nanoparticles to penetrate throughout 
the entire tissue, potentially limiting therapeutic effect. This could be 
addressed by future work extrapolating these models to models of a vascular 
network. 
The model only considers the binding of a single receptor on the blood brain 
barrier. However, nanoparticles have the potential to be decorated with 
multiple ligands; these are often used to target different cells. The wide-
expression of Lrp-1 and the transferrin receptor in the CNS and in the 
periphery may cause off-target effects, multiple ligands could be used to give 
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better specificity. By using weak affinity ligands and a moderate ligand 
density, only the collective binding of different ligands would enable strong 
binding. This technique could be used to improve specificity to particular cell 
populations. However, whilst this would work in principle in terms of cellular 
binding, it is not possible to predict what the influence of binding different 
receptors will be on cellular transport. Further studies of the mechanism of 
transcytosis will enable better understanding of the routes through the cell and 
may lead to future improvements of the models presented in this chapter and 
better formulation of nanoparticles for optimal delivery across the blood-brain 
barrier and to cells of the CNS. 
In the Battaglia laboratory, Angiopep-2 functionalised POEGMA-PDPA 
polymersomes have been used in the transwell model with a B.End3 
endothelial cell barrier. Varying the degree of polymer functionalisation altered 
the ligand density on the polymersomes. 1%, 2%, 3%, 4%, 5% and 6% 
Angiopep polymersomes were formulated giving ligand densities of 9.2×1014 
m-2, 1.8×1015 m-2, 2.7×1015 m-2, 3.6×1015 m-2, 4.6×1015 m-2 and 5.5×1015 m-2 
respectively. The transcytosis efficiency was measured at 30 minutes as seen 
in Appendix IV. This demonstrates that a higher ligand density can indeed 
reduce transcytosis efficiency. Whilst, the 𝒌𝒂𝟎 of Angiopep-2-Lrp1 interaction 
and Lrp1 receptor density are unknown, this demonstrates a similar principle 
does occur in vitro. 
 
4.4 CONCLUSIONS 
In conclusion, agent-based models of nanoparticle binding to the blood-brain 
barrier in in vitro transwell and capillary models have been studied. It has 
been demonstrated that tailoring nanoparticle properties can control binding 
specificity for a higher level of receptor expression according to these models. 
Furthermore, an increase in blood flow velocity associated with functional 
hyperaemia improves overall nanoparticle delivery, for certain formulations, 
despite the reduced binding associated with increased shear stress. In the 
future, refinement of these models using biological data from the blood-brain 
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barrier and patients could enable personalised medicine for improved specific 
delivery to different regions of the CNS. 
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CHAPTER 5: RESULTS AND DISCUSSION III 
MODELLING THE CHEMOTAXIS PROPERTIES OF 
NANOPARTICLES 
 
5.1 INTRODUCTION 
An important goal in the nanoparticle-mediated delivery of therapeutics is to 
improve their specificity, thus improving therapeutic load at target cells and 
reducing side-effects. The blood is a highly effective delivery system to all 
tissues of the body, particularly to the CNS. Nanoparticle properties such as 
size, shape, surface chemistry and active-targeting of desired tissues dictates 
their ability to penetrate into the target tissue and find target cells to release 
their cargo. In Chapter 4, receptor-mediated nanoparticle-cell binding was 
explored as a method to obtain specificity when nanoparticles interact with a 
potential target, with particular focus on transcytosis across the blood-brain 
barrier. However, another key aspect of successful delivery is in maximising 
the access of nanoparticles to the cells of interest. In order to reach their 
target cells within the CNS, nanoparticles in the blood must surpass a series 
of biological barriers. The first of which is the endothelial blood-brain barrier 
that regulates blood-tissue exchange. Nanoparticles that successfully reach 
the CNS must then penetrate through the parenchyma to reach the target 
cells. At the target cells, nanoparticles can be taken up and release their 
therapeutic cargo. 
Recent work within the field of micro- and nano-scale technology has studied 
the introduction of chemotaxis properties into synthetic systems. Chemotaxis 
allows cells and bacteria to respond to chemical stimuli with changes in 
motility. In Chapter 1, the recent development of chemotactic polymersomes, 
within the Battaglia group, was discussed. These nanoparticles are able to 
follow glucose and hydrogen peroxide gradients by a combination of self-
diffusiophoresis and self-osmophoresis. Chemotaxis to or from chemical 
stimuli within the body may be used to increase the distribution of 
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nanoparticles to their respective targets, ultimately improving both specificity 
and reducing off-target effects.  
 
5.2 AIMS AND OBJECTIVES 
In the work presented in this chapter, agent-based modelling is utilised to 
study nano- and micro- scale particles undergoing chemotaxis. The aim of this 
work is to investigate whether the introduction of non-substrate dependent 
directed motility, termed propulsion, properties can improve nanoparticle 
escape from the blood into the CNS and whether directed chemotaxis can aid 
distribution to targets. Furthermore, methods to better control chemotaxis 
efficiency for different gradients is explored. 
 
5.3 RESULTS AND DISCUSSION 
5.3.1 Building an Agent-based Model of Particle Propulsion 
In order to effectively investigate the functions of chemotactic nanoparticles, a 
3D model of nanoparticles undergoing propulsion was first developed using 
FLAME. This model initially makes the assumption that the substrate is 
homogenous and therefore the rate of propulsion is independent of substrate 
concentration. The characteristic random walk or Brownian motion of particles 
was generated by the methods of Andrews and Bray, as tested in Chapter 3, 
to give the movement vector for Brownian motion (𝑭𝑩) (Andrews and Bray, 
2004). Rotational diffusion was modelled in a similar manner to the random 
walk, using the rotational diffusion coefficient (𝑫𝒓):  
 𝑫𝒓 = 𝒌𝑩𝑻𝟖𝝅𝜼𝒓𝟑          (5.1). 
 
Three separate angles, 𝜗, 𝜄 and 𝜅 were used for rotating around the 𝑥-, 𝑦- and 𝑧- axes respectively. The angles were rotated according to rotational diffusion 
by addition of Δ𝜗, Δ𝜄 and Δ𝜅, generated through substituting 𝑫𝒓 for 𝑫𝒄 in the 
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Andrews and Bray method. A vector of propulsion (𝑭𝑷) was given as starting 
in the positive y direction: 
 
𝑭𝑷 = 𝟎𝝋𝜹𝒕𝟎           (5.2) 
 
where 𝜑 is the velocity of propulsion and 𝛿𝑡 the time-step. This vector was 
then rotated according to the rotational diffusion, thus giving directional 
movement. The vector of propulsion was then added to the random 
movement vector generated for Brownian motion to give a total movement 
vector (𝑭𝑻) of:  
 𝑭𝑻 = 𝑭𝑩 + 𝑭𝑷          (5.3). 
 
Particles were propelled at velocities of 0 μm·s-1, 10 μm·s-1, 20 μm·s-1, 50 
μm·s-1 and 100 μm·s-1. Particle motion was evaluated by calculating the mean 
squared displacement (MSD) of individual particles against time (𝑡): 
 𝑴𝑺𝑫 𝒕 = 𝒒 𝒕 − 𝒒(𝟎) 𝟐          (5.4) 
 
where 𝒒 𝒕  is the position of the particle at time 𝒕 and 𝒒(𝟎) is the position of 
the particle at time 0. The expected MSD for a particle of radius 𝑟 is calculated 
through the diffusion coefficient (𝑫𝒄) and the relationship: 
 𝑴𝑺𝑫 = 𝒌𝑫𝒄          (5.5) 
 
where 𝒌 is a constant related to the number of dimensions, in 3D 𝒌 is equal to 
6. 
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Particles acting under directed propulsion should demonstrate a non-linear 
increase in MSD across short time-scales, reverting to a non-directed 
propulsion regime of a linear increase, albeit with an increased diffusion 
coefficient, over longer time-scales. The time it takes for this switch from a 
non-linear to a linear increase is dependent on the rotational diffusion 
coefficient, effectively how long it takes for particle to re-orientate (Howse et 
al., 2007, Palacci et al., 2010). The MSD, over time, was evaluated for four 
diameters of spherical particle, 100 nm, 200 nm, 500 nm and 1 μm. The 
translational and rotational diffusion coefficients for each particle, calculated 
through the Stokes-Einstein relations, are given in Table 5.1. 
 
Diameter Dc (μm·s-1) Dr (s-1) 
100 nm 2.671 801.4 
200 nm 1.336 100.2 
500 nm 0.534 6.411 
1 μm 0.267 0.801 
Table 5.1. Translational and Rotational Diffusion Coefficients for different 
Sized Particles. Temperature (T) = 310 K, viscosity (η) = 0.0017 Pa·s. 
 
The average MSD over time for 20 individual particles (Figure 5.1) 
demonstrates that the 100 nm and 200 nm populations exhibit mainly linear 
increases in average MSD, albeit with an increased MSD with higher levels of 
propulsion (50 μm·s-1 and 100 μm·s-1). However, 500 nm and 1 μm 
populations demonstrate non-linear increases in MSD over time when a 
propulsion velocity is applied.  
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Figure 5.1: The Average Mean Squared Displacement of a Population of 
Nanoparticles versus Time. The average MSD of 100 nm, 200 nm, 500 nm and 1 
μm nanoparticle populations is plotted at 0.1 s intervals for 0.5 s with propulsion 
velocities of 0 μm·s-1, 10 μm·s-1, 20 μm·s-1, 50 μm·s-1 and 100 μm·s-1. Each data 
point represents the mean ± standard deviation of 20 simulations (n=20). 
 
Individual particle traces for MSD against time (Figure 5.2) show that for 100 
nm and 200 nm populations, the rotational time is such that direction of 
motion is re-orientated over time periods shorter than the length of simulation. 
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Figure 5.2: The Mean Squared Displacement of a Population of Nanoparticles 
versus Time. The individual MSDs of a population of 20 nanoparticles of size 100 
nm, 200 nm, 500 nm or 1 μm are plotted at 0.1 s intervals for 0.5 s with propulsion 
velocities of 0 μm·s-1, 10 μm·s-1, 20 μm·s-1, 50 μm·s-1 and 100 μm·s-1. The red line 
indicates the average MSD for all particles, the blue line indicates the expected MSD 
when the propulsion velocity is equal to 0 μm·s-1. 
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This is further demonstrated in the motion traces (Figure 5.3), where particles 
show an increased displacement with increased propulsion but lack 
orientational persistence across the whole simulation time, thus giving the 
linear increases observed in Figure 5.1. 
 
 
Figure 5.3: Nanoparticle Motion Traces with varying Size and Propulsion 
Velocity. The motion of 10 nanoparticles is tracked for 0.05 s at 0.001 s intervals. 
Nanoparticles start at a common origin in the centre of the simulation region. 
Separate colours indicate individual nanoparticles. Scale bar =1 μm. 
 
Individual 500 nm and 1 μm particles demonstrate good orientational 
persistence in forming enhanced non-linear MSD curves (Figure 5.2) and 
motion traces where particles steadily move away from the common origin 
with a more linear trajectory (Figure 5.3). The whole population for 1 μm 
particles displays a highly uniform trend across 0.5 s, as compared to the 500 
nm population, reflecting the small effect of rotational diffusion on 1 μm 
particles, thus enabling improved motility in a single direction over longer 
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periods of time. The result of this is that large particles are able to better 
follow a single trajectory over time. 
 
5.3.2 Accumulation of Particles undergoing Propulsion at Interfaces 
The increased displacement of particles acting under propulsion may aid 
distribution to the edges of a confined space, as would be expected in a 
biological system. In order to investigate this, 10 nanoparticles were simulated 
in a 2 μm box and their motion was traced across 0.05 s (Figure 5.4). The 
slow rotational times of the 500 nm and 1 μm populations allowed the 
nanoparticles to accumulate at the edges of the box, a phenomenon also 
observed with higher velocities for the 200 nm population. The motion traces 
for the 100 nm population show no such accumulation at the edge of the box, 
however as propulsion velocity increases, the particles appear to displace 
further, in accordance with the findings from Figure 5.1. Therefore they may 
interact with the edge more often than by Brownian motion alone. The 
accumulation at solid interfaces has previously been reported using a similar 
2D model of propelled 1 μm particles (Volpe et al., 2011, Volpe et al., 2014). 
This principle may be used to aid accumulation of particles at cellular 
interfaces, thus stimulating improved transport. 
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Figure 5.4: Nanoparticle Motion Traces with varying Size and Propulsion 
Velocity. The motion of 10 nanoparticles, confined in a 2×2×2 μm box, is tracked for 
0.05 s at 0.001 s intervals. Nanoparticles start at a common origin in the centre of the 
box. Separate colours indicate individual nanoparticles. Scale bar = 200 nm. 
 
5.3.3 Propulsion and Blood-Tissue Transport 
The increased displacement and accumulation at interfaces of particles 
undergoing propulsion may aid dispersion within the blood to the vessel wall 
interfaces where transport occurs. In order to test the effect of placing 
propelled nanoparticles in the context of blood flow, two different models of 
laminar flow within a capillary were used, a simple Poiseuille’s flow model and 
the model demonstrated in Chapter 3. This model incorporated both laminar 
and Brownian forces acting upon the nanoparticle by the relationship: 
 𝑭𝑻 = 𝑭𝑩 + 𝑭𝑳          (5.6) 
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where 𝑭𝑳  is the vector of movement generated from the laminar flow. To 
include laminar, Brownian and propulsion forces within a model of blood flow 
the vector for propulsion was therefore added to give: 
 𝑭𝑻 = 𝑭𝑩 + 𝑭𝑳 + 𝑭𝑷          (5.7). 
 
Particles undergoing propulsion were first simulated in the Poiseuille’s model 
of blood flow. Nanoparticles were seeded randomly at the entrance of the 
vessel and allowed to passage through the vessel. The vessel walls were set 
as no-slip, sticky boundaries, so that the number of nanoparticles stuck to the 
vessel wall could be evaluated with different sized particles and velocities of 
propulsion. The motion of the nanoparticles was tracked through a latitudinal 
cross-section of the vessel and shows a similar effect to that seen in Section 
5.3.2, where larger particles accumulate at the vessel walls and smaller 
particles demonstrate an overall increase in motility (Figure 5.5). 
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Figure 5.5: Nanoparticle Motion Traces with varying Size and Propulsion 
Velocity inside a Capillary. The motion of 10 nanoparticles is tracked for 0.05 s at 
0.001 s intervals in a latitudinal cross-section of a Poiseuille’s model of a capillary 8 
μm in diameter. Nanoparticle traces that exit the vessel or bind to the wall are 
terminated. Separate colours indicate individual nanoparticles. 
 
Figure 5.6 shows the percentage of particles that bind to the vessel wall 
during a single passage through the vessel. Binding to the vessel walls 
generally is improved by increasing the propulsion velocity in all samples. The 
naturally higher motility of 100 nm particles due to diffusion alone and lack of 
orientational persistence, makes this increase smaller in these groups, but it 
reaches significance at higher propulsion velocities (P=0.0006 for 𝜑=50 μm·s-
1 and P=2.16×10-9 for 𝜑=100 μm·s-1). 
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Figure 5.6: Binding of Nanoparticles undergoing Propulsion in a Simple Model 
of a Capillary. The percentage of nanoparticles bound when transiting through a 
Poiseuille flow model of a capillary with diameter of 8 μm, with different size particles 
and propulsion velocities of 0 μm·s-1, 10 μm·s-1, 20 μm·s-1, 50 μm·s-1 and 100 μm·s-1. 
Each data point represents the mean ± standard deviation of six simulations (n=6). 
Significance calculated using the Holm-Sidak t-test, points tested against 
nanoparticle populations of the same size but with a propulsion of 0 μm·s-1, * P < 
0.05, ** P < 0.01, *** P < 0.005 
 
In order to see if this effect was maintained in a more realistic model of blood 
flow in a capillary, particles undergoing propulsion were tested in the model 
from Chapter 3. Particles were evenly distributed across the entire vessel, to 
minimise the effects from differences in their proximity to a RBC and 
simulated for 0.05 s. 500 nm and 1 μm populations were omitted from this 
experiment because their large size would likely significantly affect the blood 
flow in this model and their large sizes are well above the optimal range of 
nanoparticle size for in vivo application. Figure 5.7 shows that whilst a similar 
conclusion can be made as to under Poiseuille’s flow, where a higher 
propulsion velocity leads to higher uptake, the differences between samples 
are more pronounced and significance is reached for 100 nm particle at a 
propulsion velocity of 20 μm·s-1 (P=0.00088).  
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Figure 5.7: Binding of Chemotactic Nanoparticles in a Capillary. The percentage 
of nanoparticles bound when transiting through a complex model of capillary blood 
flow incorporating RBCs, with different size particles and propulsion velocities of 0 
μm·s-1, 10 μm·s-1, 20 μm·s-1, 50 μm·s-1 and 100 μm·s-1. Each data point represents 
the mean ± standard deviation of three simulations (n=3). Significance calculated 
using the Holm-Sidak t-test, points tested against nanoparticle populations of the 
same size but with a propulsion of 0 μm·s-1, * P < 0.05, ** P < 0.01, *** P < 0.005 
 
Therefore, modelling would suggest that adding an element of propulsion to 
nanoparticle motion might increase overall uptake from the blood due to the 
improved distribution of nanoparticles to the endothelial wall interface. It 
should be noted that whilst improved distribution to the vessel walls is 
important for uptake, the increased motility might also alter the efficiency of 
nanoparticle binding. Moreover, the physical mechanisms underlying self-
diffusiophoresis and self-osmophoresis will likely be affected by the laminar 
flow, a concept not addressed by the simulations.  
In previous work within the Battaglia group, chemotactic polymersomes of 70-
100 nm demonstrate orientational persistence that is far greater than 
expected from rotational diffusion. Therefore, it is hypothesised that the 
mechanism of self-diffusiophoresis/self-osmophoresis is able to reduce the 
angular velocity of these particles. The mechanism for this remains subject to 
further investigation, however it has been predicted in theoretical studies and 
demonstrated with microscale particles undergoing self-diffusiophoresis 
(Golestanian et al., 2007, Howse et al., 2007). The decreased angular velocity 
of these particles may enable the improved accumulation of 100 nm and 200 
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nm particles at interfaces in a similar manner to 500 nm and 1 μm particles, 
potentially increasing their uptake from the blood. 
This effect was validated in in vitro and in vivo experiments with chemotactic 
polymersomes. Chemotactic polymersomes were able to migrate against a 
low flow through a 100 mm Petri dish towards a gradient of glucose. 
Furthermore, in polymersome uptake was enhanced by the addition of 
chemotactic properties in rat experiments studying delivery to the CNS using 
in situ perfusion of the rat brain. Chemotactic polymersomes, responsive to 
glucose and functionalised with Angiopep-2 (A-EP-EB), demonstrated a 
nearly 2-fold delivery increase into the parenchyma compared to non-
chemotactic polymersome controls (Appendix V). The use of glucose as a 
substrate ensured that there would be a high level of substrate available 
within the blood, as blood glucose is maintained at ~4-7.8mM. However, in 
future, more specific and less ubiquitous stimuli may be used to improve 
specificity of this effect. The release of non-abundant stimulus into the blood 
by a tissue will create a local high concentration that will dissipate as it 
circulates the body, thus limiting this effect to the microvasculature of the 
tissue of release. Furthermore, similar principles could be used with particles 
that respond to non-chemical stimuli such as temperature (Jiang et al., 2010) 
or magnetic fields (Tierno et al., 2008). The use of magnetic nanoparticles has 
previously been demonstrated to improve uptake to the CNS across the 
blood-brain barrier (Pulfer et al., 1999, Pulfer and Gallo, 1998, Qiao et al., 
2012). 
 
5.3.4 Chemotaxis 
To investigate whether chemotaxis could aid distribution to target cells, the 
model of particles undergoing propulsion was adapted to simulate substrate-
dependent propulsion. Force of propulsion (𝑭𝑷) is given as proportional to the 
rate of reaction (𝒖), which for an enzyme following Michaelis-Menten kinetics 
is: 
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𝒖 =    𝒖𝒎𝒂𝒙[𝑺]𝒌𝒎![𝑺]           (5.8) 
 
where 𝒌𝒎 is the concentration of substrate ([𝑺]) that gives a reaction rate 
equal to 𝒖𝒎𝒂𝒙𝟐 . 𝒖𝒎𝒂𝒙  is given by the enzymatic capacity of the enzyme, 
calculated from the conversion rate of a single enzyme (𝒌𝒄𝒂𝒕 ) and the 
concentration of the enzyme ([𝑬]): 
 𝒖𝒎𝒂𝒙 = 𝒌𝒄𝒂𝒕[𝑬]          (5.9) 
 
Therefore the rate of propulsion can be given: 
 𝑭𝑷 ∝ 𝒌𝒄𝒂𝒕 𝑬 [𝑺](𝒌𝒎! 𝑺 )           (5.10). 
 
The size of particle, size of the enzyme and the method of encapsulation or 
attachment to the nanoparticle dictate the concentration of enzyme. The size 
data, encapsulation concentration based on data from Claudia Contini, 𝒌𝒎 
and 𝒌𝒄𝒂𝒕 for glucose oxidase from Aspergillus niger in a 100 nm polymersome 
are given in Table 5.2. 
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Property Value 
Molecular Weight 160 kDa 
Encapsulation Efficiency 
(Molecules/ 100 nm 
Polymersome) 
~18 
[𝐸] 0.135 mM 𝑘! ~30 mM 𝑘!"# 920 s-1 
Table 5.2: Encapsulation and Enzyme Properties of Glucose Oxidase from A. 
niger. (Gibson et al., 1964, Swoboda and Massey, 1965). 
 
Therefore the maximal reaction velocity (𝒖𝒎𝒂𝒙) for polymersome encapsulated 
glucose oxidase is equal to 124.2 mM·s-1. The substrate dependent reaction 
velocity is given in Figure 5.9. 
 
 
Figure 5.8: Substrate-dependent Reaction Velocity. The reaction rate of glucose 
oxidase, at a concentration of 0.135 mM, against substrate concentration. 
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reaction. This relationship is complex, as demonstrated by the work of the 
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𝝋 = 𝒖𝝋𝒎𝒂𝒙𝒖𝒎𝒂𝒙           (6.8) 
 
where 𝝋𝒎𝒂𝒙 is the maximal propulsion of velocity, given as 0 μm·s-1, 10 μm·s-
1, 20 μm·s-1, 50 μm·s-1 or 100 μm·s-1, in accordance with previous rates of 
propulsion velocity. 
Particles were placed in the centre of a simulated box and different gradients 
were applied across the box (Figure 5.10). The edges of the box were treated 
as reflective boundaries, except the top and bottom edges that were treated 
as sticky boundaries. The substrate concentration was given as linear 
gradients from 0 mM to 0 mM, 0 mM to 10 mM, 0 mM to 30 mM and 0 mM to 
1000 mM (bottom to top), to reflect the different stages of the Michaelis-
Menten profile. These were when the reaction rate is equal to 0 (0 mM), 
before the exponential phase (10 mM), during the exponential phase at the 𝑘! 
(30 mM) and after the exponential phase (1000 mM) (Figure 5.10).  
 
Figure 5.9: Chemotaxis Simulation Set up. Particles were placed in the centre of 
the simulation area and gradients were applied to the particles. The propulsion 
velocity was related to the substrate concentration by the Michaelis-Menten kinetics. 
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100 nm, 200 nm, 500 nm and 1 μm particles were simulated for 0.4 s and the 
chemotaxis efficiency scored by the ratio of particles bound to the top against 
the bottom (Figure 5.11). When no substrate concentration gradient is 
present, particle segregation is driven by diffusion, therefore the chemotaxis 
ratio should be equal to 1, as observed for all particle sizes in Figure 5.11A. 
However, when substrate is present, the segregation is driven by propulsion. 
In moderate gradients, 500 nm and 1 μm particles show a directional bias 
towards the source of substrate (Figure 5.11B and C). A weak but consistent 
chemotactic effect is also observed with 200 nm particles, but no directional 
biased is observed for 100 nm particles in any gradient applied (Figure 5.11B, 
C and D). This is in line with current opinion on nano-scale chemotactic 
systems, that the high rotational times of these particles is inhibitive to 
chemotaxis over long distances and time periods (Howse et al., 2007, Palacci 
et al., 2010). When the substrate concentration is steep and the reaction 
velocity tends towards 𝑢!"# , chemotaxis is generally poor with only slight 
increases in chemotaxis scores (Figure 5.11D). 
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Figure 5.10: Chemotaxis Efficiency of Chemotactic Particles under different 
Gradients. Chemotaxis efficiency is measured against the velocity of propulsion, 
with four different sized particles, in four different gradients, 0 mM to 0 mM (A), 0 mM 
to 10 mM (B), 0mM to 30 mM (C) and 0 mM to 1000 mM (D) after 0.4 s. Each data 
point represents the mean ± standard deviation of three simulations (n=3). 
Significance calculated using the Holm-Sidak t-test, points tested against 
nanoparticle populations of the same size but with a propulsion of 0 μm·s-1, * P < 
0.05, ** P < 0.01, *** P < 0.005 
 
Interestingly, a lower velocity of propulsion appears to promote better 
chemotaxis for 1 μm particles. This may be a result of some particles being 
driven away from the substrate source due to the inability to reorientate 
themselves effectively, as a result of their slow rotational times. This is an 
example of the polar run and tumble, predicted by the work of Saha and 
colleagues (Saha et al., 2014). In order to demonstrate the relative influence 
of the polar run and tumble, particles were simulated with the maximum 
substrate gradient in the centre and the lowest concentration at the top and 
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bottom. The percentage of nanoparticles bound to the top or bottom after 0.05 
s is given in Figure 5.12. 
 
 
Figure 5.11: Polar Run and Tumble of different Particles. The percentage of 
particles bound after 0.05 s with different levels of propulsion, different particle sizes 
and different gradients of 0 mM to 0 mM to 0 mM (A), 0 mM to 10 mM to 0 mM (B), 0 
mM to 30 mM to 0 mM (C), and 0 mM to 1000 mM to 0 mM (D). Each data point 
represents the mean ± standard deviation of three simulations (n=3). Significance 
calculated using the Holm-Sidak t-test, points tested against nanoparticle populations 
of the same size but with a propulsion of 0 μm·s-1, * P < 0.05, ** P < 0.01, *** P < 
0.005 
 
1 μm particles demonstrate a high level of polar run and tumble in all 
gradients, with the percentage bound ranging from ~50% to 100% (Figure 
5.12B-D). 200 nm and 500 nm particles show polar chemotaxis that increases 
steadily with increasing gradient. However, 100 nm particles show little polar 
chemotaxis, with the only notable increase in binding occurring at high 
propulsion velocities (100 μm·s-1) and high gradients (0 mM à 1000 mM à 0 
mM) in Figure 5.12D. This suggests that the high rotational time of small 
particles reduces the contribution of polar chemotaxis to net chemotactic 
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activity. The reduction of propulsion velocity also reduces the degree of polar 
chemotaxis exhibited by particles with a slow rotational diffusion. Therefore, 
obtaining a higher net chemotaxis towards a substrate requires tailoring the 
relative influence of polar and apolar run and tumble, by adjusting propulsion 
velocity relative to the rotational diffusion. Bacteria solve this issue by limiting 
their run time to ~1s before increasing their effective rotational time in a 
tumble. The sustained length of a run can be adjusted by changing the 
rotational time accordingly. Previously it had been considered that the only 
mechanism to do this was by altering the particle size. The work of the 
Battaglia group and the Golestanian group may open new avenues to control 
the length of the run according to substrate concentration-dependent changes 
in orientational persistence. 
The propulsion velocity relative to a fixed rotational diffusion can also be 
adjusted by manipulation of the reaction rate. The reaction rate is reliant on 
the 𝒌𝒄𝒂𝒕, 𝒌𝒎, [𝑺] and [𝑬]. The 𝒌𝒄𝒂𝒕 and 𝒌𝒎 are innate to the enzyme and [𝑺] is 
a property determined by the biological system, therefore reduction of [𝑬] 
represents the easiest way to manipulate the reaction rate. In parallel with the 
earlier experiments, maximal velocities of propulsion of 0 μm·s-1, 10 μm·s-1, 
20 μm·s-1, 50 μm·s-1 or 100 μm·s-1 were obtained by adjusting [𝑬] to 0 mM, 
0.0135 mM, 0.027 mM, 0.0675 mM and 0.135 mM respectively and 
maintaining 𝝋𝒎𝒂𝒙 at 100 μm·s-1 (Figure 5.13). 
 
 
Figure 5.12: Enzyme and Substrate Concentration dependent Propulsion 
Velocity. The propulsion velocity is related to the Michaelis-Menten kinetics of 
different concentrations of enzyme and substrates. 
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Figure 5.14 and Figure 5.15 demonstrate that a similar pattern of both net 
chemotaxis and polar run and tumble can be generated from reducing the 
enzyme concentration as opposed to reducing the propulsion velocity (Figure 
5.11 and Figure 5.12). In future better understanding of propulsion velocity 
and rotational diffusion coefficient changes may allow tailored design of 
nanoparticles to give the optimal chemotaxis along a specific gradient. 
Effective chemotaxis to a high concentration of a specific stimulus released by 
target cells/tissue may improve accumulation of particles in the region, thus 
improving delivery specificity. 
 
 
 
Figure 5.13: Chemotaxis Efficiency of Chemotactic Particles under different 
Gradients with different Enzyme Encapsulation. Chemotaxis efficiency is 
measured against the encapsulation of enzyme, with four different sized particles, in 
four different gradients, 0 mM to 0 mM (A), 0 mM to 10 mM (B), 0mM to 30 mM (C) 
and 0 mM to 1000 mM (D) after 0.4 s. Each data point represents the mean ± 
standard deviation of three simulations (n=3). Significance calculated using the Holm-
Sidak t-test, points tested against nanoparticle populations of the same size but with 
a propulsion of 0 μm·s-1, * P < 0.05, ** P < 0.01, *** P < 0.005 
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Figure 5.14: Polar Run and Tumble of different Particles with different Enzyme 
Encapsulation. The percentage of particles bound after 0.05 s with different levels of 
enzyme encapsulation, different particle sizes and different gradients of 0 mM to 0 
mM to 0 mM (A), 0 mM to 10 mM to 0 mM (B), 0 mM to 30 mM to 0 mM (C), and 0 
mM to 1000 mM to 0 mM (D). Each data point represents the mean ± standard 
deviation of three simulations (n=3). Significance calculated using the Holm-Sidak t-
test, points tested against nanoparticle populations of the same size but with a 
propulsion of 0 μm·s-1, * P < 0.05, ** P < 0.01, *** P < 0.005 
 
The simulations throughout this chapter model each nanoparticle as an 
independent agent. However, complex group behaviour of chemotactic micro-
organisms has been demonstrated previously including effects such as 
swarming. It can be expected that group behaviour will also occur in nano-
scale and micro-scale chemotactic particles. Particles that are side-by-side 
can form asymbiotic (Figure 5.16A) or symbiotic (Figure 5.16B) relationships 
with one another, depending on the particles orientation with respect to one 
another. Particles that are one behind the other can lead to blocking (Figure 
5.16C) motion of one particle, repulsion (Figure 5.16D) or clumping (Figure 
5.16E) of particles. At any particular point, many such interactions may occur 
simultaneously giving rise to clumps or asters of particles and patterns, as 
predicted by the work of Saha and colleagues (Saha et al., 2014). The 
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omission of these interactions may affect the translation from the simulations 
presented here to actual bulk behaviour of chemotactic nanoparticle 
populations. 
 
 
Figure 5.15: Group Behaviour of Self-Diffusiophoretic Particles. Two particles, 
in close proximity, both undertaking self-diffusiophoresis by converting a substrate 
into product(s) will interact in different ways according to their position and orientation 
of the site of product release relative to one another. Two particles, side-by-side, with 
orientation in opposing directions, will lead to little or no net movement of either 
particle (A). When the particles’ orientation is aligned the cumulative concentration 
gradient will improve net motion of the particles (B). Particles one behind the other, 
with orientation in the same direction, leads to a blocking effect on the trailing, as no 
net concentration gradient is obtained (C). Particles in opposite orientation will either 
repel each other (D) or attract each other leading to clumping (E). 
 
There have been many attempts to create artificial chemotactic particles in 
recent years. The first attempts concentrated on producing artificial flagella 
that responded to magnetic fields to produce thrust. Dreyfus and colleagues 
used magnetic particles, linked by DNA and attached to a red blood cell to 
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produce a propelled red blood cell (Dreyfus et al., 2005). Zhang and co-
workers used a helical metal tail attached to a soft magnetic thin film of 
approximately 4.5 μm by 4.5 μm by 200 nm, to produce a magnetic 
responsive particle (Zhang et al., 2009). Snezhko and co-workers used 90 μm 
nickel spheres to self-assemble magnetic responsive snakes (Snezhko et al., 
2009). Tierno and colleagues also demonstrated a magnetic responsive 
microswimmer, however this was achieved using the conjugation of a 2.8 μm 
Dynabead to 1 μm Dynabead using an 8 nm DNA linker, which was motile in 
close proximity to a solid surface (Tierno et al., 2008). In all of these studies, 
the use of artificial flagella, though effective, restricted the size of these 
swimmers to a micrometre size. This would limit their capacity to be used in 
biological in vivo applications as the particles would be both difficult to 
administer and rapidly cleared from body by the reticuloendothelial system. 
These methods rely on application of a magnetic field, this could allow guided 
uptake of nanoparticles into regions of interest by application of narrow 
magnetic fields. 
Jiang and colleagues produced a thermophoretic Au-silica Janus particle of 1 
μm that was able to follow temperature gradients created by an intense laser 
(Jiang et al., 2010). This method requires the existence of temperature 
gradients in vivo to be useful in targeting; while slight gradients may exist, 
they are likely to be too insignificant to exploit effectively. The ability of 
nanoparticles to follow chemical gradients in vivo represents a far more 
interesting prospect as they could follow natural gradients to find targets of 
interest. These gradients could be produced when a cell/tissue releases a 
particular molecule, creating a positive gradient towards the cell/tissue, or 
when it removes/consumes molecules leading to a negative gradient to the 
cell/tissue. Paxton and colleagues used 2 μm rods to catalyse the breakdown 
of hydrogen peroxide (Paxton et al., 2005). Mano and colleagues produced a 
0.5 cm glucose responsive nanoswimmer using carbon fibres with glucose 
oxidase (Mano and Heller, 2005). A number of other groups have described 
micrometer scale swimmers that are responsive to hydrogen peroxide (Howse 
et al., 2007, Ke et al., 2010, Gibbs and Zhao, 2009). A recurrent theme in 
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these studies is that nanoscale motile particles remain elusive in the literature. 
In this chapter, particles covering nanometre to micrometre scales are used in 
simulations of chemotaxis. Some of the major challenges that have prevented 
the development of chemotactic nanoscale particles are demonstrated in 
these models. For example, when observing ability to follow chemical 
gradients, 100 nm nanoparticles displayed no directional bias and 200 nm 
nanoparticles only displayed directional bias at high propulsion (Figure 4.11 
B-C and Figure 4.14 B-C). In Chapter 1, a chemotactic nanoparticle system 
designed in the Battaglia group is discussed. In testing of this particle, a 
reduced rotational time has been observed when subjected to glucose or 
hydrogen peroxide gradients, this would make the particle behave similar to 
micrometre particles in their ability to follow concentration gradients. 
Moreover, their natural rapid rotation times when there is low substrate would 
reduce the effect of the polar run and tumble effect demonstrated in Figures 
4.12 and 4.15. Interestingly, even in the absence of chemotactic ability, 
propelled nanoscale particles may be able to distribute from the blood and 
through the CNS tissue more effectively than non-propelled systems, due to 
the increase mean squared displacement alone without directional bias. 
In this Chapter, a simplified relationship between substrate concentration and 
nanoparticle propulsion has been used (Equations 5.8-5.10). These equations 
relate enzyme kinetics to a propulsion velocity. In future work, a more 
accurate relationship between substrate concentration and propulsion velocity 
could be found. For example, techniques such as NTA permit calculation of 
the drift velocity of nanoparticles when subjected to a chamber of a known 
substrate concentration. The work of the Golestanian group has previously 
described more complex theoretical relationships between particle mobility 
and enzymatic activity. This includes variables such as the diffusion 
coefficient of reactants and substrates in addition to enzyme kinetics (Saha et 
al., 2014). This could then be included to allow more accurate modelling in the 
future and better validation of the model results in experimental tests. 
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5.4 CONCLUSIONS 
In conclusion, a model of substrate-independent and substrate-dependent 
propulsion of particles has been implemented using FLAME. This has been 
used to demonstrate how particles undergoing propulsion accumulate at solid 
interfaces, potentially improving cellular uptake. Furthermore, application of 
propulsion within the blood can aid distribution to the endothelial interface of 
the blood-brain barrier and other endothelial barriers, thus increasing potential 
uptake into tissues. Substrate-dependent propulsion has been demonstrated 
to produce net chemotaxis, if the propulsion and angular velocity are 
optimised for the given concentration gradient. In future, better understanding 
of how the angular velocity changes for particles undergoing propulsion will 
lead to higher levels of control over chemotaxis efficiency and will inform 
therapeutic nanoparticle design, giving improved specificity in delivery. 
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6.1 GENERAL CONCLUSIONS 
In this thesis, a variety of modelling approaches have been used to explore 
methods to study and improve nanoparticle delivery to the CNS across the 
blood-brain barrier. A key aspect of this project was to apply the power of 
agent-based modelling to perform predictive simulations of nanoparticle 
behaviour. In order to model nanoparticle interaction with the blood-brain 
barrier, a core model of nanoparticle behaviour, under blood flow, in a 
capillary was created. This model incorporated RBCs at a physiological level. 
It was found by the inclusion of these cells, that the effect on fluid dynamics 
within a capillary was favourable for distribution of nanoparticles to the 
endothelial wall interface. The inclusion of RBCs in the simulations was 
important in improving the applicability of the in silico simulations to 
corresponding experiments in vivo. Furthermore, the core model gave 
considerable insight into how the fluid dynamics of blood flow in capillaries 
operates as a highly efficient delivery mechanism. This role of capillary blood 
flow, in the context of RBCs, in delivery had been relatively unexplored. 
Previous studies had focused on other aspects of capillary flow such as RBC 
morphology (Chambers and Mitragotri, 2007, Fedosov et al., 2014, Guest et 
al., 1963, Kaoui et al., 2009, McWhirter et al., 2009, McWhirter et al., 2011, 
Skalak and Branemar.Pi, 1969) or had used non-physiological haematocrits of 
0% or 38% in delivery studies (Tan et al., 2012, Yu et al., 2011). The core 
model was designed to exploit the inherent parallelisation optimisation 
features in the FLAME framework. The structure of this model permitted facile 
manipulation of the model to answer different research questions, whilst 
maintaining the same basic core model.  
It was demonstrated that this model could be used to aid considered 
nanoparticle design. Nanoparticle size was investigated in delivery through 
fenestrated endothelium and particularly in the enhanced permeability and 
retention effect. An important aspect of this work was to demonstrate the 
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importance of considering size in the context of polydispersity. These 
principles also apply to the work within the remainder of the thesis, but was 
omitted to reduce the number of variables to be considered. Moreover, whilst 
fenestrations are not present at the blood-brain barrier, they can be found at 
the choroid plexus and circumventricular organs. These present alternative 
potential entry routes into the CNS across the epithelial blood-cerebrospinal 
fluid barrier (Langlet, 2014, Langlet et al., 2013). Moreover, disruption of the 
endothelial tight junctions in the blood-brain can be found in a number of CNS 
diseases or is induced through deliberate disruption (Neuwelt et al., 1980, 
Dallasta et al., 1999, Bell et al., 2012). The fenestration model can be simply 
adjusted to model nanoparticle uptake across a disrupted blood-brain barrier. 
The established model and another model based on in vitro transwell models 
of the blood-brain barrier were then used to screen nanoparticles with different 
properties, for their ability to bind to the blood-brain barrier and cross the 
blood-brain barrier by transcytosis. Previously, it has been demonstrated that 
transcytosis efficiency of antibodies was dependent on the binding strength, 
with low affinity antibodies unable to stably bind sufficiently to induce 
transcytosis and high affinity antibodies unable to unbind and be released into 
the parenchyma. This screening demonstrated that the overall affinity for 
nanoparticles could be controlled by manipulating a number of nanoparticle 
properties, including size, ligand density and receptor-ligand binding affinity. 
This demonstrates that nanoparticles have a greater flexibility in formulation 
than antibodies, as binding strength is controllable by the three different 
parameters studied and also quite probably by shape also. The effect of these 
properties on binding has been studied previously both theoretically and in 
biological studies (Decuzzi and Ferrari, 2006, Gosk et al., 2004, Fakhari et al., 
2011, Takae et al., 2005, Chithrani et al., 2006). However the conversion into 
transcytosis efficiency, based on an emerging hypothesis in endothelial 
transcytosis, has been relatively unexplored (Gosk et al., 2004, Wiley et al., 
2013, Yu et al., 2011, Yu et al., 2014). These parameters are often neglected 
in the literature on delivery to the CNS. Therefore, this work, in conjunction 
with the findings of Yu and colleagues, demonstrates that in future work on 
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nanoparticle delivery to the CNS, it is important to consider these parameters 
and the potential effect they may have on delivery efficiency. Overall, this 
work demonstrates that developing nanoparticles with an intermediate overall 
affinity could potentially improve transcytosis efficiency.  
The nanoparticle binding models were also used to establish whether 
nanoparticle properties could improve uptake specificity when receptor 
expression is altered and/or when blood flow is changed. It was found that by 
altering nanoparticle properties, binding strength could be tuned to increase 
binding specificity to high receptor expression levels but not to low receptor 
expression. Furthermore, nanoparticle properties could be used to stabilise 
binding under the increased blood flow associated with functional hyperaemia. 
These two principles, used separately or in tandem, can improve the 
specificity of nanoparticle binding. Improving specificity of delivery to different 
regions of the CNS remains a highly unexplored area, with most studies to 
date focusing on general CNS delivery levels or therapeutic outcomes. Given 
the innate fragility of neural tissue, delivery in to the affected region of the 
CNS will require more attention if nanoparticle-mediated therapy for CNS 
disorders is going to become safe and effective. Thus far, only two methods 
have been published that address this issue. The first of these methods uses 
magnetic nanoparticles and a magnetic field to guide the nanoparticles into 
the region of interest (Pulfer et al., 1999, Pulfer and Gallo, 1998, Qiao et al., 
2012). The second method uses transient site-specific disruption of the blood-
brain barrier by ultrasound-mediated rupture of micro-bubbles in the blood 
(Hynynen et al., 2005, Kinoshita et al., 2006b, Kinoshita et al., 2006a, 
Mesiwala et al., 2002, Sheikov et al., 2004). The magnetic-guided approach is 
an interesting concept that should improve specificity of nanoparticles, 
however only a small selection of nanoparticles are responsive to magnetic 
fields. Furthermore, the use of such ‘hard’ nanoparticles gives an overall 
poorer interaction with biological material than ‘soft’ nanoparticles such as 
liposomes and polymersomes. Disruption of the blood-brain barrier, though 
effective in increasing drug penetrance, has inherent risks due to the integral 
role of the blood-brain barrier in maintaining CNS homeostasis. The blood 
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contains substances that within the CNS are neurotoxic, these include 
plasminogen, albumin and pro-thrombin (Nadal et al., 1995, Gingrich and 
Traynelis, 2000, Gingrich et al., 2000). Disruption, even if only transient, may 
therefore damage the underlying tissue. This damage can further trigger a 
cascade of events ultimately leading to progressive damage of the CNS. 
Further research on the effect of such a disruption is required before this 
method can be considered safe for long-term treatment strategies. Therefore, 
the design of new methods to improve delivery to specific regions of the CNS 
will be highly beneficial to future nanoparticle-mediated CNS therapy. In this 
thesis a number of methods have been suggested, that are used 
endogenously to improve delivery, notably increased receptor expression and 
functional hyperaemia. If they are realised in later experimental work, they 
may have considerable potential to aid CNS therapy whilst reducing 
potentially harmful off-target effects. 
Finally chemotactic nanoparticles were explored as a method to increase 
accumulation at the blood-brain barrier interface and follow gradients to target 
cells. It was demonstrated that nanoparticles operating under propulsion had 
an increased displacement. Furthermore, when placed within the core model 
of capillary blood flow, propelled particles accumulated at the endothelial 
interface. It was predicted that this would lead to increased uptake across the 
blood-brain barrier into the CNS. This work directly led to corresponding 
experiments in rats, where a 2-fold increase in uptake to the CNS was 
observed with chemotactic, blood-brain barrier targeted nanoparticles 
compared to non-chemotactic controls (Nyberg and Battaglia, unpublished). 
Chemotactic nanoparticles were further demonstrated to be able to follow 
chemical gradients, a method that has potential to be harnessed to improve 
penetration through CNS tissue to target cells or regions. The chemotactic 
capability was dependent on the relationship between rotational time and 
propulsion velocity. It was demonstrated that the latter might be controlled by 
the enzyme concentration. The relationship between propulsion and rotational 
time appears to be complex and will require further study before any exact 
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relationship can be ascertained (Cecchin et al., Submitted, Golestanian et al., 
2007, Howse et al., 2007). 
The blood-brain barrier depicted in these simulations focuses on the role of 
the endothelium in both barrier function and transport into the CNS. However 
the endothelium is closely associated with other cells of the neurovascular 
unit, particularly pericytes and astrocytes. The density and organisation of 
these cells creates spatial limits that nanoparticles must migrate through. 
Furthermore, pericytes and astrocytes both possess phagocytic behaviour for 
the non-specific uptake of nanoparticles (Balabanov et al., 1996, van Deurs, 
1976, al-Ali and al-Hussain, 1996, Nguyen et al., 2011). Additionally they 
express Lrp1, thus allowing the specific uptake of Lrp1-targeted nanoparticles 
(Wilhelmus et al., 2007, William Rebeck et al., 1993). Their close proximity to 
the barrier makes them the first cells the nanoparticles come across within the 
CNS. This may limit the ability of nanoparticles to be distributed and targeted 
to other cells in the CNS that are located more distally to the barrier, such as 
neurons and oligodendrocytes. Moreover, there is a basal laminar that 
separates the endothelium from the CNS parenchyma.  This may prevent or 
slow the migration of large nanoparticles, as has been demonstrated in the 
basal laminar of neuromuscular junctions (Oldfors and Fardeau, 1983). It is 
evident that optimising nanoparticle transport across the blood-brain barrier is 
only part of the challenge in CNS delivery. 
 
6.2: FUTURE PERSPECTIVES 
The work within this thesis represents proof-of-concept studies into how 
nanoparticles can be adapted for improved general and specific uptake to the 
CNS across the blood-brain barrier. The models presented were deliberately 
simplistic to improve their flexibility to different research questions and to 
reduce the effect of complex interactions in the final analysis. The major 
drawback of such an approach is that direct comparison with experimental 
work from the Battaglia lab and the literature is complex. In future it is 
important to validate aspects of the methodology in biological systems and 
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refine the methodology to better reflect the situation in in vitro and in vivo 
systems. Once the methods are refined, they could be extrapolated to larger 
scale models of the cerebrovasculature and eventually towards patient-
personalised medicine, as discussed later. The extrapolation to larger scale 
models is important to permit better in silico to in vivo translation, allowing the 
model to explain experimental observations and predict experimental 
outcomes. 
 
6.2.1 Validation and Refinement 
In any in silico study, the desire is to produce models that can be operated 
alongside traditional biological models. Ideally, each separate model improves 
the understanding of the other. In silico methods can be used to generate 
research hypotheses for in vitro or in vivo experimentation. The resulting data 
can then be used to improve the accuracy and complexity of the in silico 
modelling thus improving its power. Work within the Battaglia group has 
validated or informed some of the methodology used in this thesis, including, 
simulations of Brownian motion, timing of cellular trafficking in transcytosis, 
effect of ligand density on transcytosis efficiency and improved uptake of 
propelled particles under blood flow. However, future work will focus on 
validating concepts such as the increased specificity for higher levels of 
expression and increased specific uptake under functional hyperaemia 
conditions. Moreover, it is hoped that future work could identify specific values 
such as the 𝒌𝒂𝟎 of Angiopep-2-Lrp-1 interaction, the receptor density of Lrp-1 
at the blood-brain barrier and the propulsion-angular velocity relationship, that 
will improve the predictive aspects of the simulations. 
 
6.2.2 Application to Large-scale Modelling 
The main core model in this thesis focuses on uptake in a simulation of a 
single capillary. However, a network of capillaries is critical to blood-mediated 
delivery to the CNS, with variances in capillary morphology, branching and 
flow properties. Using image processing of in vivo vascular networks, 
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modelling has been undertaken at this scale (Groen et al., 2013, Mazzeo and 
Coveney, 2008, Torii et al., 2010). Integrating the methodology presented in 
this thesis can improve the in silico to in vivo translation. Furthermore, as 
computational power increases, these models can be made more and more 
complex. They can integrate dynamic changes that occur in the 
cerebrovasculature, such as arteriole vasodilation in functional hyperaemia, 
the role of pericytes in functional hyperaemia and regulation by the 
neurovascular unit. As greater complexity is integrated into simulations, it is 
hoped that the accuracy and predictive capabilities of the model improve.  
 
6.2.3 Towards Personalised Medicine 
One of the newest and most exciting potential avenues for treatment of many 
disorders is the idea of personalised medicine. The concept of personalised 
medicine is to design treatment strategies in a patient-specific manner using 
patient data such as genome sequences and proteomics (Barretina et al., 
2012, Hamburg and Collins, 2010, Hood et al., 2004). A major advantage of 
large-scale modelling techniques, suggested in the previous section, is the 
ability to use patient data to tailor nanoparticle formulation accordingly. In a 
number of CNS diseases, changes to cerebrovasculature structures, blood 
flow alterations, neurovascular coupling deficiencies and blood-brain barrier 
dysfunction have been shown to occur, as discussed in Chapter 1. In recent 
years, progress in CNS imaging, such as MRI, fMRI, positron emission 
tomography (PET) and single photon emission` computed tomography 
(SPECT), has enabled the generation of high-quality data from patients. 
Integration of such primary data from patients into large-scale in silico models 
may allow rapid screening of delivery efficiency to give the best treatment 
strategies. This can include best methods of delivery to target sites, but also 
better understanding of the state of disease progression and therefore more 
accurate determination of therapeutic targets. Currently, several major 
projects and initiatives are being undertaken based on the principles of large-
scale modelling of whole tissues, including the Human Brain Project 
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(https://www.humanbrainproject.eu) and the Virtual Physiological Human 
(http://www.vph-institute.org). Initiatives such as these are already creating 
organ level models encompassing patient-specific data, such as in the 
FUSIMO (http://www.fusimo.eu) or p-medicine (http://www.p-medicine.eu) 
projects. Moreover, the p-medicine project is beginning to integrate patient-
specific data and the Virtual Physiological Human with the goal of achieving 
personalised medicine. Although modelling at this scale represent serious 
biological and computational challenges, the benefit of such initiatives has 
great potential to revolutionise therapeutic strategies towards the CNS. 
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APPENDIX I 
APLEY PRIZE SUBMISSION 
 
INTRODUCTION 
The central nervous system (CNS) includes the brain and spinal cord and is 
involved in processing, co-ordinating and dissipating information to/from the 
rest of the body. Diseases affecting the CNS will account for an estimated 
11.84% of all deaths by 2015. Despite the high burden of disease, few 
effective treatment options exist for CNS disorders. One of the major reasons 
for this is the poor penetration of potential therapeutics into the CNS tissue. 
This is due to the formation of a blood-brain barrier, between the CNS tissue 
and the blood, by the endothelial cells that constitute blood vessel walls. This 
barrier prevents almost all unregulated exchange across the endothelial walls 
into the CNS tissue. Whilst this effectively blocks many potential therapeutic 
molecules, the natural entry of specific large macromolecules may provide a 
gateway to access the CNS.  
A specific transport system known as receptor-mediated transcytosis (RMT) 
has gained recent interest for CNS delivery. RMT involves a cargo molecule 
binding a specific receptor on the blood side (apical side) of an endothelial cell 
that initiates uptake into the cell in a membrane bound structure called a 
vesicle, transport across the cell and release, unaltered, on the CNS side 
(basolateral side) of the cell. Recent developments have utilised nanoparticles 
that can carry a vast array of potential cargo and be decorated with specific 
ligands for RMT receptors to increase CNS penetrance. However, whilst these 
systems have been successful in increasing CNS penetrance, further 
optimisation is required to maximise therapeutic delivery. Moreover, new 
methods to deliver to specific regions of the CNS are required to avoid 
potentially catastrophic off-target effects. 
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Agent-based modelling is a type of specifically designed for systems analysis. 
It deconstructs a system into components, known as agents, and assigns 
mathematical expressions to describe their behaviour. Subsequently, by 
combining the different agent together in simulations, through agent-agent 
and agent-environment interactions, emerging systems behaviour can be 
observed.  
 
AIM 
This work sets out to use agent-based modelling of blood flow within the CNS 
vasculature to investigate physical, physiological and biological parameters 
that effect uptake of nanoparticles across the blood-brain barrier. 
 
RESULTS 
Developing Agent-based Models of Blood Flow 
First an agent-based model of blood flow in a single microvessel was 
developed by integrating finite element methods for fluid flow with agent-
based simulations of nanoparticle behaviour in the blood. Incorporated in this 
is the inclusion of RBCs that constitute ~40% (v/v) of the blood but are 
reduced to 10% in the microvessels where transport occurs. The effect of 
these RBCs on blood flow was investigated by varying the volume of RBCs 
from 0% to 40%. It was found that physiologically relevant concentrations of 
RBCs (10-12%) produced fluid dynamics effects that maximised the number 
of molecules that come into close proximity contact with the vessel wall and 
consequently receptors. 
 
Modulating Nanoparticle-Endothelial Interactions 
The interaction of a nanoparticle with the endothelium is a key property for 
determining effective uptake of the particle into the CNS. This interaction for 
RMT is propagated through the binding of ligand(s) on the nanoparticle to 
receptor(s) on the endothelium. Therefore, the nanoparticle-endothelial 
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interaction is governed by, the density of the receptor, the density of the 
ligand, the strength of receptor-ligand association, the contact surface area of 
the nanoparticle-endothelial interface and the shear forces acting at the 
endothelial-nanoparticle interface. Previous equations have been adapted to 
study these interactions to look at various phenomena of transport across the 
BBB. 
Previously, it has been demonstrated that RMT efficiency can be controlled 
through the strength of interaction between the ligand and receptor, with 
intermediate association strengths more favourable for efficient transcytosis. 
This is because transcytosis involves the effective binding on the apical 
membrane but also unbinding on the basolateral membrane. In this work a 
similar effect with nanoparticles is demonstrated, where the overall RMT 
efficiency can be modulated by the ligand-receptor affinity, ligand density and 
particle size. 
 
Achieving Specific Delivery 
The flexibility of the parameters that influence transcytosis means different 
formulations can be designed for optimal transport in particular conditions. 
One of the major goals of this project is to elucidate methods where specific 
delivery in different regions of the CNS can be achieved. One area that has 
been previously studied for specific delivery is receptor expression level. In 
this work it has been demonstrated that using a higher density of a lower 
specificity ligand will specifically target regions of the vessel wall where 
receptor expression is higher. This is because without forming multiple bonds, 
the binding is unstable and will be broken. However if the receptor and ligand 
density are both increased more bonds will be formed that collectively 
stabilise the interaction.  
Another area that could be exploited is differences in blood flow, as a result of 
natural variation between vascular beds, disease abnormalities or inducible 
flow regulation mechanisms. In this work a particular flow regulation 
mechanism specific to the CNS, called neurovascular coupling, is 
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investigated. Neurovascular coupling refers to the local increase in blood flow 
rates when part of the neural system of the CNS is stimulated, called 
functional hyperaemia. We have looked at optimising uptake under conditions 
representing normal and functional hyperaemia conditions. The aim of this 
would be to design a formulation that undertakes efficient RMT under 
functional hyperaemia such that we can control uptake into a set region by 
inducing local functional hyperaemia. 
 
Chemotaxis 
Many cells are able to follow chemical stimuli to find improved conditions or 
desirable targets. Recently, translational work has looked at developing these 
properties in nanoparticles. Using agent-based simulations, the important 
considerations for the design of chemotactic systems at the nanoscale are 
demonstrated. Furthermore this work demonstrates how such particles can be 
used to follow biological signals to target cells; accrue at interfaces where 
uptake is more likely to occur and how this can be used to maximise the 
availability of nanoparticles at vessel walls. 
 
CONCLUSIONS 
In this work an agent-based model of blood flow at the blood-brain barrier is 
produced and used to study strategies for improving general and specific 
uptake of nanoparticles into the CNS. 
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APPENDIX II 
MODEL OF BROWNIAN MOTION 
 
#include <stdio.h> 
#include <stdlib.h> 
#include <math.h> 
#include <time.h> 
 
/************************** Definitions ***************************/ 
#define dt 0.001                            /*** Time Step in s ***/ 
#define Kb 0.000000000000000000000013806488 /* Boltzmann Constant */ 
#define T 310                               /** Temperature (K) ***/ 
#define viscosity 0.0017                    /*** Viscosity H20 ****/ 
 
/******************** Box-Muller Transformation *******************/ 
 
double BoxMuller() 
{ 
/* Create Stored Variables */ 
    static double n2 = 0.0; 
    static int n2_cached = 0; 
/* If no stored value */ 
if (!n2_cached) { 
/* Create Random Values between -1 and 1 */ 
double x, y, r; 
        do { 
            x = 2.0*rand()/RAND_MAX - 1; 
            y = 2.0*rand()/RAND_MAX - 1; 
            r = x*x + y*y; 
        } while (r == 0.0 || r > 1.0); /* If x^2 + y^2 < 1 */ 
        { 
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            double d = sqrt(-2.0*log(r)/r); 
            double n1 = x*d; 
/* Store 2nd value */            
            n2 = y*d; 
            n2_cached = 1; 
/* Return result */ 
            return n1; 
        } 
/* If stored value */ 
} else { 
        n2_cached = 0; 
/* Return stored value */ 
return n2; 
    } 
} 
 
/****************************** Main ******************************/ 
int main () 
{ 
/* Initialise Random Number Generator */ 
    srand (time (NULL)); 
/* Initiate Particle Variables */ 
    double x = 0.0; 
    double y = 0.0; 
    double z = 0.0; 
    double radius = 0.00000005; 
    double Dc = (Kb * T)/(6 * M_PI * viscosity * radius); 
/* Calculate Standard Deviation (Andrews and Bray) */ 
double SD_Dc = sqrt (2.0 * dt * Dc); 
/* Start Iteration Loop */ 
    int iteration; 
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    for (iteration = 1; iteration < 1001; iteration++) 
    { 
/* Display Iteration Number */ 
printf ("%d\n", iteration); 
/* Assign deltax, deltay and deltaz (in nm) */ 
double deltax = 1000000000.0 * Std_Dev * BoxMuller(); 
        double deltay = 1000000000.0 * Std_Dev * BoxMuller(); 
        double deltaz = 1000000000.0 * Std_Dev * BoxMuller(); 
/* Update x, y and z Variables */ 
        x += deltax; 
        y += deltay; 
        z += deltaz; 
} 
/* Print Results */ 
    printf ("(%f, %f, %f)\n", x, y, z); 
return 0; 
} 
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APPENDIX III 
FLAME MODEL OF BROWNIAN MOTION 
 
BROWNIAN.xml 
 
<xmodel version="2" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
    
xsi:noNamespaceSchemaLocation='http://flame.ac.uk/schema/xmml_
v2.xsd'> 
<name>Model of Brownian Motion</name> 
<author>Gavin Fullstone</author> 
 
<!--********************* Environment *********************--> 
<environment> 
 <functionFiles><file>FUNCTIONS.c</file></functionFiles> 
</environment> 
 
<!--************************ Agents ***********************--> 
<agents> 
<xagent> 
<name>Nanoparticle</name> 
  <memory> 
   <variable><type>int</type><name>id</name></variable> 
   <variable><type>double</type><name>x</name></variable> 
   <variable><type>double</type><name>y</name></variable> 
   <variable><type>double</type><name>z</name></variable> 
   <variable><type>double</type><name>radius</name></variable> 
   <variable><type>double</type><name>Dc</name></variable> 
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   <variable><type>double</type><name>SD_Dc</name></variable> 
  </memory> 
<!--** Functions **--> 
    <functions> 
     <function> 
      <name>Brownian</name> 
   <currentState>0</currentState> 
         <nextState>1</nextState> 
  </function> 
 </functions> 
</xagent> 
</agents> 
 
<!--*********************** Messages **********************--> 
<messages> 
</messages> 
</xmodel> 
 
FUNCTIONS.c 
 
#include <stdio.h> 
#include <stdlib.h> 
#include <math.h> 
#include <time.h> 
 
/******************** Box-Muller Transformation *******************/ 
double BoxMuller() 
{ 
/* Create Stored Variables */ 
APPENDIX 263 
    static double n2 = 0.0; 
    static int n2_cached = 0; 
/* If no stored value */ 
if (!n2_cached) { 
/* Create Random Values between -1 and 1 */ 
double x, y, r; 
        do { 
            x = 2.0*rand()/RAND_MAX - 1; 
            y = 2.0*rand()/RAND_MAX - 1; 
            r = x*x + y*y; 
        } while (r == 0.0 || r > 1.0); /* Check that x^2 + y^2 
is less than 1 */ 
        { 
            double d = sqrt(-2.0*log(r)/r); 
            double n1 = x*d; 
/* Store 2nd value */ 
            n2 = y*d; 
            n2_cached = 1; 
/* Return result */ 
            return n1; 
        } 
/* If stored value */ 
    } else { 
        n2_cached = 0; 
/* Return stored value */ 
        return n2; 
    } 
} 
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/********************** Nanoparticle Functions ********************/ 
int Brownian () 
{ 
/* Initiate Access to Memory Variables */ 
    xmachine_memory_Nanoparticle * xmemory = current_xmachine-
>xmachine_Nanoparticle; 
/* Assign deltax, deltay and deltaz (in nm) */ 
    double deltax = 1000000000.0 * xmemory->SD_Dc * 
BoxMuller(); 
    double deltay = 1000000000.0 * xmemory->SD_Dc * 
BoxMuller(); 
    double deltaz = 1000000000.0 * xmemory->SD_Dc * 
BoxMuller(); 
/* Update x, y and z Variables */ 
    xmemory->x += deltax; 
    xmemory->y += deltay; 
    xmemory->z += deltaz; 
/* Print Results */ 
    printf ("(%f, %f, %f)\n", x, y, z); 
    return 0; 
} 
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TRANSCYTOSIS EFFICIENCY OF ANGIOPEP-2 FUNCTIONALISED 
POLYMERSOMES 
This experiment, performed by Sophie Nyberg from the Battaglia group, used 
angiopep-2 functionalised polymersomes with different degrees of 
functionalisation (1%, 2%, 3%, 4%, 5% and 6% functionalised polymer). The 
percentage transcytosed was measured by fluorescence intensity in the 
basolateral compartment of an in vitro transwell seeded with B. End 3 cells 
after 30 minutes. 
 
Transcytosis Efficiency of Angiopep-2 Functionalised Polymersomes. 
Transcytosis efficiency of polymersomes functionalised with different densities of 
Angiopep-2, after 30 minutes, in a transwell model of the blood brain barrier. Data 
provided by Sophie Nyberg. Mean ± standard deviation, n=3. 
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APPENDIX V 
DELIVERY OF CHEMOTACTIC NANOPARTICLES INTO THE CNS OF 
RATS 
This data, obtained by Sophie Nyberg from the Battaglia group, demonstrates 
the percentage of the total injected dose of polymersomes entering the CNS 
in rats after 10 minutes of in situ perfusion. In this experiment, the carotid 
arteries were isolated and perfused at a set flow perfusion rate with an 
artificial blood mix containing a known quantity of polymersomes. After 10 
minutes, the rats were euthanised and the brain separated into the capillary 
fraction and the capillary depleted fraction corresponding to the parenchyma. 
The data below represents the percentage of polymersomes in the 
parenchyma as measured by the fluorescence microscopy. 
 
Delivery of Chemotactic Nanoparticles into the CNS of Rats. Fluorescence 
quantification of polymersome uptake into the rat brain parenchyma after 10 minutes 
of in situ perfusion. Polymersome formulations are chemotactic Angiopep-2-
POEGMA-PDPA/PEO-PBO (A-EP-EB+), non-chemotactic Angiopep-2-POEGMA-
PDPA (A-EP) and non-CNS-targeting POEGMA-PDPA (EP). *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001. Mean ± standard error of the mean. Provided by Sophie 
Nyberg. 
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